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Abstract
Amyloid beta (Aβ) has been postulated to be the principle initiator of the
pathogenesis of Alzheimer’s disease (AD). Therefore, understanding the underlying
mechanisms of Aβ induced neurotoxicity in the early stages of AD would be
essential for finding potential therapeutic targets of AD.
Aβ-binding alcohol dehydrogenase (ABAD) has been shown to be a mitochondrial
binding site for Aβ. Expression of ABAD has been found to be increased in brains
of AD sufferers. Two dimensional electrophoresis studies have revealed that
endophilin 1 was upregulated in Tg mAPP/ABAD mice brains as compared to Tg
mAPP, Tg ABAD and non-Tg mice brains. Increased expression of endophilin 1 has
also been found in brains of AD patients as compared to non-demented control
brain tissues. Endophilin1 has been reported to regulate c-Jun N-terminal kinase
(JNK) activation. In this study, expression of dominant negative forms of
endophilin 1 (DN-endophilin 1) in mouse cortical neurons exhibited a significant
reduction of Aβ induced JNK activation. Furthermore, using cell counting methods,
it was shown that the transfection of DN-endophilin 1 increased neuron survival
after Aβ treatment.
Aβ has also been proposed to disrupt the interaction of ABAD and Cyclophilin D
(CypD), which would trigger mitochondrial permeable transition, thereby leading to
neurotoxicity. For fluorescence resonance energy transfer (FRET) analysis of the
interaction of ABAD and CypD, a mitochondria targeted, EYFP tagged ABAD
ix
plasmid (pMito-ABAD-EYFP) and an ECFP tagged CypD (pCypD-ECFP) plasmid
were developed. Positive FRET signals in SK-N-SH cells co-expressing
pMito-ABAD-EYFP and pCypD-ECFP indicated that ABAD interacts with CypD
in the mitochondria of mammalian cells.
RAGE (receptor for advanced glycation end products) has been reported to bind to
Aβ and mediate the toxic effects of Aβ peptides on neurons and microglia. It has
been shown previously that Tg mAPP/DN-RAGE mice display preserved cognitive
function as compared to Tg mAPP mice. To investigate possible mechanisms
involved in rescuing cognitive function by RAGE blockage, two dimensional
electrophoresis was used to analyze differential protein expression between Tg
mAPP and Tg mAPP/DN-RAGE mice cortex. Altered expression of four proteins,
including NADH dehydrogenase flavoprotein 2 (NDUFV2), glyoxalase 1 (GLO1),
proteasome subunit beta type 4 (PSMB4, or β7 subunit of proteasome) and nitrilase
family, member 2 (Nit2) have been observed between Tg mAPP/DN-RAGE mice
cortex and Tg mAPP mice cortex. NDUFV2 is a 24kDa subunit of complex 1 which
is involved in ATP synthesis. GLO1 is a cytosolic enzyme that plays a role the
glutathione-dependent detoxification of α-oxoaldehydes, such as methylglyoxal.
PSMB4 is a subunit of the 26s proteosome which is in the degradation of
ubiquitinylated proteins. The function of Nit2 is still unclear.
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1Chapter 1: Introduction
2Chapter 1: Introduction
1.1 An overview of Alzheimer’s disease
Alzheimer’s disease (AD) is the most prevalent cause for dementia in the aged
population and affects almost half of all patients with dementia. Advancing age is
the dominant risk factor for AD. The diagnosis of AD is still rare in people under 65,
but becomes more prevalent with each decade of life. 10% of those over 65 and
almost 50% of those over the age of 85 have AD (Jones et al. 1993). With the aging
of the world population, AD has become a major health problem worldwide. It has
been estimated that there are 26.6 million cases of AD in the world and the number
of people with AD will double every 20 years to 106.8 million by 2050
(Brookmeyer et al. 2007).
AD is a fatal, progressive neurodegenerative disorder. Clinically, the usual first
symptom of AD is memory loss which progresses from minor forgetfulness to a
more pervasive loss of short-term memory, then of long-term memories. As the
disorder progresses, aphasia, disorientation and disinhibition often occur. In the
later stages, Alzheimer's disease may also include behavioural and personality
changes. The average duration of the disease from onset of symptoms to death is
approximately 7-10 years (Smith and Swash 1978).
Alzheimer’s disease is imposing a severe burden upon the individuals affected,
along with their families and care givers. AD also has a substantial negative
economic impact on the society. Recent research shows that, in the UK, the cost to
3provide long-term care to older people with dementia will increase to £16.7 billion
by 2031 (Comas-Herrera et al. 2007).
1.1.1 Neuropathology of Alzheimer’s disease
At present, clinical diagnosis of AD is based on progressive impairment of memory
and decline in at least one other cognitive domain, and exclusion of other diseases
that might also cause dementia, such as frontotemporal dementia, dementia with
Lewy-bodies, stroke, brain tumor, normal pressure hydrocephalus or depression.
While the clinical diagnostic accuracy for Alzheimer’s disease can exceed 90% in
mid or late stages, definitive diagnosis of AD is only possible through direct
pathologic examination of brain tissue derived from either biopsy or autopsy due to
the absence of biologic markers (Jobst et al. 1994).
The characteristic neuropathology of AD was first described by a German
psychiatrist, Alois Alzheimer, in 1907. There are two hall mark pathological
findings in the brains of AD sufferers (Alzheimer 1907; Mott and Hulette 2005;
Souder 2005):
 Extracellular amyloid plaques (or fibrils) including diffuse and neuritic plaques,
which are mainly composed of the amyloid beta peptide (Aβ) (Selkoe 2001).
The neuritic plaques are intimately surrounded by dystrophic axons and
dendrites, reactive astrocytes and activated microglia.
 Intracellular neurofibrillary tangles (NFTs) which are intraneuronal bundles of
paired helical filaments. The main structural component of NFTs is an
4abnormally phosphorylated form of tau protein. Tau is a widely expressed
phosphoprotein from the microtubule associated family, the main function of
which is to maintain microtubule stability. In Alzheimer’s disease,
hyperphosphorylated tau aggregates, reducing its ability to bind microtubules
and leading to cytoskeletal degeneration and neuronal death (Lovestone and
Reynolds 1997). NFTs are not specific to Alzheimer’s disease, and are also
found in a variety of other neurodegenerative disorders such as frontotemporal
dementia, subacute sclerosing panencephalitis, Hallervorden-Spatz disease,
Parkinson dementia complex and dementia pugilistica (Perl 2000).
Besides plaques and tangles, AD brains also exhibit a number of pathological
abnormalities, including cerebrovascular deposition of amyloid, a profound loss of
neurons and synapses, profuse reactive gliosis, microglial activation and
inflammatory processes (Roher 1993; Aisen 2002).
1.1.2 APP processing
Although numerous proteins are associated with the amyloid plaques in AD, the
principal protein component of the plaques is the approximately 4-kDa Aβ. Aβ is
derived from the amyloid precursor protein (APP) via endoproteolytic cleavage. APP
is a ubiquitously expressed type I integral membrane glycoprotein. It is abundantly
expressed in the brain. The human APP gene is located on the long arm of
chromosome 21, and spans approximately 240 kb and contains at least 18 exons
(Kang et al. 1987). Alternative splicing generates APP mRNAs encoding several
5isoforms that range from 365 to 770 amino acid residues. The major Aβ peptide
encoding proteins are 695, 751, and 770 amino acids (referred to as APP695, APP751
and APP770). APP processing is a normal event in nearly all neuronal and
nonneuronal cells. Full-length APP is sequentially processed by at least three
proteinases termed α-, β- and γ-secretases (Wilquet and De 2004). This process can
be divided in two different pathways, the nonamyloidogenic and the amyloidogenic
pathway. The majority of APP is processed in the nonamyloidogenic pathway. In the
nonamyloidogenic pathway, full-length APP is first cleaved by α-secretase within the
Aβ peptide domain, leading to the release of APPsα, production of membrane-tethered
α-carboxyl-terminal fragments (α-CTFs) and precluding the generation of intact Aβ.
Membrane-anchored α-CTF is then cleaved by γ-secretase within the membrane,
releasing the p3 peptide and APP intracellular domain (AICD). In the amyloidogenic
pathway, APP is cleaved at the amino-terminus of Aβ by a β-secretase. This cleavage
generates a large secreted derivative (APPsβ) and a membrane-bound β-CTFs.
Cleavage of CTF by γ-secretase results in the production of Aβ peptides of varying
length. The two species of most interest are a 40–amino acid Aβ peptide (Aβ40) and a
42–amino acid Aβ peptide (Aβ42) (Figure 1.1). The molecules responsible for these
proteolytic activities of APP processing have been identified. Several lines of studies
indicate that α-secretase is a member of the ADAM (adisintegrin and metalloprotease)
family of proteases (Allinson et al. 2003). The identity of β-secretase has been shown
to be the novel transmembrane aspartic protease, beta-site APP-cleaving enzyme 1
(BACE1; also called Asp2 and memapsin 2). BACE2, a protease homologous to
6BACE1, was also identified (Stockley and O'Neill 2007). γ-secretase is a multiprotein
complex consisting of presenilin (PS), nicastrin, aph-1 (anterior pharynx-defective-1),
and pen-2 (PS-enhancer-2) and that all four proteins are necessary for full proteolytic
activity (De Strooper 1993).
Figure 1.1 Proteolytic processing of amyloid precursor protein (APP). APP is first
cleaved by α-secretase within the Aβ domain, leading to APPsα secretion and
precluding Aβ generation. Membrane-anchored α-carboxy terminal fragment
(α-CTF) is then cleaved by γ-secretase within the membrane, releasing the p3
peptide and APP intracellular domain (AICD). Alternatively, amyloidogenesis takes
place when APP is first cleaved by β-secretase, producing APPsβ. Aβ and AICD are
generated upon cleavage by γ-secretase of the β-CTF retained in the membrane.
From: Wilquet and De (2004) Curr Opin Neurobiol. 14, 582-588
71.1.3 Early-onset AD
Although the exact mechanisms of the pathophysiology of AD are still unknown,
increasing evidence from histopathological, biochemical, genetic and animal model
studies suggested that Aβ plays a key role in the pathogenesis of Alzheimer’s
disease.
There are two broad types of AD, the familial AD (FAD) and the sporadic AD
(SAD). In FAD, the disease segregates in families, following an autosomal
dominant inheritance pattern. FAD only affects a small subset of patients of
younger age, usually before their fifties (Mullan et al. 1993). In SAD, no clear
family history is indicated and the disease usually occurs over the age of 60s.
Because of the variation in age at onset, AD is also categorized into early onset and
late onset forms. People suffering AD before the age of 60 are generally placed in
the early-onset category and account for about 1% of all AD cases.
1.1.3.1 Genetic mutations linked with early onset AD
Early onset AD is usually familial and follows an autosomal dominant inheritance
pattern with a high penetrance. To date three different genes have been implicated
in the pathology of the rare early onset familial Alzheimer’s disease: mutations of
the APP (mAPP) gene on chromosome 21(Goate et al. 1989; Levy et al. 1990),
mutations in the presenilin 1 and 2 (PS1 and PS2) genes on chromosome 14 and 1,
respectively (Rogaev et al. 1995; Levy-Lahad et al. 1995). Presenilin 1, presenilin 2
and amyloid precursor protein have a clear-cut autosomal dominant pattern with a
8penetrance above 85%. Although the precise functions of presenilins are unclear,
several studies indicated that PS1 and PS2 are catalytic components of γ-secretases
(De Strooper et al. 1999; Haass and De 1999). In vitro studies demonstrated that the
pathogenic mutations in the APP and presenilin genes are associated with abnormal
processing of APP, which leads to increased production and elevated plasma levels
of Aβ, especially Aβ42 or increased ratio of Aβ42: Aβ40 (Citron et al. 1992; Cai et
al. 1993; Suzuki et al. 1994).
Transgenic (Tg) animals carrying mutations in amyloid precursor protein and
presenilin genes displayed enhanced production and progressive aggregation of Aβ.
These animal models also reproduced the major features of Alzheimer’s disease:
amyloid plaques and memory impairment. However, no significant tau pathology or
extensive neuron loss, as found in AD brain, was detected in these transgenic
animals (Games et al. 1995; Hsiao et al. 1996).
Although the mutations in APP, PS1 and PS2 genes account for only 1% of all AD
cases, they have provided important insights for understanding some of the key
underlying biological mechanisms of AD. These various genetic mutations, all lead
to overproduction of Aβ42 in the brain before Alzheimer’s disease symptoms arise,
indicating that the accumulation of Aβ42 is the initiating factor in the pathogenesis
of Alzheimer’s disease.
Biochemical analysis of Aβ further supported this idea. In vitro, Aβ peptides
aggregate via a complex multistep-nucleated polymerization involving formation of
dimers and small oligomers followed by growth into protofibrils and fibrils. On
9electron microscopy, amyloid fibrils are composed of multiple protofibrils wrapped
around each other, forming a crossed β-pleated sheet (Caughey and Lansbury 2003).
Moreover, Aβ42, which is up-regulated by most of the genetic mutations that have
been linked to early onset AD, has a higher propensity to aggregate than the shorter
species (Jarrett et al. 1993).
Additionally, Down syndrome patients, who have three copies of chromosome 21
which harbours the APP gene, began to develop amyloid plaques and tau tangles in
their 30s and 40s (Kang et al. 1987).
1.1.3.2 Amyloid deposition precedes NFT formation
NFT is another characteristic neuropathologic lesion in AD brain. In patients with
the presenilin 1 mutations or individuals with Down’s syndrome, the presence of
amyloid plaques preceded the appearance of neurofibrillary tangles (Lippa et al.
1998). Furthermore, transgenic mice overexpressing both mutant human tau and
mutant human APP had the same number and structure of amyloid plaques but a
significantly higher number of tau positive NFTs than transgenic mice
overexpressing only mutant human tau (Lewis et al. 2001). These results indicated
that the mutant amyloid precursor protein and the consequent Aβ production
precede and promote the formation of NFTs.
In summary, these data collectively supported the hypothesis that increased
production or deposition of Aβ is the initiating signaling event in AD.
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1.1.4 Late onset AD
Late onset AD is the most common form of AD. Most late onset AD cases are
sporadic, with no family history of the disease. In early onset AD, gene mutations
lead to overproduction of Aβ, whereas, in late onset AD, the pathological
mechanisms leading to increased Aβ generation are unclear. A twin study on
incident cases indicated that almost 50% of the late onset AD risk is attributable to
genetic factors (Raiha et al. 1996). It is probable that environmental factors have to
interact with genetic susceptibility at multiple genes to cause development of the
disease.
Several non-genetic risk factors for late-onset AD including female gender, poor
early-childhood education, head injury, small cranial diameter and high cholesterol
level were proposed (Tol et al. 1999). The evidence for these risk factors, however,
was not convincing. The most well established risk factor for AD is increasing age.
It was estimated that everyone would develop AD if we live to 140 years of age
(Serretti et al. 2005).
The ApoE gene on chromosome 19q13 was identified as a strong risk factor for late
onset AD. There was an increased prevalence of apolipoprotein E (ApoE) epsilon in
late onset AD (Corder et al. 1998). The precise mechanism by which the ApoE4
allele is associated with late onset AD is unclear. It appears that, like the effects of
APP mutations, PS1and PS2 mutations on APP processing, ApoE4 can promote the
deposition of Aβ42 (Esler et al. 2002; Golabek et al. 1996).
Despite the robust association of the ApoE4 allele with late onset AD, the ApoE4
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allele is not required for late onset AD. 50% of late onset AD patients did not posses
the ApoE4 allele. This indicated that the ApoE4 allele functions as a susceptibility
marker, which in conjunction with other genetic and/or environmental factors can
increase the risk of late onset AD (Pirttila et al. 1996). This also pointed to the
possibility that there remains additional, yet to be discovered susceptibility genes
for late onset AD.
1.1.5 The toxic species of Aβ
The central role of Aβ in the pathogenesis of AD has been well established. Aβ is
initially produced from APP intracellularly and then secreted (Hartmann et al.
1997). In vivo, Aβ peptides exist in various conformations including monomeric
form, different oligomeric states and β sheet fibrils. Due to the dynamic nature of
this peptide, the nature of the toxic species of Aβ remains unknown (Pedersen and
Otzen 2008).
1.1.5.1 Soluble Aβ levels correlate with AD progression
The presence of amyloid plaques did not correlate well with clinical progression of
AD. In contrast, synaptic loss was shown to correlate well with the degree of
cognitive decline in AD patients (Lue et al. 1999). Moreover, soluble Aβ levels
were found to correlate best with memory and cognitive deficits in AD patients.
Even in very mildly impaired AD patients, soluble Aβ levels in the cortex showed a
significant correlation with the degree of synaptic loss (Lue et al. 1999).
Comparisons of transgenic lines having varying APP expression indicated that
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decrease in presynaptic terminals is critically dependent on soluble Aβ oligomer
levels, not on amyloid plaques (Selkoe 2002).
Consistent with these results, several studies demonstrated that diffusible soluble
Aβ oligomers, but not monomers or insoluble amyloid fibrils, are toxic to cultured
neurons and responsible for the neurotoxicity and synaptic dysfunction present in
Alzheimer’s disease (Walsh et al. 2002). For example, micro-injection of soluble
Aβ oligomers into rats inhibited long-term potentiation in the hippocampus (Walsh
et al. 2002). Moreover, synaptic toxicity was observed in young transgenic mice
overexpressing mutant APP before plaque formation (Mucke et al. 2000).
These data collectively indicated that the soluble Aβ oligomers are involved in the
early stages of the pathogenesis of AD. Three types of Aβ oligomers were identified
in vitro: 1) very short oligomers ranging from dimer to hexamer size (Bitan et al.
2003); 2) Aβ-derived diffusible ligands (ADDLs), small oligomers ranging from 17
to 42 kDa (Lambert et al. 1998); 3) protofibrils, which can be seen on electron
microscopy as short fibril intermediates (Yong et al. 2002). Detailed relationships
between these different oligomers are not clear yet. The diversity and unstable
nature of these Aβ intermediates, however, makes it difficult to identify the specific
species of Aβ oligomers that is responsible for the neurotoxic effects in AD.
1.1.5.2 Intraneuronal Aβ accumulation causes the onset of synaptic dysfunction in
AD
Another important question is: Do Aβ oligomers induce neurotoxicity via an
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intracellular pathway or an extracellular pathway?
Aβ peptides are generated intracellularly at different subcellular sites. Aβ40 is
generated solely in the trans-Golgi network (TGN), whereas Aβ42 is generated in
the endoplasmic reticulum (ER) as well as Golgi compartments (Hartmann et al.
1997; Greenfield et al. 1999). Although much of the intracellularly generated Aβ is
enroute to secretion, there is a significant pool of Aβ peptides which is not secreted.
Stable oligomers of Aβ‚ were initially formed intracellularly in a variety of cell
types, including primary human neurons (Walsh et al. 2000). In a 3XTg-AD mouse
model, which developed an age-dependent accumulation of both plaques and
tangles in disease-relevant brain region (Oddo et al. 2003), earliest cognitive
impairment manifested at 4 months and correlated with the accumulation of
intraneuronal Aβ in the hippocampus and amygdala, before any plaques or tangles
appeared. Clearance of the intraneuronal Aβ by immunotherapy rescued the early
cognitive deficits (Billings et al. 2005).
Taken together, these experiments suggested that deficits in synaptic plasticity,
learning and memory in AD may be induced by the accumulation of both
intracellular and extracellular Aβ oligomers.
1.1.6 Amyloid cascade hypothesis
When all the above data is taken together, this supports a modified version of the
amyloid cascade hypothesis (Golde 2003) (Figure 1.2). Initially, it was proposed
that an imbalance between the production and removal of Aβ leads to its
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progressive accumulation, triggering a series of signaling cascades leading to
synaptic dysfunction and neuronal loss, clinically manifested with memory loss and
impaired cognitive functions (Selkoe 2000). This hypothesis remains valid, except
that soluble Aβ oligomers and intraneuronal Aβ, instead of amyloid plaques, initiate
the cascade leading to neuronal death and dysfunction.
15
Figure 1.2 Schematic illustration of a modified version of the amyloid cascade
hypothesis. This version takes into account the possibility that soluble Aβ oligomers
and intraneuronal Aβ oligomers other than those found in amyloid deposits initiate
the pathological cascade. This a schematic illustration of a hypothetical sequence of
the pathogenetic steps of AD, based on currently available evidence.
Modified from: Golde (2003) J Clin Invest, 111, 11-18
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1.2 Mitochondrial dysfunction and oxidative stress in AD
Although the etiology of AD is still unclear, mitochondrial dysfunction and
oxidative stress have been proposed as underlying mechanisms of disease
pathogenesis in AD. In contrast to amyloid plaques and NFTs, mitochondrial
dysfunction and oxidative stress are two early events in the pathology of AD.
1.2.1 Mitochondria is the major site for ATP production and ROS generation
Mitochondria consist of two lipid membranes: the inner and the outer mitochondrial
membrane (Sherratt 1991). The inner membrane houses the electron transport chain
(ETC) and also covers the mitochondrial matrix, which contains the components of
tricarboxylic acid cycle and β-oxidation. The outer membrane is basically porous,
allowing low-molecular-weight substances to move between the cytosol and the
intermembrane space (Sherratt 1991).
There are several important cellular functions of mitochondria: producing ATP,
generating reactive oxygen species (ROS), regulating intracellular Ca2+, and
releasing proteins that activate the apoptotic pathway.
Mitochondria are the major source of energy for the brain (Ricci et al. 2003).
Mitochondrial ATP is produced via oxidative phosphorylation (Leuner et al. 2007).
Electrons from oxidative substrates are transferred to oxygen, through a series of
oxidation and reduction reactions, to generate water. In the process, protons are
pumped from the matrix across the mitochondrial inner membrane through the ETC
which consists of five membrane-spanning enzyme complexes (Figure 1.3). NAD
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(Nicotinamide adenine dinucleotide)H, is initially oxidized at complex I. The
electrons from NADH are transferred to the first mobile electron acceptor, oxidized
Coenzyme Q (CoQ). CoQ can also accept electrons from complex II donated by
FAD (flavin adenine dinucleotide)H. CoQ donates electrons in the next step to
cytochrome b of complex III. In complex III, electrons are transferred to
cytochrome c1. Cytochrome c1 passes its electron to the second mobile electron
acceptor, cytochrome c. This in turn reduces molecular oxygen to water in complex
IV. The oxidation–reduction reactions are coupled to transfer of protons across the
inner mitochondrial membrane. This proton efflux creates a proton electrochemical
gradient, forming a mitochondrial membrane potential. The mitochondrial
membrane potential is maintained at ～150–180 mV negative to the cytosol and
provides the force that drives an influx of protons and calcium into the
mitochondria. This potential energy is in turn used to phosphorylate ADP to ATP
via complex V (Parker et al. 1994).
An important aspect of ETC is the generation of ROS, which is a physiologically
important by-product of respiration (Reddy and Beal 2005). During the transfer of
electrons to molecular oxygen, an estimated 1–5% of electrons in the ETC divert
their direction and participate in the formation of superoxide radicals (O2-). The
production of mitochondrial O2- occurs at discrete points in the ETC at complexes I,
II and III) (Pollodori et al. 2007) (Figure 1.3).
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Figure 1.3 A schematic model of the energy transfer down the mitochondrial
respiratory chain and ROS generation in mitochondria. The mitochondrial
respiratory chain generates energy through the flow of electrons down the
respiratory chain composed of five complexes. Complexes I, II, and III are involved
in the generation of ROS.
From: Leuner et al. (2007) Antioxid Redox Signa. 9, 1659-1675
The mitochondrial electron transport system is the major intracellular source of
oxygen radicals and H2O2. Paradoxically, mitochondria are one of the major targets
of ROS. ROS can cause oxidative damage to lipids, proteins, and nucleic acids in
the mitochondria (Ricci et al. 2003; Pollodori et al. 2007).
The brain is particularly vulnerable to ROS damage because of its high oxygen
consumption rate, abundant lipid content, and relative paucity of antioxidant
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enzymes compared with other organs (Vera 2005; Pollodori et al. 2007). One of the
main etiologic hypotheses regarding AD is the involvement of free radical–induced
oxidative damage in neuronal degeneration. Impairment of mitochondrial function
leads to ATP reduction and increased free radical generation, which then results in
neurodegeneration and neuron loss in AD (Zhu et al. 2004).
1.2.2 Mitochondria dysfunction and oxidative stress identified in postmortem
tissue of AD patients
Direct evidence of the involvement of mitochondrial dysfunction in AD came from
postmortem studies of AD brain. The alterations of mitochondrial efficiency and
function were mostly related to alterations in concentration and efficiency of the
constituents of the respiratory chain. In the brains of AD patients, there was a mild
generalized reduction of the activity of the electron transport chain complexes (I-IV)
(Parker, Jr. et al. 1994). In a positron emission tomography study (Kessler et al.
1991), a decline in cerebral metabolic rate in parietal and temporal lobes in AD
subjects was observed indicating possible abnormalities in mitochondrial function.
Metabolic defects were present in those at high risk for the disease before
symptoms develop. More interestingly, a correlation was reported between
decreased COX (complex IV) activity and deficits in cognitive abilities (Salmon et
al. 2005).
Several lines of evidences indicated a role of oxidative stress in the pathogenesis of
AD. An elevated level of 4-hydroxynonenal (HNE), a markers for lipid
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peroxidation, was detected in the cortex and hippocampus of patients with AD
compared to control subjects (McGrath et al. 2001). Moreover, increased levels of
oxidized proteins and DNA were observed in brain tissues of AD patients as
compared to age matched, non-demented controls (Lyras et al. 1997).
1.2.3 A causal relationship between Aβ and mitochondrial
dysfunction/oxidative stress
Several in vitro studies demonstrated that Aβ can induce mitochondrial dysfunction
and oxidative stress. Extracellular Aβ treatment led to a significant decrease in
mitochondrial membrane potential and ATP levels in neuronal cell culture (Canevari
et al. 2004). It was also observed that after exposure to Aβ, there was a significant
decrease in mitochondrial respiratory chain enzymatic complexes I, II/III, and IV
activities, with complex IV being the most affected (Canevari et al. 2004).
Intracellular Aβ accumulation was suggested as an early step in the neurotoxicity
cascade of Aβ. APP containing the Swedish mutation (APPsw) resulted in an
overall increase of Aβ including both Aβ40 and Aβ42. PC12 cells bearing the
APPsw exhibited an increased Aβ secretion compared to control PC12 cells. PC12
cells bearing APPsw also displayed mitochondria impairment, including decreased
mitochondrial membrane potential, reduced ATP level, and reduced cytochrome c
oxidase activity (Marques et al. 2003). Using the fluorescence dye DAF-2DA, it
was found that nitric oxide (NO) levels were significantly enhanced in PC12
APPsw cells compared to control cells. DAPT is a functional γ-secretase inhibitor
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which reduces intracellular Aβ production. PC12 APPsw cells treated with DAPT,
exhibited a normalization of NO and ATP levels as well as mitochondrial membrane
potential (Keil et al. 2004).
Evidence from transgenic animal models of AD provided further support that Aβ
accumulation is responsible for the impairment of mitochondria and oxidative stress
observed in AD. For example, Tg2576 mice, an AD transgenic mouse model that
overexpress mutant human APP, developed amyloid plaques and cognitive defects
at 6-7 months of age. Increased H2O2 levels and decreased cytochrome c oxidase
activity were found in 2-month-old Tg2576 mice (Manczak et al. 2006) when
compared with their age-matched non-Tg littermates. More interestingly, a
correlative analysis revealed that soluble Aβ40 and soluble Aβ42 directly correlated
with H2O2 production whereas insoluble Aβ40 and insoluble Aβ42 did not
(Manczak et al. 2006). This result is consistent with the modified amyloid
hypothesis that suggests it is the soluble Aβ oligomers that trigger the pathologic
mechanisms in AD. Findings from immunofluorescent analysis showed the
presence of mitochondrial oxidative DNA damage in 2-month-old Tg2576 mice and
increases in DNA damage corresponding to the stages of disease development in
Tg2576 mice indicating that free radicals generated by overproduction of Aβ may
be responsible for the mitochondrial oxidative DNA damage found in Tg2576 mice
(Manczak et al. 2006).
These data together suggested that intraneuronal Aβ accumulation or extracellular
Aβ oligomers lead to mitochondrial dysfunction and oxidative stress, which in turn,
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results in synaptic dysfunction and ultimately neuron death in AD. However, the
underlying signaling events linking Aβ and abnormalities in mitochondria are
unclear. Both direct and indirect pathways have been proposed to mediate Aβ
induced mitochondrial toxicity.
1.2.4 Mitochondrial Aβ
Emerging evidence suggested that Aβ progressively accumulates in mitochondria
(Manczak et al. 2006). Tg mAPP mice were Tg mice with targeted overexpression
of a mutant human form of amyloid precursor protein (a minigene encoding
hAPP695, 751, and hAPP770 bearing V717/F, K670M, N671L) (Caspersen et al.
2005). Cortical neurons cultured from Tg mAPP mice demonstrated mitochondrial
deposition of Aβ. Aβ was also detected in mitochondria in patients with
Alzheimer’s disease. Furthermore, Aβ was more abundant in the inner
mitochondrial membrane and matrix fractions than in the outer mitochondrial
membrane. The distribution of mitochondrial Aβ appears to parallel that of brain
regions affected by AD-type pathology (Caspersen et al. 2005).
Consequently, there arises the question: How does Aβ gain access to mitochondria?
Whether Aβ is produced in mitochondria or reaches the mitochondria from other
subcellular locations is still unclear.
APP carries a dual leader sequence, permitting targeting to the endoplasmic
reticulum (ER), or to mitochondria (Lin and Beal 2006) (Figure 1.4). In cultured
cells overexpressing APP, using immunoelectron microscopy, immunoreactivity of
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APP was detected in mitochondria. No mitochondrial localization was observed
when the leader sequence was mutated (Lin and Beal 2006; Anandatheerthavarada
et al. 2003; Anandatheerthavarada and Devi 2007). More importantly, studies of
post-mortem brain samples from human Alzheimer’s disease and control subjects
found that full-length and C-terminally-truncated APP was associated with
mitochondria in samples from the brains of individuals with Alzheimer disease, but
not with mitochondria in samples from subjects without the disease. Furthermore,
in brain samples of AD patients, levels of mitochondrial APP were higher in more
affected brain areas and in subjects with more advanced disease (Devi et al. 2006).
These data imply that localization of APP to mitochondria may possibly be an AD
specific process.
Figure 1.4 Mitochondria and Alzheimer disease. Amyloid precursor protein (APP)
has a dual leader sequence, permitting targeting to the endoplasmic reticulum or to
mitochondria. The targeting of APP to mitochondria may be an Alzheimer
disease–specific process: mitochondrial localization of APP occurs only in disease
subjects and only in affected brain areas and mitochondrial APP levels increase
with disease severity.
From: Lin and Beal (2006) Nat Med, 12, 1241-1243
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Active γ-secretase complexes were detected in mitochondria (Hansson et al. 2004).
However, β-APP is incompletely translocated through the mitochondrial outer
membrane. It was suggested that a 22-kDa region (N-terminal) of β-APP is located
inside the mitochondria and that the remaining 73-kDa portion, containing the Aβ
sequence and -secretase cleavage site, is exposed on the cytoplasmic side
(C-terminal). The Aβ sequence and γ-secretase cleavage site have to be in the
transmembrane region for a correct processing by the γ-secretase (Lin and Beal
2006). These data indicated that Aβ may not be generated intramitochondrially.
It was reported that Aβ is generated intracellularly at ER or trans-Golgi network
(TGN) site (Greenfield et al. 1999). Brefeldin A (BFA) is an inhibitor of protein
transport from ER/intermediate compartment. Mitochondrial fractions from Tg
mAPP cortical neurons displayed an immunoreactive Aβ band whereas
mitochondria from non-Tg littermates under the same conditions did not. When
cultured neurons from Tg mAPP mice were incubated with BFA for 16 hours, the
intensity of the immunoreactive Aβ band increased. (Caspersen et al. 2005). These
results suggested that transfer of Aβ from ER to mitochondria may occur in
neurons.
These findings collectively indicated that Aβ peptides can enter the mitochondria
and impair mitochondrial function, which in turn results in overproduction of
reactive oxygen species, eventually leading to neuron loss in AD.
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1.3 Identification of Aβ binding alcohol dehydrogenase, a
mitochondrial receptor for Aβ
Using a yeast two-hybrid system, Yan et al. 1997 identified an intracellular receptor
for Aβ, termed Aβ binding alcohol dehydrogenase (ABAD) (Yan et al. 1997).
ABAD is also named as endoplasmic reticulum amyloid binding protein (ERAB), 3
hydroxyacyl CoA dehydrogenase type 2 (HADH 2), Short chain L 3 hydroxyacyl
CoA dehydrogenase type 2 (SCHAD) and MHBD.
ABAD is a member of the short chain dehydrogenase family. It shares features with
other members of this family, such as the requirement for a dinucleotide cofactor,
NAD(H), and a Rossmanfold structural topology with an invariant sequence,
Tyr-X-XX- Lys, corresponding to residues 168–172 in ABAD, all of which are
required for enzymatic activity. Unique features of ABAD include its presence in
endoplasmic reticulum and mitochondria, its capacity to bind Aβ and promote
Aβ-induced cell stress, and its ability to use a broad array of substrates, including
linear alcohols, 3-hydroxyacyl-CoA derivatives, D-β-hydroxybutyrate, and steroids.
In neurons, ABAD is especially enriched in mitochondria where it appears to serve
important functions in metabolic homeostasis (He et al. 1998).
Expression of ABAD was found to be increased in brains of AD patients compared
to non-demented age matched controls (Yan and Stern 2005). It was proposed that
the interaction of ABAD and Aβ results in mitochondrial dysfunction/oxidative
stress, which account for neurodegeneration and neuron death in AD.
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1.3.1 The physiological functions of ABAD
Although firstly identified as a mitochondrial receptor for Aβ, ABAD is an
important enzyme that is required for regulation of development and maintenance
of homeostasis.
1.3.1.1 Scully/ABAD deficiency in Drosophila
Studies of ABAD deficiency have provided considerable insight into the role of the
enzyme during development and neuronal homeostasis. Inactivation of the
Drosophila counterpart of ABAD, termed scully, resulted in a lethal phenotype with
multiple developmental abnormalities. Certain salient features of the scully/ABAD
deficient flies included mutant testes which were small and undeveloped. The testes
displayed deficiency of 3-hydroxyacyl-coA dehydrogenase activity, indicating that
ABAD is the principal enzyme with such activity in this tissue. Photoreceptor cell
mitochondria appeared smaller, and showed fewer and swollen cristae compared
with neighboring wild-type cells. This mitochondrial phenotype (pleomorphism) is
a typical pathology in humans with inherited β-oxidation deficiencies. (Torroja et
al.1998).
These data together strongly suggested a role of ABAD in fatty acid β-oxidation.
However, considering that fatty acids are not a key energy substrate in the central
nervous system, ABAD clearly has other properties in mammalian systems.
1.3.1.2 ABAD and the metabolism of β-Hydroxybutyrate
The broad enzymatic properties of ABAD as an oxidoreductase suggested that
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ABAD might facilitate cellular utilization of ketone bodies such as
D-β-hydroxybutyrate by promoting the generation of acetyl-CoA to feed into the
tricarboxylic acid cycle. Ketone bodies can reach appreciable concentrations in
normal humans/adult animals during starvation. Under these conditions, the
oxidation of D-β-hydroxybutyrate becomes the dominant source for energy
production in brain. This has led researchers to study a role for ABAD in the
cellular response to nutritional/metabolic stress (Yan and Stern 2005).
A severe form of metabolic stress was induced by cerebral ischemia. Wild-type
mice were subjected to transient middle cerebral artery occlusion and displayed
increased levels of ABAD in neurons near the infarcted area, compared with the
nonischemic hemisphere, using a polyclonal antibody to mouse ABAD.
Immunohistochemical analysis demonstrated an ～ 5-fold increase of ABAD
expression in cortical neurons consequent to stroke indicating the involvement of
ABAD in the cellular response to metabolic stress (Yan et al. 2000).
In vitro studies showed that ABAD promotes utilization of ketone bodies, probably
at the level of D-β-hydroxybutyrate. For example, overexpression of ABAD in COS
cells, which have low endogenous levels of this enzyme, maintained cellular
functions under conditions where D-β-hydroxybutyrate is the principal energetic
substrate. Furthermore, there was an increased flux of acetyl-CoA through the
tricarboxylic acid cycle in ABAD-transfected COS cells (Yan et al. 2000).
A murine stroke model in transgenic mice was employed to determine
consequences of overexpressing ABAD in cortical neurons. ABAD transgenic mice
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displayed a reduction in stroke volume and maintenance of neurologic function.
Overexpression of ABAD in Tg mice was associated with increased flux of acetyl-
CoA through the tricarboxylic acid cycle and increased ATP in cerebral cortex
following infusion of D-β-hydroxybutyrate (Yan et al. 2000). These data indicated
that increased expression of ABAD confers a protective response under metabolic
stress, such as that imposed by ischemia.
Another important piece of evidence came from observations in patients with
methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency. MHBD, which
was identified based on its participation in the catabolism of isoleucine and
branched-chain fatty acids, was found to be identical to ABAD. Patients with
defects in MHBD/ABAD activity showed severe neurologic symptoms, including
psychomotor retardation and progressive infantile neurodegeneration (Chen and
Yan 2007).
Taken together, these data indicated that ABAD might play several important roles
in metabolic homeostasis related to energy metabolism and catabolism of isoleucine
and branched-chain fatty acids.
1.3.2 Pathologic role of ABAD in an Aβ rich environment
Although ABAD seems to protect neurons under metabolic stress, it takes on a
quite different role in cells subjected to an environment rich in Aβ (Yan et al.
1999).
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1.3.2.1 In vitro studies of the Aβ-ABAD interaction
Following exposure to aggregated Aβ, cell stress was increased in neuroblastoma
cells transfected to overexpress ABAD (Canevari et al. 2004; Lustbader et al. 2004).
COS or SK-N-SH cells, which were simultaneously cotransfected with constructs
encoding ABAD and mutant APP, displayed mitochondrial dysfunction, DNA
fragmentation and cell death. Similar cotransfection studies with ABAD mutants
devoid of enzymatic activity did not induce cell toxicity, although the level of
expression of the transfected constructs was comparable (Yan and Stern 2005).
These data suggested that ABAD might contribute to the Aβ induced mitochondrial
dysfunction/oxidative stress.
1.3.2.2 In vivo studies of the Aβ-ABAD interaction
To further investigate the pathologic function of ABAD in an Aβ rich environment,
double transgenic mice overexpressing both ABAD and mutant APP (Tg
mAPP/ABAD) were developed (Lustbader et al. 2004). These double Tg mice
exhibited exaggerated oxidative stress and elevated generation of ROS in
comparison with brains from non-Tg littermates and Tg mAPP, Tg ABAD mice.
Moreover, brains of Tg mAPP/ABAD mice displayed a strong reduction in brain
COX activity by 4 months of age and brain ATP levels were significantly reduced
at 9 months. A ßradial-arm water maze test was used to detect
hippocampal-dependent learning and memory deficits in Tg mice. Young mice (4.5
to 5 months of age) of non-Tg, Tg mAPP, or Tg ABAD transgenic littermates all
showed strong learning and memory capacity. In contrast, Tg mAPP/ABAD mice
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failed to learn efficiently, indicating severe impairment in spatial learning and
memory (Lustbader et al. 2004).
Studies of primary culture neurons from different genotypes found that, after 4 days
in culture, neurons from Tg mAPP/ABAD displayed exaggerated mitochondrial
dysfunction including decreased activity of COX, leakage of ROS, decreased
membrane potential, and diminished ATP. After culturing for 6 days, there was an
increase in caspase-3 like activity and DNA fragentation in Tg mAPP/ABAD mice.
Using lactate dehydrogenase (LDH) assay, it was found that cell viability was
strongly decreased in double transgenic mice. In the presence of antioxidants
including vitamin E and N-acetylcysteine (NAC), increase of caspase-3-like activity,
DNA fragmentation, and loss of cell viability in neurons from Tg mAPP/ABAD
mice were strongly attenuated (Takuma et al. 2005).
1.3.2.3 Colocalization of Aβ and ABAD
Using immunoprecipitation and immunoblotting methods, Aβ-ABAD complexes
were detected in AD brain. Very few Aβ-ABAD complexes were observed in
age-matched non-demented brain. In Tg mAPP and Tg mAPP/ABAD mice brain,
evident Aβ-ABAD complexes were detected whereas non-Tg mice brains displayed
very low levels of Aβ-ABAD complexes. Confocal studies showed that Aβ and
ABAD colocalize in mitochondria matrix in both Tg mAPP/ABAD mice brain and
AD brain (Caspersen et al. 2005). These data together supported the hypothesis that
ABAD and Aβ directly interact in mitochondria in AD, and that this interaction
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promotes leakage of ROS, mitochondrial dysfunction and cell death.
1.3.2.4 Structural analysis of the Aβ-ABAD interaction
The interaction between ABAD and Aβ is highly specific and starts to occur at
nanomolar concentrations. At micromolar concentrations, Aβ, likely in its
oligomeric form, inhibited ABAD enzyme activity (Yan et al. 1999).
Crystal structural studies demonstrated that Aβ inhibits ABAD activity by
preventing NAD binding to the enzyme (Lustbader et al. 2004) (Figure 1.5).
Aβ-bound ABAD displayed substantial distortion of the NAD-binding pocket and
the catalytic triad. The majority of the LD loop, the beginning of the following α
helix, and the latter part of the LF loop of human ABAD were disordered. In the
absence of Aβ, the LF loop was still disordered in the ABAD structure in complex
with NAD, whereas the LD loop region was well ordered. This indicated that Aβ
binding may have influenced the dynamics and conformation of the LD loop.
Subsequent site-directed mutagenesis within and beyond the disordered LD loop
region prevented interaction with Aβ using surface plasmon resonance (Yan et al.
1999; Lustbader et al. 2004). A synthesized peptide encompassing LD loop of
human ABAD [termed ABAD decoy peptide (ABAD-DP)] inhibited binding of
Aβ40 and Aβ42 to immobilized intact ABAD. These data further confirmed that the
LD region alone is sufficient to mediate Aβ-ABAD interaction. To test the effects
of ABAD-DP in cell culture, the cell-membrane transduction domain of the human
immunodeficiency virus-1 (HIV-1) Tat protein was added to ABAD-DP to generate
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Tat-ABAD-DP. Pretreatment of primary cortical neurons with Tat-ABAD-DP
prevented ROS generation and cytochrome C release though the reversed peptide
was without effects (Lustbader et al. 2004).
Based on these data, Yan and Stern 2005 proposed that endogenous levels of
ABAD interacting with the amyloid peptide in an Aβ-rich environment are
sufficient to trigger a series of events ultimately leading to neuronal dysfunction
(Yan and Stern 2005). This hypothesis provides new insight into the initiative
events in the pathogenesis of AD. However, the signaling cascade linking
ABAD-Aβ interaction to mitochondrial dysfunction remains elusive.
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Figure 1.5 Crystal structure of Aβ bound human ABAD (β-Amyloid-binding
alcohol dehydrogenase). (A) A ribbon diagram with labeled secondary structures
and the LD, LE, and LF loops. Helices are shown in green, β strands are shown in
blue, and loops are shown in pink. Disordered regions are shown by dotted lines. (B)
Superposition of Aβ-bound human ABAD (pink) and rat ABAD in complex with
NAD (blue). The LD loop of 3β-hydroxysteroid dehydrogenase (3β-HSD) (PDB
code 1FJH) is shown in yellow. NAD is shown as a stick model with gray for
carbon atoms, red for oxygen atoms, blue for nitrogen atoms, and yellow for
phosphate atoms. The proposed Aβ-binding loop is indicated. (C) Superposition of
the active sites of Aβ-bound human ABAD (pink) and rat ABAD (blue), showing
distortion of the NAD binding site and the catalytic triad S155, K162, and Y168.
Colors are the same as in (B). (D) A section of the crystal packing interactions,
showing the large solvent channels. Each ABAD molecule is shown in a different
color. The ordered ends of the LD loop, residues 94 and 114, are marked as red and
blue balls, respectively, and the hypothetical loops are shown in pink as dotted
lines.
From: Lustbader et al. (2004) Science, 304, 448-452
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1.4 Identification of Endophilin 1 by two dimensional
electrophoresis analysis
To investigate possible signaling events subsequent to ABAD-Aβ interaction,
previous experiments done by Jim Aiton and Margaret Taylor in our laboratory,
studied differential protein expression between different genotypes of mice brain
using a proteomic approach. They identified differential expression of several
proteins such as creatine kinase, peroxiredoxin II and ATP beta subunit, which have
been associated with AD or oxidative stress, between Tg mAPP/ABAD, Tg mAPP,
Tg ABAD, and non-Tg littermates. More interestingly, they found upregulation of
endophilin 1 in Tg mAPP/ABAD and Tg mAPP mice compared to Tg ABAD and
non-Tg animals. Immunoblotting studies with a monoclonal antibody to endophilin
1 further confirmed the result of the proteomic studies. More importantly, they also
found that endophilin 1 is increased in brains of AD sufferers as compared to
age-matched non-demented controls.
1.4.1 Endophilin 1 is a multifunctional protein
Endophilin 1 is a cytoplasmic Src homology 3 (SH3) domain-containing protein. It
is abundantly expressed in the brain and is localized in synaptic terminals (Ringstad
et al. 2001). Endophilin 1 contains an N-terminal domain with predicted α helical
and coiled-coil conformation, the C-terminal SH3 domain and a short hinge region.
Endophilin 1 exists as 80–90 kDa homodimer or heterodimer in rat brain cytosol
and its dimerisation required the coiled-coil region (Reutens and Begley 2002).
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Endophilin 1 plays a critical role in regulating synaptic vesicle formation in the
clathrin-coated vesicle endocytic pathway. It participates in invagination, fission
and vesicle release. The N-terminal portion of endophilin 1 was shown to have
lysophosphatidic acid acyl transferase (LPAAT) activity. Conversion of the
inverted cone-shaped lysophosphatidic acid into cone-shaped phosphatidic acid was
hypothesized to induce positive-to-negative lipid membrane curvature required for
vesicle formation (Schmidt et al. 1999). Through its SH3 domain, endophilin 1 was
reported to interact with the endocytic proteins including synaptojanin 1, dynamin 1,
and the amphiphysins and this interaction is critical for the clathrin-mediated
endocytosis (Micheva et al. 1997; Gat et al. 2000) (Figure 1.6)
Through its interaction with non-endocytic proteins, endophilin 1 also functions in
many non-endocytic pathways. For example, The SH3 domain of endophilin 1
bound to a proline-rich domain in the third intracellular loop of the
G-protein-coupled β1-adrenergic receptor. Overexpression of endophilin 1 led to an
increase of isoproterenol-induced receptor internalization and a decrease of receptor
coupling to the G-protein. The SH3 domain of endophilin 1 also bound to the
Cbl-interacting protein of 85 kDa (CIN85). This complex, when recruited by Cbl,
can influence internalization, degradation and intracellular signaling of tyrosine
kinase receptors for hepatocyte and epidermal growth factor (Reutens and Begley
2002).
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Figure 1.6 Multiple functions of endophilin 1. Endophilin 1 affects the
clathrin-coated vesicle endocytic pathway, at steps from invagination through to
vesicle uncoating. Shown inset are the properties of the N-terminal domain of
endophilin 1 required for endocytosis: binding to lipid bilayers, tubulation and
lysophosphatidic acid acyl transferase activity (LPAAT), which converts
lysophosphatidic acid (LPA) to phosphatidic acid (PA). The SH3 domain interacts
with other endocytic proteins such as dynamin and synaptojanin. Also, the SH3
domain of endophilin 1 modulates signaling pathways by interacting with
non-endocytic proteins including Rat germinal centre kinase-like kinase (rGLK),
metalloprotease disintegrins and G-protein-coupled β1-adrenergic receptor.
From: Reutens and Begley (2002) Int J Biochem Cell Biol, 34, 1173-1177
37
1.4.2 Endophilin 1 regulates GLK induced JNK activation
McPherson‘s group (Department of Neurosurgery and Neurology, McGill
University) screened a rat brain expression library with the SH3 domain of
endophilin 1 and identified rat germinal center kinase like kinase (rGLK) as an
endophilin 1 binding partner. Overlay assays of rat brain extracts revealed
endophilin 1 as a major SH3 domain-binding partner for rGLK (Ramjaun et al.
2001).
GLK is a member of the second class of the Ste20 family of kinases. It is composed
of an N-terminal kinase domain and a C-terminal regulatory domain with multiple
SH3 domain consensus-binding sites. Overexpression of GLK specifically activated
the JNK (c-Jun N-terminal kinase) pathway in HEK293 cells. Furthermore,
expression of dominant-negative forms of MEKK1 and MKK4 inhibited
GLK-induced JNK activation, suggesting that GLK may function upstream of
MEKK1 and MKK4 (Diener et al. 1997).
To determine whether endophilin 1 regulates GLK-mediated JNK activation,
specifically, Ramjaun et al. 2001 evaluated JNK activation using an
anti-phospho-JNK antibody following transfection of HEK293 cells with GLK and
different endophilin 1 constructs. Overexpression of FLAG tagged GLK and FLAG
tagged JNK induced JNK activation. Overexpression of full-length, untagged
endophilin 1 along with FLAG-GLK and FLAG-JNK caused a further increase in
JNK activation versus coexpression of FLAG-GLK and FLAG-JNK in HEK293
cells. In contrast, overexpression of a GFP-tagged form of the SH3 domain of
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endophilin 1(GFP-SH3) or of the untagged N terminus of endophilin 1 lacking the
SH3 domain (delta SH3) along with FLAG-GLK and FLAG-JNK completely
blocked GLK mediated JNK activation (Ramjaun et al. 2001). Together, these data
suggested that endophilin 1 regulates GLK mediated JNK activation in HEK 293
cells.
1.4.3 JNKs in the Central Nervous System
1.4.3.1 JNK is a member of the mitogen-activated protein (MAP) kinase family
Eukaryotic cells respond to external stimuli via signal transduction pathways, many
of which include protein kinases of the mitogen-activated protein (MAP) kinase
family. These pathways are characterized by modules composed of three protein
kinases: MAPKKKs phosphorylate and thereby activate MAPKKs, which in turn
phosphorylate MAPKs. JNK cascade is one of the three major subfamilies of
MAPKs. The others are extracellular signal-regulated kinase (ERK) and p38 (Zhu
et al. 2002).
JNK protein kinases with molecular masses of 46 kDa and 55 kDa are coded for by
3 genes, JNK1, JNK2 and JNK3. JNK1 and JNK2 are ubiquitously expressed in all
tissues whereas JNK3 is predominantly restricted to brain and is expressed in
neurons (Brecht et al. 2005). JNK1 is present as the 46 kDa isoform, JNK2 is
equally expressed as 46 kDa and 54 kDa isoforms, and JNK3 dominates as the 46
kDa isoform. Thus, the 46 kDa proteins comprise all three JNK proteins, whereas
the 54 kDa proteins are mainly restricted to JNK2 (Brecht et al. 2005).
39
JNK is activated by dual phosphorylation of the Thr-Pro-Tyr motif located in the
activation loop by a number of MAPKKs such as MKK (mitogen-activated kinase
kinase) 4 and MKK7. At the MAPKKK level, the JNK activating kinases are more
diverse, including MEKKs (MAPK kinase kinases), MLKs (mixed-lineage kinases),
DLKs (dual leucine-zipper kinases), ASK (activator of S-phase kinase), and TAK
(transforming growth factor β-activated kinase). JNKs and upstream kinases also
interact with scaffold proteins, which have been reported as important regulatory
elements of the JNK pathway including JIP, β-arrestin and JSAP1 (Bossello and
Folorni 2007; Okazawa and Estus 2002). As described in the previous section, in
HEK293 cells, GLK functions upstream of MKK4 and MEKK1 and specifically
activates JNK. Further studies revealed that endophilin 1 regulates GLK mediated
JNK activation (Ramjaun el al. 2001).
1.4.3.2 High basal activity of JNK in the central nervous system
Biochemical analysis revealed a high level of basal JNK activity in the CNS. The
activity of JNK was 10- to 24-fold higher in the neocortex, hippocampus, brainstem,
hypothalamus and amygdala than in peripheral organs (Xu et al. 1997). Western
blot analysis with an antibody specific for JNKs revealed that protein levels of JNK
in most regions of the CNS were similar to those in peripheral organs, indicating
that the high levels of JNK activity in the CNS are not caused by increased JNK
expression (Xu et al. 1997). JNK signaling cascade can be rapidly and strongly
activated throughout the brain by noninvasive stimulation such as physical restraint
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and exploration of a new environment suggesting the possibility that the JNK
cascade plays an important physiological role in the CNS (Xu et al. 1997). JNK1
appears to be the major isoform responsible for the high level of basal JNK activity
in the CNS as deletion of JNK1 markedly reduced the basal JNK activity of the
whole brain lysates (Xu et al. 1997). The physiological functions of JNKs are still
poorly understood.
1.4.3.3 JNK cascade leads to apoptosis via both mitochondrial and transcriptional
pathways
On top of the high basal activity, JNK signaling can be activated by stress or
cytokines, which often leads to apoptosis. An important role of JNK signaling in
stress-induced apoptosis has been demonstrated in the CNS (Kumage et al. 1999;
Brecht et al. 2005). Gene targeting studies showed that JNK3 is an essential
component of the stress induced JNK signaling whereas JNK1 and JNK2 have a
critical role in neural development (Kuan et al. 1999; Kuan et al. 2003). These
results indicated the functional diversity of JNK isoforms and suggested that JNK3
may have a preferential role in stress-induced neuronal apoptosis.
The downstream events of JNK activation leading to apoptosis involve both
mitochondrial and transcriptional mechanisms. For the mitochondrial mechanism,
several studies demonstrated that JNK directly phosphorylates Bim, leading to
activation of Bax/Bak-mediated cytochrome c-release and apoptosis (Dougherty et
al. 2004). Besides Bim, JNK was shown to phosphorylate Bad to trigger the
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mitochondrial cell death pathway. Moreover, evidences also indicated that JNK can
induce the release of another pro-apoptosis factor Smac from the mitochondria
(Aoki et al. 2002).
Upon activation, JNKs translocate into the nucleus to phosphorylate and activate
nuclear transcription factors. Several substrates for JNK have been identified, such
as c-Jun, ATF-2, Elk1, and p53 (Zhang and Zhang 2005). c-Jun is the major
substrate of JNK. Once phosphorylated by JNK, the transcription activity of c-Jun
was increased, leading to upregulation of many genes with AP-1 enhancer
sequences (Ham et al. 2000). Transgenic mice carrying a mutated form of c-Jun
that can no longer be phosphorylated by JNK displayed increased resistance to
glutamate excitotoxicity (Kuan and Burke 2005). These data indicated that the
induction of c-Jun/AP-1-mediated transcription is a major component of the
apoptotic pathway downstream of JNK signaling.
1.4.4 JNK cascade and Alzheimer’s disease
1.4.4.1 Increased JNK activation in the brains of AD patients
Increased activation of JNK has been associated with the pathogenesis of AD. With
a monoclonal anti-activated JNK antibody, immunoblot analysis of cortical brain
homogenates revealed an upregulation of activated JNK in AD compared to
age-matched non-demented control cases (Zhu et al. 2001). Furthermore, an
immunohistochemistry study found that JNK was activated in cerebral neurons of
PS1-linked AD patients. Activated JNK was localized to both neuronal cell bodies
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and neurites around amyloid deposits (Shoji et al. 2000).
Consistent with the in vivo findings, under oxidative stress condition, PC12 cells
overexpressing mutant APP demonstrated significant increase of JNK activation as
compared to cells transfected with control vector plasmid (Marques et al. 2003).
Moreover, exposure of cortical neurons to Aβ peptides resulted in an increase in
JNK activation. Activated JNK was found to activate the c-Jun transcription factor,
which in turn stimulates the transcription of Fas ligand. The binding of Fas ligand
to its receptor Fas induced a cascade of signaling events that eventually lead to cell
death (Morishima et al. 2001).Additionally, intraneuronal Aβ has been reported to
induce JNK activation in neuronal cell cultures (Shouji et al. 2000). These studies
collectively suggested that elevated JNK signaling is associated with AD.
There are two ways through which JNK signaling might be involved in the
pathogenesis of Alzheimer’s disease. First, Aβ peptides activate JNK signaling in
neurons which then lead to cell death. Secondly, JNK may directly phosphorylate
tau leading to the formation of neurofibrillary tangles.
Normally the inactive JNK resides quiescently in the cytosol. After Aβ treatment,
activated JNK translocate into the nucleus and activates transcription factors such
as c-Jun and ATF-2 (Kihiko et al. 1999). Immunoreactivity of activated JNK was
also localized to discrete regions within cytosol after exposure to Aβ and displayed
a punctate distribution (Bosello and Forloni 2007). This may reflect mitochondrial
targeting of JNK or association of JNK with cytosolic substrates such as tau.
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1.4.4.2 Activation of JNK/C-Jun cascade leads to neuron death in AD
Massive neuron loss is a major characteristic in the brains of patients suffering from
AD (Shimohama 2000). Therefore, elucidating the signaling events that underlie
Aβ-mediated induction of cell death should provide insights into the mechanisms of
the pathogenesis of AD.
As stated above, an enhanced activation of JNK was detected in neuronal cultures
after exposure to Aβ. Application of synthetic inhibitors of JNK to these neuronal
cultures protected against Aβ-mediated neuron death (Marques et al. 2003;
Morishima et al. 2001). These observations indicated a causal role for JNK
activation in Aβ-mediated neuron death in CNS.
Phospho-JNK can translocate into the nucleus and activate transcription factors.
c-Jun, a component of transcription factor AP-1, is a major substrate for JNK in the
nucleus. c-Jun immunoreactivity was increased in affected brain areas of patients
with AD and colocalized with TUNEL labeling, an indicator of apoptosis (Marcus
et al. 1998). Neurons from c-Jun null mice showed resistance to Aβ toxicity
(Kihiko et al. 1999). Moreover, in primary neuronal cultures, Aβ induced JNK
activation led to c-Jun activation which eventually results in neuron death via the
Fas signaling cascade (Morishima et al. 2001). These observations indicated a
positive correlation of the activation of the JNK/c-Jun pathway and neuron loss in
AD.
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1.4.4.3 Colocalization of activated JNK and Tau
In AD, NFTs correlate with neuronal loss and clinical symptoms of dementia. NFTs
accumulate over the years in affected brain regions of AD and largely are
comprised of abnormally hyperphosphorylated tau protein (Mckee et al. 1991).
Many kinases have been implicated in tau hyperphosphorylation such as Glycogen
synthase kinase-3 (GSK-3), cyclin dependent kinase-5 (cdk-5), extracellular
signal-regulated kinases and JNK (Crespo-Biel et al. 2007). Unlike other tau
phosphorylation kinases, JNK phosphorylate Thr205 and Ser422 of tau, which are
more highly phosphorylated in Alzheimer tau than in normal adult tau (Sato et al.
2002; Okazawa and Estus 2002).
As noted above, the expression of activated JNK was upregulated in AD. In severe
AD cases, phospho-JNK immunoreactivity was exclusively associated with
cytoplasmic NFTs. However, in mild cases of AD, in addition to neurofibrillary
pathology, immunoreactivity of phospho-JNK was also localized to neuronal nuclei
(Zhu et al. 2001).
These findings together suggested that enhanced JNK activation in AD may be
involved in the phosphorylation of tau, which could contribute to the progress of the
disease.
1.4.4.4 The molecular mechanisms of Aβ induced JNK activation
The precise molecular mechanisms, by which Aβ induces JNK activation and
neuronal apoptosis, especially at early stages, remain to be established. It was
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proposed that reactive oxygen species might mediate Aβ induced neurotoxicity
(Tamagno et al. 1996). Support of this hypothesis came from a study which showed
that JNK was activated in Tg APP mice with extensive oxidative stress but not in
Tg APP mice without oxidative stress (Hensley et al. 1996; Zhu et al. 2004).
Furthermore, an in vitro study showed that Aβ peptides elicited both activation of
JNK as well as apoptosis through simultaneous production of hydrogen peroxide
and HNE (4-hydroxy-2-nonenal ) (Tamagno et al. 1996).
Based on the finding that protein expression level of endophilin 1 was increased in
brains of AD patients and AD transgenic mice models, a novel signaling
mechanism that may mediate Aβ induced JNK activation in AD is proposed (See
Chapter 3). In an Aβ rich enviroment, Aβ-ABAD interaction results in enhanced
expression of endophilin 1, which then stimulates GLK mediated JNK activation
(Figure 1.7).
Figure 1.7 Hypothetic signaling
cascade linking Aβ and ABAD
interaction to neuron death.
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1.5 ABAD-Cyclophilin D interaction
1.5.1 Mitochondrial membrane permeabilization
In addition to its role in Ca2+ homeostasis regulation, ATP and ROS production,
mitochondria also plays a major role in apoptosis induction. Cell death stimuli
induce mitochondrial membrane permeabilization (MMP), upon which, prodeath
proteins sequestered in the inner mitochondrial membrane space are released into
the cytosol (Mattson and Kroemer 2003). For example, cytochrome c is confined to
the mitochondrial intermembrane space preventing it from interacting with
apoptotic-protease-acting factor 1 (Apaf1), a cytosolic protein. Upon
permeabilization, cytochrome C binds to Apaf-1, leading to activation of
pro-caspase-9. Caspase-9 then proteolytically activates caspase-3, one of the
principle proteases that participate in apoptosis pathway. Similarly, Smac/DIABLO
and Omi/HtrA2, two intermembrane proteins, are normally physically separated
from cytosolic inhibitors of apoptosis proteins (IAP), Smac/DIABLO and
Omi/HtrA2 neutralize IAPs, and thus relieve the IAP-mediated inhibition of
caspase-3 and -9 (Norenberg and Rao 2007). MMP is a major event in physiological
as well as pathological cell death. Mitochondrial dysfunction and subsequent
oxidative stress can lead to MMP and cell death (Norenberg and Rao 2007).
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1.5.2 Mitochondria permeability transition
A number of mechanisms have been reported to trigger MMP, one of which has
been proposed to occur by means of the phenomenon of mitochondria permeability
transition (MPT) (Schinzel et al. 2005). MPT is described as an abrupt increase of
inner membrane permeability to solutes with molecular masses of <1,500Da. These
events are caused by the opening of a highly regulated MPT pore (MPTP), which
leads to dissipitation of the mitochondrial membrane potential and an influx of
solutes, causing expansion of the matrix. The latter event may lead to rupture of the
outer mitochondrial membrane and cause cytochrome C release and subsequent
caspase activation, resulting in cell death (Schinzel et al. 2005).
MPTP is a complex which is formed at contact sites between the inner and outer
mitochondrial membranes (Crompton 1999) (Figure 1.8). It is comprised of the
voltage-dependent anion channel (VDAC), the adenine nucleotide translocator
(ANT), and cyclophilin D (CypD) which is the mitochondrial isoform of the
peptidylprolyl cis-trans isomerase cyclophilin chaperone family. ANT is located in
the inner mitochondrial membrane and VDAC in the outer mitochondrial
membrane. CypD can be isolated from the matrix fraction, and generally assumed
to reside in that compartment. Upon oxidative stress or other stimuli for MPT,
CypD are recruited to the ANT, resulting in the formation of MPTP (Norenberg and
Rao 2007).
ANT acts as a regulatory component of the MPTP (Halestrap and Brennerb 2003).
CypD has been postulated to be an essential component of MPTP. An in vitro study
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showed that CypD deficiency protected cells from H2O2 induced cell death. In a
middle cerebral artery occlusion mice model, CypD deficiency was reported to
confer significant protection against ischemic brain injury (Schinzel et al. 2005).
1.5.3 The interaction of ABAD and Cyclophilin D
As stated in section 1.3.1 and 1.3.2, overexpression of ABAD protected cells from
metabolic stress. In contrast, overexpression of ABAD in an Aβ rich environment
accentuated Aβ induced neuron toxicity.
Interestingly, Yan and Stern observed that ABAD binds CypD (unpublished
observation, Yan and Stern, 2004). Therefore, they hypothesized that another
contributor to the beneficial effects of ABAD on cellular functions might be related
to its sequestration of CypD in the mitochondrial matrix. By maintaining the CypD
in the matrix compartment, this chaperone molecule is unable to translocate to the
inner mitochondrial membrane, where it could bind to the ANT and potentially lead
to MPT and neuron death. However, in an Aβ rich environment, the Aβ-ABAD
interaction might displace CypD, resulting in its translocation to the inner
mitochondrial membrane, thereby leading to the induction of MPT (Yan and Stern
2005) (Figure 1.9).
Cyclosporine A (CsA) is an immunosuppressant drug, which interacts with CypD
and inhibits the opening of the MPTP (Mattson and Kroemer 2003). In Tg
mAPP/ABAD neuron cultures, CsA treatment virtually completely suppressed
induction of caspase-3-like activity and DNA fragmentation. A significant
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reduction of neuron death was also observed (Takuma 2005). These data indicated
that the opening of the MPTP is likely to be involved in the cell death pathway of
cultured neurons from Tg mAPP/ABAD mice.
To examine the hypothesis that the interaction of ABAD and CypD protect neurons
from MPT and cell death, FRET (Fluorescence Resonance Energy Transfer) method
was used to study if ABAD interacts with CypD in mitochondria.
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Figure 1.9 A schematic illustration of potential roles of ABAD in physiologic and
pathophysiologic conditions. Under physiological conditions, ABAD-CypD
interaction maintains CypD in the mitochondrial matrix, preventing it to translocate
to the inner membrane of mitochondria. In an Aβ rich environment, ABAD-Aβ
interaction displaces CypD, results in its translocation to the inner membrane of
mitochondria, which leads to the opening of MPTP and cell death. Ψm, inner
mitochondrial membrane potential; MPT, membrane permeability transition pore;
ROS, reactive oxygen species.
From: Yan and Stern (2005) Int J Exp Pathol, 86, 161-171
Figure 1.8 MPTP topology.
The basic unit of the MPTP is
the VDAC-ANT-CypD complex
located at contact sites between
the mitochondrial inner and
outer membranes.
Inner
membrane
Outer
membrane
VDAC ANT
CypD
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1.6 Receptor for advanced glycation end products
It is well established that Aβ accumulation plays a key role in neuronal dysfunction
and neuropathologic changes of Alzheimer’s disease. It has been proposed that,
early in the disease process, low levels of Aβ are recruited to cellular receptors.
Thus, the interaction between Aβ and cellular receptors could contribute
importantly to amplifying Aβ induced neurotoxicity in AD (Yan et al. 2000).
Many cellular receptors have been identified to bind Aβ such as receptor for
advanced glycation end products (RAGE), macrophage scavenger receptors, formyl
peptide receptor-like-1, N-methyl-D-aspartate receptor, α7 nicotinic acetylcholine
receptor, insulin receptor and integrin receptors (Lue et al. 2005; Verdier et al.
2004).
RAGE is the most ubiquitously expressed receptor that binds Aβ. It is expressed by
neurons, microglia, astrocytes, cerebral endothelial cells, pericytes, and smooth
muscle cells (Yan et al. 2000). My PhD focused on studying the involvement of
RAGE in the pathogenesis of AD.
1.6.1 RAGE and its ligands
RAGE is a multi-ligand cell surface receptor in the immunoglobulin superfamily
(Schmidt et al. 2000). It is an integral transmembrane protein composed of 404
amino acids. Full length RAGE contains three immunoglobulin-like domains; an
N-terminal V-type (variable) region, followed by two C-type (constant regions).
The V domain is responsible for ligand binding and contains two putative
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N-glycosylation sites. Deglycosylation was shown to affect RAGE binding of
certain ligands. The transmembrane domain of full-length RAGE is followed by a
short cytoplasmic domain consisting of a sequence of highly-charged amino acids,
which is essential for RAGE-mediated signal transduction. Three major types of
splice isoforms of RAGE have been identified: full-length, C-truncated, and
N-truncated (Ding and Keller 2005). C-truncated RAGE lacks the transmembrane
and cytoplasmic domains and is a secreted protein (sRAGE), whereas N-truncated
RAGE, which lacks the V-type domain and is incapable of binding ligands, is
expressed in the plasma membrane.
RAGE was first indentified as a receptor for advanced glycation end products
(AGEs) (Schmidt et al. 1996). AGEs are post-translational modifications of
proteins that are formed when the amino group of proteins, especially N-terminal
amino groups and side chains of lysine and arginine, react nonenzymatically with
monosaccharides. This leads to protein-bound Amadori products by way of
intermediate Schiff base products. The Amadori products, through oxidation and
dehydration, ultimately lead to irreversible AGEs. The levels of AGEs were shown
to be increased in aging and AD brain (Staniszewska et al. 2005; Takeuchi et al.
2004).
RAGE was identified as an extracellular binding site for Aβ. Binding of both
soluble and fibrillar Aβ preparation to RAGE were observed (Yan et al. 1998).
However, it is difficult to define the exact species of Aβ bound to RAGE since
soluble oligomers are quite prone to fibrillogenesis.
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RAGE also engages other physiologically and pathophysiologically relevant ligands.
S100/Calgranulins are a family of low molecular weight, calcium binding proteins.
Upon binding calcium, these proteins underwent conformational changes allowing
for interaction with target proteins and induce diverse cellular responses. S100
proteins were associated with sites of inflammation and AD-affected regions (Lue et
al. 2005). Amphoterin is a highly conserved, 30kDa polypeptide, which functions
as an inflammatory mediator and act as a marker of necrotic cell damage. In AD
brain, amphoterin levels were significantly increased and localized in amyloid
plaques and activated microglia (Taguchi et al. 2000). RAGE functions as a signal
transduction receptor for both S100 proteins and amphoterin.
1.6.2 Increased expression of RAGE in AD
RAGE expression in brain varies at different stages of life. It is highly expressed in
the embryonic stage and can be colocalized to outgrowing neurites. During the
adult period, levels of RAGE mRNA/protein fall off. However, RAGE expression
levels are increased again during normal aging (Luth et al. 2005).
Several studies demonstrated that RAGE antigen levels are enhanced in
AD-affected regions such as the hippocampus and superior frontal gyrus, compared
to age-matched non-demented controls. In contrast, no differences in RAGE levels
in brain regions that had limited amyloid plaques and NFTs were detected (Sasaki et
al. 2001). Furthermore, immunohistochemistry studies of AD brain revealed that
RAGE overexpressing cells are located in proximity to AD pathology sites. In the
54
hippocampal region of AD brain, there was an increase of RAGE immunoreactivity
in neurons, microglia, and astrocytes. Double immunohistochemistry for RAGE and
an activated microglia marker, MHC II showed that activated microglia clustered at
amyloid plaques displayed the most intense RAGE immunoreactivity (Sasaki et al.
2001). Together, these data implicated that enhanced RAGE expression is
associated with the pathologic changes in AD.
1.6.3 The effects of Aβ-RAGE interaction on neuronal cells
In vitro studies showed that Aβ treatment causes early activation of MAP kinase
pathways and nuclear translocation of nucleofactor kappa B (NF-κB) in neuronal
cultures that overexpress RAGE. At a later time point, activation of caspase 3 was
observed, resulting in induction of apoptotic pathway (Yan et al. 1996). Moreover,
exposure of neuroblastoma cells to aggregated Aβ40/42 resulted in increased
expression of macrophage colony stimulating factor (M-CSF) in a dose-dependent
manner. Increased production of M-CSF antigen was associated with enhanced
expression of M-CSF transcripts and activation of NF-κB. Anti-RAGE IgG and
antioxidant N-acetylcysteine can block M-CSF expression (Yan et al. 1998).
NF-κB is a transcription factor involved in the regulation of several cellular target
genes. In the absence of stimulatory signals, NF-κB resides in the cytoplasm as a
heterodimer by its physical interaction with an inhibitory phosphoprotein, IκB.
Upon stimulation, NF-κB dissociates from IκB and then enters into the nucleus,
where it induces expression of many genes involved in immune and inflammatory
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responses (Widera et al. 2006). This factor is widely expressed in the central
nervous system and is present in both neurons and glial cells, where it could be a
positive regulator of genes whose products mediate a full array of inflammatory
cytokines. Previous experiments showed that NF-κB activation is increased in AD
brains compared with controls (Ferrer and Lopez 2008). Consistent with this
observation in human AD, the level of activated NF-κB was found to be increased
in brains of Tg2576 (described in section 1.2.3) compared with wild-type
littermates, and this increase was associated with amyloid plaques (Townsend and
Pratico 2005).
M-CSF is a neuronal survival and microglial growth and activation factor. M-CSF
released by neurons stimulates its cognate receptor, c-fms on microglia. M-CSF
mediates microglial activation through enhancing cell proliferation and migration,
as well as cell survival (Lue et al. 2005). Increased expression of M-CSF was
observed in neurons near amyloid plaques. Furthermore, M-CSF levels in the
cerebrospinal fluid of patients with AD were elevated ～5 fold and its receptor,
c-fms was also increased in AD brain (Lue et al. 2005).
These data suggested that in neuron cells, binding of Aβ to RAGE leads to
oxidant-mediated activation of NF-κB, followed by increased levels of M-CSF
transcripts and the protein.
1.6.4 The effects of Aβ-RAGE interaction on microglial cells
Exposing human microglia to pre-aggregated Aβ42 resulted in secretion of
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inflammatory cytokines, chemokines including interleukin IL-6,
tumor-necrosis-factor (TNF)-α and monocyte chemoattractant protein-1 (MCP-1),
IL-8, macrophage inflammatory protein (MIP)-1α and M-CSF (Lue et al. 2001).
When human microglia cells were exposed to oligomeric/fibrillar Aβ42 in the
presence of anti-RAGE, Aβ induced M-CSF production was significantly reduced
(Yan et al. 1996). Moreover, in the presence of Aβ42 oligomers, blockade of RAGE
in RAGE-bearing human microglia caused a marked decrease in MCP-1 and TNF-α
secretion (Yan et al. 1998).
These data together indicated that RAGE mediates Aβ induced microglial activation,
and this event may have influence over the course of inflammatory processes in
AD.
There are two salient features of RAGE-dependent signaling. First, RAGE
expression is upregulated in the presence of its ligands, thus ligand-receptor
interaction is prolonged and causes sustained changes of cellular properties. Second,
interaction of ligands with RAGE activates divergent signaling pathways, which, in
many cases, results in the activation of NF-κB. The promoter of the RAGE gene
contains three NF-κB binding sites (Yan et al. 2000). Therefore, as a result of
RAGE-ligand interaction, activation of NF-κB positively regulates RAGE gene
expression. These characteristics of RAGE may possibly underlie the contribution
of the receptor to the pathogenesis of AD. During AD, accumulation of RAGE
ligands leads to an ascending spiral of the receptor-induced inflammatory responses
as a consequence of the positive feedback loops described above.
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1.6.5 Neuropathological characterization of Tg mAPP/RAGE mice
Studies on transgenic animal models have provided important insights into the
involvement of RAGE in cellular dysfunction associated with Aβ. Tg mAPP
animals have been widely used as an animal model for AD. Most of these Tg
models displayed only subtle changes in neuronal function and neuropathology,
especially at early time points. It has been hypothesized that RAGE act as a
cofactor magnifying Aβ-induced cell stress at early stages. Arancio et al. 2004
developed Tg mice with neuronal overexpression of wild-type (WT) RAGE and
double Tg mice with targeted neuronal expression of transgenes for mAPP and
RAGE (Arancio et al. 2004).
The nuclear binding activity of NF-κB was studied by gel shift analysis using
nuclear extracts from cerebral cortex. At 3-4 months of age, Tg mAPP/RAGE mice
displayed a strong gel shift band whereas non-Tg littermates, Tg mAPP and Tg
RAGE displayed no corresponding changes.
In respect to the association of NF-κB activation with inflammation, microgliosis
and astrocytosis in double Tgs and single Tgs were compared. Studies of Tg
mAPP/RAGE at 3-4 and 7-8 months of age did not find a significant increase in
microgliosis or astrocytosis compared with non-Tg littermates or single Tgs.
However, at 14-18 months, double Tgs showed significantly more
plaque-associated reactive microglia and astrocytes. It is possible that the latter
represent an exaggerated secondary inflammatory response to amyloid plaques
(Arancio et al. 2004).
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The perturbation of neuronal function was studied using the radial arm water maze.
At 3-4 months of age, non-Tg littermates showed strong learning and memory
capability. Similar results were obtained with Tg RAGE, as well as Tg mAPP mice.
However, Tg mAPP/RAGE mice displayed impairment of spatial learning and
memory. At 5-6 months, the deficit in learning/memory in Tg mAPP/RAGE was
worse than in younger double Tg animals. A deficit, though less severe, was also
observed in age-matched Tg mAPP mice whereas Tg RAGE and non-Tg littermates
still showed intact spatial memory. Decreased density of cholinergic fibres and
synapses were identified as AD-like pathology. These pathological changes were
found to be temporarily associated with altered spatial learning/memory in young
Tg mAPP/RAGE mice. Taken together, these data suggested that neuronal
dysfunction and neuropathologic changes are accelerated in Tg mAPP/RAGE mice
(Arancio et al. 2004). .
1.6.6 Neuropathological characterization of Tg mAPP/DN-RAGE mice
(Arancio et al. 2004).
To further verify a direct role of RAGE in signal transduction for Aβ induced
cellular perturbation, double Tgs with neuron targeted overexpression of a dominant
negative form of RAGE (DN-RAGE) and mAPP were employed. DN-RAGE is a
truncated form of the receptor with intact extracellular and transmembrane domains,
but a deleted cytosolic tail.
At 3-4 months of age, Tg mAPP/ DN-RAGE displayed a marked decrease of the
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activation of NF-κB compared to Tg mAPP/RAGE mice. Consistently, at the same
time point, Tg mAPP/ DN-RAGE also showed a preserved spatial learning/memory
compared with Tg mAPP/RAGE. Furthermore, at 5-6 months of age, when Tg
mAPP mice displayed a significant deficit in learning/memory, Tg mAPP/
DN-RAGE animal showed a better maintained cognitive function.
Neuropathologic changes, as evaluated by cholinergic-positive fibers in the
subiculum, were virtually completely prevented in Tg mAPP/DN-RAGE mice,
compared with Tg mAPP animals, at both 3-4 and 14-18 months of age.
Together, these data provided further support to the idea that RAGE functions as a
signal transduction receptor mediating neuronal dysfunction in the Aβ-rich
environment provided by the mutant APP transgene.
In summary, these data indicated that increased levels of RAGE in an Aβ-rich
environment promote neuronal dysfunction, even prior to appearance of amyloid
plaques. At later stages, the neuroinflammatory response seems to be accelerated in
Tg mAPP/RAGE animals.
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Chapter 2： Materials and Methods
General chemicals and reagents were obtained from Sigma unless otherwise
indicated. See Appendix 1 for a list of suppliers.
2.1 Molecular Biology Techniques
2.1.1 Polymerase Chain Reaction (PCR)
PCR was performed in a 50 μl reaction volume containing 10 μM of forward and
reverse primers (Invitrogen), 200 μM dNTPs (Promega), 1.25 unit of PfuTurbo
DNA polymerase (Strategene) and 1X PCR buffer (supplied with DNA polymerase)
and 100-200 ng template DNA. Typical PCR conditions were: initial denaturation at
95°C for 10 minutes followed by 30 cycles of 95°C for 45 seconds, 52°C for 45
seconds and 72°C for 1 minute with a final extension of 10 minutes at 72°C.
2.1.2 Restriction enzyme digest
Restriction digestion was performed using restriction enzymes (New England
Biolab) following the manufacture’s instructions. In general, 2 μg plasmid DNA or
PCR products were incubated with 5-10 units of appropriate restriction enzymes in
the appropriate buffer as recommended by the supplier. These reactions were
incubated routinely at 37 °C for 4 hours to insure complete digestion.
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2.1.3 Agarose gel electrophoresis and gel purification
Linearized plasmid DNA, PCR products and DNA fragments produced by
restriction digestion were separated based on molecular weight using agarose gel
electrophoresis. Agarose was melted in tris-borate ethylenediamine-tetraacetic acid
(TBE) buffer and ethidium bromide was added to a final concentration of 0.5 μg/ml
and poured into and set in an AGTI submarine gel casting apparatus unit (VWR).
20% 6X agarose gel loading buffer (50% glycerol, 49.75% TBE, 0.25%
bromophenol blue) were added to the samples. Samples with DNA fragments ≤1kb
were loaded onto 1% (w/v) agarose gels and samples ≥1kb onto 2% (w/v) agarose
gels. For sizing and quantification of DNA, Hyperladder 1 (New England Biolab)
was loaded into the lanes beside the samples. Gel electrophoresis was carried out in
TBE at 60-80V for 30-45 minutes. Analytical gels were visualized with a UV lamp
and photographed by a digital camera (Mitsubishi 85mm lens, Thistle Scientific).
To extract digested DNA fragments and PCR products for ligation reaction, DNA
bands on preparation gels were visualized under a low intensity UV lamp
(230V-50Hz, Ultratec, Ltd.) and then excised from the gel using a sterile scalpel
blade. DNA purification was conducted using the Wizard SV Gel and PCR Cleanup
Kit (Promega) according to the manufacture’s instructions.
2.1.4 Ligation reaction
Ligation of plasmid vector and insert DNA was carried out in a final reaction
volume of 20 μl. Both 1:1 and 1:3 insert/vector molar ratios were used for each
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ligation. 100 ng insert was mixed with appropriate amount of vector and incubated
at 65°С for 5 minutes. The reaction was left on ice to cool down, after which 0.5 μl
T4 DNA ligase (Strategene) and 2 μl ligase buffer (supplied with T4 ligase) were
added and the reaction mixture was incubated for 16-20 hours in a water bath at
16°С. 
2.1.5 Preparation of Competent E. coli Strains (DH5α and BL21)
E. coli strains glycerol stocks (laboratory stocks) were inoculated into 5 ml LB
(Lubria broth) and incubated overnight for 16-20 hours at 37°С by shaking at 
210rpm. Next day, 1 ml overnight culture was diluted in 50 ml LB, grow with
shaking until an OD at 600 nm of 0.3-0.4 was reached. The cells were centrifuged
at 3500g for 10 minutes at 4°С. The supernatant was discarded and the cell pellet 
was resuspended in 20 ml sterile CaCl2 (100 mM), left on ice for 30 minutes. Then
the cells were centrifuged at 1000g for 5 minutes at 4°С. After incubation on ice for 
a further 30 minutes, the cells were used immediately for transformation or
flash-frozen in liquid nitrogen and stored at -80°Сfor future use.
2.1.6 Transformation of Competent E. coli Strains (DH5α and BL21)
1-10 μl of plasmid DNA/ligation reaction was added to 200 μl competent bacteria
and incubated on ice for 30 minutes. The bacteria were heat shocked for 45 seconds
at 42°С and chilled on ice for 2 minutes. 1 ml LB or SOC medium (2% w/v
tryptone, 0.5% bacto-yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10
mM MgSO4, 20 mM glucose) was added to the transformed bacteria and the
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cultures were incubated for 1 hour at 37°C with shaking at 210rpm. 100 μl of the
culture medium were spread onto an agar plate containing the appropriate antibiotic.
The remaining bacteria culture was centrifuged, and the pellet was resuspended in
100 μl culture medium and spread onto a second agar plate. Agar plates were placed
inverted in a 37°С incubator for 16-20 hours, after which single colonies
corresponding to transformants were isolated for screening/inoculation into LB.
2.1.7 Preparation of Glycerol Stocks of Transformed E. coli
Glycerol stocks were prepared from overnight bacterial cultures. 0.6 ml of bacterial
culture was mixed with 0.4 ml of 50% sterile glycerol and frozen at -80°С for future 
use.
2.1.8 Preparation of plasmid DNA
Bacteria were cultured overnight at 37°С in LB supplemented with the appropriate 
antibiotic (ampicillin 50 μg/ml, kanamycin 35 μg/ml). Small-scale preparation of
DNA for analysis, cloning and transfection was carried out using Qiagen’s miniprep
kit according to the manufacturer’s instructions. Large-scale preparation of DNA
for analysis, cloning and transfection was carried out with the Qiagen Endofree
Maxi Kit or the Promega PureYield Midi Prep kit according to manufacturer’s
instructions.
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2.2 Cell culture
All plastic-ware used was from Nunc (VMR) unless otherwise stated. All cells were
cultured in T-75 flasks (80cm3) at 37°С in a humidified atmosphere containing 5% 
CO2.
2.2.1 General cell culture
SK-N-SH human neuroblastoma cells (ATCC) were routinely cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (v/v) foetal
calf serum (FCS) (Globepharm), 2 mM L-glutamine, 100 units/ml of penicillin (pen)
and 0.1 mg/ml streptomycin (strep). Human Embryonic Kidney (HEK293) cells
(Laboratory stocks) were routinely cultured in MEM supplemented with 10% FCS,
5% (v/v) non-essential amino acids (NEAA), 2 mM L-glutamine, 100 units/ml of
pen and 0.1 mg/ml strep. SH-SY-5Y human neuroblastoma stable cell line
overexpressing APP Swedish mutation (Dr Richard Killick, Institute of Psychiatry,
King’s College London) was maintained in the same medium for SK-N-SH cells
with the addition of 500 μg/ml G-418 sulfate (Gibco).
2.2.2 Passage of cell lines
Cells were passaged at 70–80% confluency by washing with 2-3 ml
trypsin/ethylenediaminetetraacetic acid (EDTA) (Gibco) at 37°С for 2-3 minutes.
10 ml of appropriate culture medium was added to the detached cells and they were
then seeded into flasks or petri dishes/coverslips (VWR) at appropriate densities.
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2.2.3 Primary cortical neuron culture
Brains of 14 day mouse embryos were taken and the cortices were removed under a
dissecting microscope. The cortices were placed in a 15 ml tube containing PBS
(Phosphate buffer saline; 0.01 M NaH2PO4, 0.14 M NaCl, pH 7.4) with 25 μl
trypsin (1mg/ml), and incubated at 37°С for 5 minutes. After addition of 10 ml 
Trypsin stop [MEM, 10% FCS and 300 μl DNase (1000 unit/ml)], the tube was
inverted several times and left to settle for 5 minutes. All but ~ 400 μl supernatant
was removed. The cells were triturated 20-30 times with a glass pasteur pipette in
order to dissociate the cells into a single-cell suspension. 5 ml of cortical neuron
medium was added to the cell suspension and the number of cells was counted
using a haemocytometer.
Cortical neurons were cultured in MEM supplemented with 5 mg/ml glucose, 24.5
mM KCl, 2 mM L-glutamine, 25 unit/ml pen, 25 μg/ml strep, 10% FCS and 10%
horse serum (HS). Prior to amyloid beta (Aβ) treatment, cortical neurons were
maintained in serum free medium containing MEM, 24.5 mM KCl, 2 mM
L-glutamine, 25 unit/ml pen, 25 μg /ml strep and 1 mg/ml B27 (Gibco).
2.2.4 Preparation of aggregated Amyloid Beta
1 mM stock solution was made by dissolving 5 mg of Aβ25-35 (Bachem) in 5 ml of
sterile milli-Q purified water (MQ), aliquot and stored at -40°С. Aggregated Aβ was
prepared by mixing an equal amount of sterile PBS to the Aβ25-35 stock solution
and incubating at 37°С for 3 to 5 days. Aggregated Aβ25-35 was then applied to
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cortical neurons at a concentration of 50 μM. Neurons were serum-deprived for 72
hours prior to Aβ treatment.
2.2.5 Transfection of different cell lines
HEK, SK-N-SH and SH-SY-5Y cells were transfected using Genejammer Reagent
(Strategene). Appropriate amount of Genejammer (three times the volume in μl of
Genejammer reagent per 1.0 μg of DNA) was incubated in reduce serum Optimem
TM medium (Gibco) for 5 minutes. The appropriate amount of DNA was added to
the transfection reaction and incubated for a further 10-15 minutes. The standard
culture medium was removed from the culture dishes and replaced with fresh serum
containing medium. The reaction mixture was applied dropwise to the culture
dishes. Four hours later, an equal volume of serum containing medium was added to
the cells. For transient transfections, after 48 hours incubation under standard
growth conditions (i.e., 37°С and 5% CO2 in a humidified incubator), cells were
either harvested for electrophoresis or fixed for immunocytochemistry.
SK-N-SH cells were also transfected with the Amaxa Cell line nucleofector
Solution V following the manufacture’s instructions. A cell suspension containing
2X106 to 3X106 cells was centrifuged at 800g for 10 minutes and the cell pellet was
resuspended in 100 μl nucleofector solution V and mixed with 2-6 μg of DNA
plasmids. The reaction mixture was transferred into an Amaxa cuvette and the
nucleofector program X-05 was selected. Transfected cells were then seeded onto
35 mm petri dishes containing glass coverslips.
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Cortical neurons were transfected using Amaxa mouse neuon nucleofactor kit
according to the manufacture’s protocol. A cell suspension containing 5X106
neurons was centrifuged at 800g for 5 minutes. The supernatant was discarded and
the cell pellet was resuspended in 100 μl nucleofactor reagent. 2 μg of plasmid
DNA was transfected into the cell suspension using program O-05. Transfected
neurons were then seeded onto 35 mm petri dishes pre-coated with poly-D-lysine.
Poly-D-lysine petri dishes were prepared by covering the 35 mm petri dish surface
with 2 ml of 50 μg/ml poly-D-lysine in sterile PBS overnight. The petri dishes were
washed once with sterile MQ before use.
2.2.6 Liquid nitrogen cell stocks preparation and recovery
Liquid nitrogen stored cell stocks were prepared by trypsinizing confluent cultures
and centrifuging the dissociated cells (1000g, 5 minutes, room temperature). Cell
pellets were resuspended in medium containing 50% FCS, 40% normal growth
medium for that cell line and 10% dimethyl sulfoxide (DMSO). 1 ml aliquots were
pipetted into cryotubes, which were brought to -80°С slowly by placing in an acryo 
1°С freezing container (Naglene) in a -80°С freezer overnight. The cryotubes were 
then placed in liquid nitrogen for long term storage. Cell stocks were recovered by
thawing for 1 minute in a water bath at 37°С and placing in a T-75 flask together
with 10 ml pre-warmed culture medium. Media was replaced 24 hours later to
remove DMSO.
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2.3 Fluorescence microscopic analysis
2.3.1 Immunocytochemistry
48 hours after transfection, cells were washed in pre-chilled PBS three times for
five minutes. The cells were fixed in 4% paraformaldehyde (PFA) for 20 minutes at
room temperature, followed by four washes in PBS. Coverslips were mounted onto
glass slides in Mowiol 488(Calbiochem) with Dapi solution [10% (wt/vol) Moviol
488, 1 µg/ml DAPI] and sealed using clear nail varnish. The slides were kept at 4°С
or -20°С prior to confocal microscopy. Fluorescence images were visualized and
recorded using a Leica TCS SP2 Confocal Laser Scanning Microscope (Leica,
Heidelberg, Germany), equipped with a DMIRBE inverted microscope (Leica) with
63X 1.32 NA and 40X 1.25 NA oil immersion HCX Plan Apo objectives.
2.3.2 Fluorescence resonant energy transfer (FRET) analysis
FRET is a phenomenon that occurs when two fluorophores tagged proteins are in
sufficient proximity (<10 nm) and an appropriate relative orientation such that an
excited fluorophore (donor) can transfer its energy to a second, longer-wavelength
fluorophore (acceptor). Thus, excitation of the donor can produce light emission
from the acceptor, with attendant loss of emission from the donor when the two
proteins are in such proximity that they interact with each other. Therefore, FRET
can be used as an assay to detect direct protein–protein interactions in cells. In this
study, enhanced cyan fluorescent protein (ECFP) and enhanced yellow fluorescent
protein (EYFP) were used as one pair of fluorophores for FRET study. Acceptor
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photobleaching method was used to determine FRET in this study. Its principle is
that energy transfer is reduced or eliminated when the acceptor is bleached, thereby
yielding an increase in donor fluorescence.
SK-N-SH cells were transfected with plasmids encoding ECFP or EYFP tagged
proteins. 48 hours after transfection, cells were fixed and mounted in Movial with
Dapi solution. The slides were examined on a Leica Multiphoton confocal laser
scanning microscope system (TCS MP; Leica), which contained 405, 458, 476, 488,
514, 543, and 633 nm laser lines. ECFP and EYFP were excited using 458 and 514
nm laser lines respectively. Detection parameters were optimized to eliminate
crosstalk. ECFP emission was collected at 460-500 nm and EYFP emission was
collected at 525-600 nm.
The FRET analysis was performed using the regulator function of the Leica
Confocal Software Acceptor Photobleach module. Three to four fields with
fluorescent cells on each slide and up to eight regions of interest (ROIs) within each
cell were selected. Pre-bleach images of ECFP and EYFP were captured using 458
and 514 nm lasers at 20% of their full power. For EYFP acceptor photobleaching
experiments, cells were photobleached in the ROIs to approximately 20% of its
prebleach intensity by the 514 nm laser at its full power. Postbleach images were
then captured. FRET efficiency (FRETeff) was calculated using the formula
FRETeff = (Dpost – Dpre)/Dpost where Dpre and Dpost are the fluorescence
intensities of ECFP before and after photobleaching, respectively.
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2.4 Western Blotting
2.4.1 Sample preparation for SDS-PAGE
48 hours after transfection, culture media was removed from cell culture dishes and
washed with pre-chilled PBS twice. To obtain cell extracts, 2X SDS sample buffer
was added to the dishes and the cells were harvested using a cell scraper. 2X SDS
sample buffer is composed of Tris-HCl (62.5 mM, pH6.8), 2% SDS, 10% Glycerol,
50 mM DTT, and 0.01% bromphenol blue. For each 35 mm petri dish, 100-200 μl
2X SDS sample buffer and for each 60 mm petri dish, 500 μl 2X SDS sample buffer
were applied. Cell extracts were sonicated four times for five seconds and left on
ice for 30 minutes. The cell lysates were then centrifuged at 13,000g for 15 minutes
at 4°С. The supernatants were collected and stored at -20°С or -80°С until further 
use.
Mouse cortex was minced in 1 ml pre-chilled radioimmunoprecipitation (RIPA)
buffer, sonicated for six times, each of ten seconds. RIPA buffer contained 10 mM
Tris-HCl, pH8, 50 mM NaCl, 0.5% Na-deoxycholate, 0.2% SDS and 1% Nonidet
P-40. This buffer also contained 1x Protease Inhibitor Cocktail (Roche) and 2 mM
phenylmethylsulfonylfluoride (PMSF). The cortex extract was left on ice for 15
minutes and centrifuged at 13,000g for 15 minutes at 4°С. The supernatant was 
aliquot and frozen at -80°С until assayed.
To prepare cell lysates for detection of activated JNK, SH-SY-5Y cells or cortical
neurons were harvested in kinase buffer containing 20 mM Tris (pH7.5), 150 mM
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NaCl, 1 mM EDTA (pH 7.4), 1 mM EGTA, 10% Triton, 2.5 mM Sodium
pyrophosphate, 1 mM Beta-Glycerolphosphate, 1 mM Sodium orthovanadate, 1
μg/ml Leupeptin, 1X Protease Inhibitor Cocktail and 2 mM PMSF. The cell extracts
were sonicated for four times, each of five seconds, centrifuged at 13,000g for 15
minutes. The supernatants were then stored at -80°С.
2.4.2 Sodium orthovanadate activation
Sodium orthovanadate solution was prepared by adjusting a 200 mM stock solution
to pH 10.0 using either NaOH or HCl as appropriate. The solution was boiled until
colourless and left to cool to room temperature. Adjust pH of this solution back to
10.0 and repeat boiling, cooling and pH adjusting until the solution remained
colourless and stabilized at pH 10.0.
2.4.3 Bradford assay
Protein concentration was determined using Bradford’s reagent. Samples were
diluted in MQ to a final volume of 500 μl, to which 500 μl of Bradford reagent was
added. A series of 0, 2, 4, 8 μg/ml sample of bovine serum albumin (BSA) were
used to make standard curve. Absorbencies were read at 595 nm using a Beckman
DU 530 life science UV spectrometer. The protein concentrations of samples were
calculated based on their absorbencies and dilution fold.
2.4.4 SDS-PAGE
Protein samples were prepared as described in section 2.4.1 and diluted in
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Invitrogen NuPAGE LDS Sample buffer (4X) in the presence of reducing agent.
The samples were boiled for five minutes and loaded onto Invitrogen NuPAGE
Bis-Tris precast gradient (4-12%) polyacrylamide gels together with 5 μl of
SeeBlue Plus2 protein standards (Invitrogen). The proteins were separated by
electrophoresis in a Novex Xcell Mini-cell (Invitrogen) using Invitrogen NuPAGE
morpholineethanesulfonic acid (MES) running buffer (50 mM MES, 50 mM Tris
base, 3.5 mM SDS and 1 mM EDTA). Electrophoresis was conducted at a constant
200volts (V) for 40 minutes. After electrophoresis, protein gels were either
visualized by Coomassie staining or blotted to membranes for immunoreactivity
detection.
2.4.5 Coomassie staining of SDS-PAGE gels
Gels were stained with Coomassie stain solution [0.1% (w/v) Coomassie brilliant
blue R-250, 45% (v/v) ethanol, 10% (v/v) glacial acetic acid)] for 40 minutes at
room temperature. To remove excess Coomassie brilliant blue, the gels were
destained for 3-4 hours or overnight in destaining solution [10% (v/v) glacial acetic
acid, 40% (v/v) methanol] with 3-4 changes of destaining solution.
2.4.6 Western blotting
The SDS-PAGE resolved proteins were transferred onto nitrocellulose membranes
or polyvinylidene difluoride (PVDF) membranes by electroblotting using the
Novex X cell blot module (Invitrogen). Electroblotting was carried out at 30V for
one hour in Invitrogen NuPAGE transfer buffer supplemented with appropriate
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amounts of methanol and antioxidant according to the manufacturer’s instructions.
The efficiency of the transfer was evaluated by staining membranes with Ponceau S
solution [0.1% Ponceau S (w/v), 5% acetic acid)] for three to five minutes at room
temperature. Ponceau was washed off with PBS.
Detailed protocols for different antibodies are described in Appendix 2. In general,
nonspecific binding sites on the membranes were blocked by incubating the blots in
5% non-fat dry milk in TBS/T (Tris buffer saline; 20 mM Tris-HCl, 137mM NaCl,
and 0.1% Tween-20, pH 7.5) at 4ºC overnight. Primary antibodies to specific
proteins were diluted in 5% non-fat dry milk in TBS/T. Blots were washed in
TBS/T and incubated with the primary antibodies for one hour at room temperature.
Primary antibodies were removed by washing the blots three times, for ten minutes
each with TBS/T. The blots were then incubated with HRP-conjugated secondary
antibodies (Santa Cruz) diluted in 5% fat free powdered milk in TBS/T for one hour,
followed by three ten minute washes in TBS/T. All incubations and washes were
done with rocking. Immunoreactive bands were detected using SuperSignal West
Pico enhanced chemiluminescence reagent (ECL, pierce) according to
manufacturer’s instructions. Exposure to Fujifilm (Kodak) was used to measure
chemiluminescence, and exposure time was varied depending on the strength of the
signal.
2.4.7 Removal of Primary and secondary antibodies from a Western blot
The membrane was incubated with 10% glacial acetic acid (v/v) four times for 15
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minutes each. After washing in PBS for 6 times, each of 10 minutes, the membrane
was incubated with primary and secondary antibodies as described in section 2.4.6.
2.5 Two dimensional electrophoresis
All chemicals and reagents used in two dimensional electrophoresis are of
electrophoresis grade and obtained from Amersham-Pharmacia-Biotech. All gels
and electrophoresis instruments used in two dimensional electrophoresis studies
were from Amersham-Pharmacia-Biotech as well.
2.5.1 Preparation of whole-cortex lysate
Wild type and transgenic mice cortices were kindly provided by Prof. Shidu Yan
(College of Physicians and Surgeons, Columbia University). These cortices were
sent on dry ice and immediately stored at -80°С upon arrival. To prepare cortex
lysates for two dimensional electrophoresis, mice cortices were minced in lysis
buffer, sonicated on ice six times for 30 seconds each, with at least 30
second-intervals in between, and left to stand on ice for a further 15 minutes. Two
different lysis buffers were used. One is lysis buffer 1 which contains 8 M Urea, 2
M Thio-Urea, 4% chaps, 1% IPG buffer (pH 3-10), 40 mM Tris base and 100 μl
sigma protease inhibitor. The other is lysis buffer 2 which contains 8 M Urea, 4.5%
chaps, 1% DTT, 2% IPG buffer (pH 3-10), 10 μl of nucleic acid inhibitor, 10 μl
PMSF and 40 μl Roche protease inhibitor cocktail. The lysates were then subjected
to centrifugation at 13,000g, 4°С for 45 minutes. The supernatants were transferred
into clean microcentrifuge tubes and flash frozen in liquid nitrogen for equalization
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of protein content and two dimensional electrophoresis.
2.5.2 Equalization of protein loading
To ensure that equal protein amounts were loaded onto first dimensional isoelectric
focusing (IEF) gels, the samples were pre-run on one-dimensional Bis-Tris 4-12%
polyacrylamide mini-gels and visualized by staining with Coomassie. The
concentrations of proteins were assessed visually and adjusted accordingly. This
method was found to be more reliable than using Bradford assay to determine
protein concentration.
2.5.3 First dimensional electrophoresis-Isoelectric focusing
The first dimensional electrophoresis, isoelectric focusing (IEF), was performed on
either a Multiphor II apparatus or an EtttanTM IPGphor II Isoelectric Focusing Unit.
ImmobilineTM DryStrip gels contain a preformed pH gradient immobilized in
homogenous polyacrylamide (IPG) gels. 18 cm IPG gels with pH gradient 3-10 and
24 cm IPG strips with pH 3-10, 4-7 and 6-9 were used for IEF. The gels are cast on
plastic backing and delivered dried. Prior to IEF, they were rehydrated with
Destreak TM Rehydration Solution.
For IPG strips with pH intervals 3-10 and 4-7, cortex sample was applied by in-gel
rehydration and for basic IPG gels (pH 6-9), paper bridge loading was used.
2% IPG buffer was added corresponding to the pH range of ImmobilineTM
DryStrips to Destreak TM Rehydration Solution. Add 1 mg of protein sample (if
protein sample was loaded with in-gel rehydration) in destreak rehydration solution
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to a final volume of 450 μl, and pipette the solution along the entire length of an
Immobiline Drystrip Rehydration Tray. Place the IPG strips in the reswelling tray
channel gel side down and distribute the rehydration solution evenly by gently
sliding strip over solution. Overlay each strip with a sufficient amount Immobiline
DryStrip Cover Fluid (2 to 3 ml) to completely cover the strip. Allow strips to
rehydrate at room temperature for 20-24 hours.
18 cm IPG strips were focused on a Multiphor II electrophoresis system using a
MultiTemp III Thermostatic Circulator maintaining a constant temperature at 20°C.
The Immobiline DryStrip tray and Immobiline DryStrip aligner were placed onto
the Multiphor II unit and individual rehydrated IPG strips (acidic/pointed end up)
were placed into wells of the DryStrip tray and then the IEF started. Running
conditions are shown in Table 2.1.
Table 2.1 Standard protocols for isoelectric focusing of 18 cm Immobiline DryStrip
gels (pH 3-10) on Multiphor II electrophoresis system. Running conditions:
Temperature 20 °C; current 50 μA per strip.
Step Voltage (V) Time (hour: minute)
Step 1- Gradient 500 V 0:10 or 2 hours
Step 2- Step and Hold 500 V 2:00 or 4 hours
Step 3- Gradient 3500 V 3 hours
Step 4- Step 3500 V 24 or 14-18 hours
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24 cm IPG strips were focused using an EttanTM IPGphor II electrophoresis unit. An
EttanTM IPGphor II Manifold was placed onto EttanTM IPGphor II unit and the IPG
strips were transferred into the Manifold. Moistened electrode pads were placed
onto the ends of the strips. The electrode assembly was positioned over the top of
all the electrode pads. For basic IPG strip, a paper bridge was soaked in the sample
(up to 400 µl) and was placed between the anode electrode pad and the Immobiline
DryStrip. Running conditions were dependent on the pH gradient and the lengths of
the IPG gel strips used (Table 2.2).
Table 2.2 Protocols for running 24 cm Immobiline DryStrip gels with different pH
gradients on Ettan IPGphor II Isoelectric Focusing Unit. Running conditions:
Temperature 20 °C; current 50 μA per strip.
pH
intervals
Step voltage
(mode)
Voltage
(V)
Time
(hour: minute)
pH 3-10 1 Step and hold 500 01:00
2 Gradient 1000 08:00
3 Gradient 8000 03:00
4 Step and hold 8000 2:30-3:45
pH 4-7 1 Step and hold 500 01:00
2 Gradient 1000 07:00
3 Gradient 8000 03:00
4 Step and hold 8000 3:45-5:36
pH 6-9 1 Step and hold 500 01:00
2 Gradient 1000 05:00
3 Gradient 8000 03:00
4 Step and hold 8000 5:36-8:45
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Focused IEF strips were used immediately or stored at −80°C until further use.
Prior to second dimensional electrophoresis, each strip was equilibrated in 15 ml
equilibration buffer containing 50 mM Tris-HCl, pH 8.8, 30% glycerol, 2% SDS,
and 6 M urea with 1% DTT for 15 minutes at room temperature. This is followed
by a second equilibration for 15 minutes using the same buffer, except that DTT
was replaced with 2.5% iodoacetamide to prevent thiol reoxidation.
2.5.4 Second dimensional electrophoresis-SDS PAGE
Second dimensional electrophoresis was performed with either a Hoefer-DALT
apparatus or an Ettan DALT six electrophoresis unit.
For Hoefer-DALT system, 10% SDS polyacrylamide gels (22 × 25cm) [10% , 0.4
M Tris, pH 8.8, 0.1% SDS, 0.1% ammonium persulphate and 0.01% N,N,N_,N_-
tetramethylethylenediamine (TEMED)] were used. Gel solution was prepared in a
vacuum flask, omitting the TEMED and ammonium persulfate. After degassing for
30 minutes, the TEMED and ammonium persulfate were added and the solution
gently swirled to mix, immediately the gels were cast. The gel cassette was filled to
3 to 10 mm below the top. Each gel was overlayed with a layer of water
immediately after pouring to minimize gel exposure to oxygen and to create a flat
gel surface. The gels were left to set for a minimum of two hours. The equilibrated
IPG strips were rinsed and blotted to remove excess equilibration buffer and then
applied onto SDS gels. A low-molecular-weight electrophoresis calibration kit was
used for protein molecular mass (daltons) reference standards (phosphorylase b,
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94,000; bovine serum albumin, 67,000; ovalbumin, 43,000; carbonic anhydrase,
30,000; soybean trypsin inhibitor, 20,100; and α-lactalbumin, 14,400). The markers
were applied to a paper IEF sample application piece in a volume of 15-20 µl. The
application piece was picked up with forceps and applied to the top surface of the
gel next to one end of the IPG strip. 2% low melting point agarose in running buffer
was melted and trace bromphenol was added. The IPG strip was sealed in place
using this solution. The tank was filled with 1X Laemmli SDS electrophoresis
buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS) and the MultiTemp III
temperature controller was adjusted to 15°С. The protein gels were separated at 
200V and 20 mA/gel for 16-20 hours.
For the Ettan DALT electrophoresis system, DALT Gel 12.5 gel, a precast 12%
polyacrylamide gel, was used for the second dimensional electrophoresis. The gel
was inserted into a cassette that allowed it to be run in a vertical mode with liquid
buffers. The gel was used together with the DALT Buffer Kit which contained
concentrated buffers for running the gel, gel buffer for seating the gel in the DALT
Precast Gel Cassette, and sealing solution for attaching the IPG strip to the top of
the slab gel. The anode assembly was inserted into the tank. One bottle of 10X
cathodic buffer was diluted in 800 ml MQ. 37.5 ml of the bottle content 100X
Anode buffer included in the DALT Buffer Kit was added to the tank. After which,
the electrophoresis unit was filled with 4.5 liter of MQ. The MultiTemp III
temperature controller was adjusted to 4°С. A DALT Gel 12.5 was inserted into the 
precast gel cassette. The equilibrated IPG strips were rinsed in the diluted cathodic
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buffer and applied onto DALT gels. Molecular weight marker proteins were applied
along with the IPG gel. For each strip, 2 ml of sealing solution from the buffer kit
was used to seal the IPG strip in place. The cassettes were now placed into the tank.
The upper chamber was filled with 1X cathodic buffer. The gels were separated at
10 V/gel, 2 mA/gel for one hour and then at 15 V/gel, 5 mA/gel for 16-20 hours.
After electrophoresis, the gels were removed from between the glass plates and
visualized by silver staining using PlusOneTM silver staining kit following the
protocols detailed in Table 3. All staining steps were done at room temperature
using high quality (18 megaohm) MQ. Gels were stained in ion staining boxes, with
constant shaking on orbital shaker.
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Table 2.3 Protocol for silver staining of two dimensional electrophoresis gels using
PlusOneTM silver staining kit. Gels were developed in developing solution until
desired intensity was reached. Gels were stored at 4oC in plastic boxes with
preserving solution until further use.
Step Solutions (per gel) Amount Time
Fixation Ethanol
Glacial acetic acid
200ml
50ml
2X60 minutes
Sensitizing
Ethanol
Glutardialdehyde (25% w/v)
Sodium thiosulphate (5% w/v)
Sodium acetate
Make up to 250ml MQ
75ml
1.25ml
10ml
17g
60 minutes
Washing MQ 5X 8minutes
Silver
reaction
Silver nitrate solution (2.5%w/v)
Formaldehyde (37% w/v)
Make up to 250ml with MQ
25ml
0.1ml 60 minute
Washing MQ 4X1 minute
Developing Sodium carbonate
Formaldehyde (37% w/v)
Make up to 250ml MQ
6.25g
200μl 2-3 minutes
Stopping EDTA-Na.2H2O
Make up to 250ml with MQ
3.65g 2X45 minutes
Preserving
solution
20% Ethanol
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2.5.5 Image analysis and protein identification
The images of the silver stained 10% SDS-polyacrylamide gels were captured using
a Typhoon 8,600 fluorescence scanner and were printed onto laser transparent
papers after processing with Adobe Photoshop. Differential protein expression
between different genotypes of mice cortex was analyzed by eye using these gel
images. The protein spots were only identified when the expression levels in all
three gels of the same genotype were different from that in all three gels of another
genotype.
Images of silver stained precast DALT 12.5 gels were captured and digitalized at a
resolution of 600 DPI using a Typhoon 9,200 laser scanner. Protein quantification
on all two dimensional gels was performed using ImageMaster 2D software
(Amersham-Pharmacia-Biotech). Spot features were detected using default and
altered settings. Since some real spots were missed and many extraneous spots were
detected, spots were manually edited. After spot detection, three to five spots
common to all gels and scattered across the area of the gel image were selected as
landmarks for gel-to-gel alignment. The two dimensional gel containing the highest
number of observed protein spots was selected as the reference gel for the
experiment. The remaining 2D gels were matched to the reference gel for spot
identification. On average, >80% of all protein spots on each two dimensional gel
was successfully matched to their respective protein spots on the reference gel. Spot
pairing was manually checked for missed pairs and mismatched spots and was
edited. All de novo protein spots on non-reference gels were added to the reference
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gel image during the matching process. For each protein spot in the reference gel, a
molecular weight (mol wt) was assigned using mol wt standard markers.
Spot quantity was expressed in vol% (volume of a spot / total volume of all the
spots in a gel) to minimize variations caused by staining and destaining procedures.
In this study, for each condition three gels were used for image analysis. The gap
values for each spot, which represents the difference between the lowest spot
volume of three gels in one condition and the highest spot volume from all three
gels in another condition, were calculated by ImageMaster software. If the gap
value is positive, it means that the volumes of the protein spots in these two groups
of gels do not overlap. The protein spots identified with positive gap values were
further analyzed by a two-tailed t test to determine if they were statistically
different using a significance level of 5% (P values<0.05). Differences in protein
densities between two conditions were then visually reconfirmed with ImageMaster
2D software that provided a simultaneous and enlarged display of the protein spot
as it appeared within all two dimensional gels. Identified spots were then excised
and sent for MALDI-TOF analysis in Mass Spectrometry service center at
University of St Andrews.
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Chapter 3: Increased expression of Endophilin 1 leads to
increased activation of JNK
3.1 Introduction
In order to study the underlying biochemical events leading to accelerated/enhanced
cognitive dysfunction and mitochondrial defects in Tg mAPP/ABAD mice (Section
1.3.2.2), Dr Jim Aiton and Margaret Taylor from our laboratory previously
performed two dimensional electrophoresis analysis on four different genotypes of
mice brains (Non-Tg, Tg mAPP, Tg ABAD, Tg mAPP/ABAD). They studied
differential protein expression between the brains of these four genotypes and found
that the antioxidant protein, Peroxiredoxin II protein was consistently up-regulated
in Tg mAPP and Tg mAPP/ABAD mice brains as compared to non-Tg and Tg
ABAD mice brains (Yao et al. 2007). As part of these studies, a second protein was
also found to be upregulated in the Tg mAPP and Tg mAPP/ABAD mice brains as
compared to non-Tg and Tg ABAD mice brains (Figure 3. 1.). This 42 kDa protein
was identified by MALDI-TOF analysis to be endophilin 1 (gene: SH3GL2) (Swiss
Prot Accession No Q62420) which has a predicted molecular weight and isoelectric
point (pI) of 42,000 Da and 5.4 respectively.
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Figure 3.1 Two dimensional gel images of endophilin 1 showing increased level of
protein expression in Tg mAPP and Tg mAPP/ABAD mice brains as compared to
non-Tg and Tg ABAD mice brains (Figure from Dr Peter Coote, Centre for
Biomolecular Science, University of St Andrews).
To confirm the findings from proteomic analysis that endophilin 1 is upregulated in
Tg mAPP and Tg mAPP/ABAD mice brains, Margaret Taylor and Prof ShiDu
Yan’s group (College of Physicians and Surgeons, Columbia University) performed
western blot analysis with an endophilin 1 monoclonal antibody. The intensities of
the immunoblot bands for endophilin 1 were normalized to β-actin signals. A
consistent upregulation of endophilin1 in both the cerebral cortex and hippocampus
of Tg mAPP and Tg mAPP/ABAD mice was found compared with non-Tg mice
(Figure 3.2A and B). Immunocytochemistry confirmed that the expression level of
endophilin 1 was indeed increased in the Tg mAPP/ABAD transgenic animals as
compared to the non-Tg (Figure 3.2C). To assess whether the observed increase in
endophilin 1 expression was relevant in AD, they next screened human brain tissues.
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By western blot analysis (Figure 3.3A) and immunocytochemistry (Figure 3.3B)
again a consistent increase in endophilin 1 expression was observed in the temporal
cortex of AD patients as compared to non-demented age matched controls.
Figure 3.2 Confirmation that endophilin 1 is increased in Tg mAPP/ABAD mice.
Western blot analysis of endophilin 1 and β-actin from hippocampus (A) and
temporal cortex (B) of Tg mAPP/ABAD animals and non-Tg controls. Right panels
of A and B denote the quantification of intensity of all immunoreative bands for
endophilin 1 using NIH image program. N = 3-4 mice per group. (C)
Immunocytochemistry expression of endophilin 1 in cerebral cortex from indicated
transgenic mice. Right panel of C showed intensities of immunostaining for
endophilin 1 by quantification with Universal image program (Figure supplied by
Prof Shi Du Yan, College of Physicians and Surgeons, Columbia University).
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Figure 3.3 Confirmation that endophilin 1 is increased in the brains of AD patients.
(A) Western blot analysis of endophilin 1 and β-actin from hippocampus and
temporal cortex of Alzheimer’s patients and non-demented age matched controls.
Right panel indicates quantification of the intensity of immunoreactive bands for
endophilin 1 by NIH image program. N = 5 per group. (B) Immunocytochemistry
of endophilin I from hippocampus and temporal cortex of Alzheimer’s patient and
non-demented age matched control. Quantification of the intensity of
immunostaining for endophilin I was performed by Universal image program.
(Figure supplied by Prof Shi Du Yan, College of Physicians and Surgeons,
Columbia University).
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3.2 Aims of chapter
Our own and collaborators’ work had indicated that endophilin 1 is up-regulated in
its expression in the AD brain. Increased expression of endophilin 1 has never been
associated with a disease but has been associated with an increase in JNK activity
(Ramjaun et al. 2001). JNK activity itself has been associated with AD (Okazawa
and Estus 2002). Therefore in this chapter, the role of endophilin 1 and JNK activity
in both cell-lines and primary neuronal cultures was explored
3.3 Results
3.3.1 Endophilin 1 regulates GLK mediated JNK activation in HEK293 cells
Initially the experiments performed by Ramjaun et al. 2001 which demonstrated
that endophilin 1 regulates GLK induced JNK activation in HEK293 cells were
repeated (Ramjaun et al. 2001). The level of activated JNK was monitored with an
anti-phospho-JNK antibody.
Plasmids expressing FLAG-GLK, FLAG-JNK, Endophilin 1 full length, Delta SH3
and GFP-SH3 were kindly provided by Prof McPherson (Department of Neurology
and Neurosurgery, McGill University). The FLAG epitope, which is an eight amino
acid peptide (AspTyrLysAspAspAspAspLys), is tagged to the N-terminus of GLK
and JNK respectively for protein expression verification. Since the molecular
weight of FLAG-GLK and FLAG-JNK is 100 kDa and 45 kDa respectively, using
anti-FLAG antibody (Sigma), the expression of both FLAG-GLK and FLAG-JNK
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can be identified. The plasmids expressing endophilin 1 full length and delta SH3
are expressed on a pCDNA3 vector background whilst the GFP-SH3 fusion protein
is expressed on a pEGFPN2 vector background (Figure 3.4 and Figure 3.5).
pEGFPN2 and pEGFPN3 are two plasmids from clontech which encode a
red-shifted variant of wild-type GFP (EGFP) which has been optimized for brighter
fluorescence and higher expression in mammalian cells. (Excitation maximum =
488 nm; emission maximum = 507 nm.). The only difference between these two
plasmids is that in the region of multiple cloning sites immediately before EGFP
sequence, pEGFPN3 has a Xcm 1 site whereas pEGFPN2 contains a Eag 1 site.
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Figure 3.4 The plasmids expressing endophilin 1 full length (A) delta SH3 domain
of endophilin 1 (B) are expressed on a pCDNA3 vector background whilst the
GFP-SH3 fusion protein is expressed on a pEGFPN2 vector background (C).
Figure 3.5 Endophilin 1 constructs used in the experiments, showing full-length
and truncated versions of endophilin 1.
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HEK293 cells were seeded onto 60 mm petri dishes and cultured until reaching
60-80% confluency. The cells were then transfected using the lipofectamine method
(section 2.2.5) with the following combinations of plasmids: 2 μg pEGFPN3 control
vector; 2 μg FLAG-GLK + 2 μg FLAG-JNK; 2 μg FLAG-GLK + 2 μg FLAG-JNK
+ 2 μg Endophilin 1; 2 μg FLAG-GLK + 2 μg FLAG-JNK + 2 μg GFP-SH3
(plasmid encoding for EGFP tagged SH3 domain of endophilin 1). After 48 hours,
the cells were lysed in 2X SDS sample buffer. After sonication and boiling, proteins
were separated on a mini 4-12% Bis-Tris gel. The separated proteins were
transferred to a nitrocellulose membrane. The membrane was blocked with 5%
fat-free dry milk in TBS/T overnight and washed in TBS/T for ten minutes. The
nitrocellulose blot was incubated with phospho-JNK (Thr183/Tyr185) antibodies in
TBS/T+5% fat-free milk for one hour. After three five-minute washes in TBS/T, the
blot was incubated with an HRP-conjugated anti-mouse secondary antibody raised
in goat for one hour. The immunoreactive bands were then detected with ECL
detection reagents and quickly exposed to an autoradiography film. The membrane
was stripped and reprobed with β-actin antibody to control for equal loading. To
confirm similar expression levels of FLAG-JNK, the blot was also stripped and
reprobed again with anti-FLAG antibody. The results shown in Figure 3.6 were
consistent with previous published results: overexpression of GLK and JNK
induced activation of the 46 kDa isoform of JNK and overexpression of endophilin
1 with GLK and JNK led to a further increase of the activation of 46 kDa JNK. In
contrast, overexpression of GFP-SH3 along with GLK and JNK suppressed
activation of 46 kDa JNK.
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EK293 cells were transfected with 2 μg pEGFPN3 control vector (Lane 1),
LAG-GLK + 2 μg FLAG-JNK (Lane 2), 2 μg FLAG-GLK + 2 μg
JNK + 2 μg Endophilin 1 (Lane 3), and 2 μg FLAG-GLK + 2 μg
JNK + 2 μg GFP-SH3 (Lane 4). 48 hours following transfections, the cells
arvested and processed for Western blot analysis. The subsequent blot was
with anti-phospho-JNK 1:2000 and secondary anti-mouse-HRP 1:5000 (A)
n stripped and reprobed for β-actin 1:5000 and secondary anti-mouse-HRP
(B) to control for equal protein loading. To control for similar expression
of FLAG-JNK, the blot was stripped and reprobed again with anti-FLAG
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volvement of endophilin 1 in oxidative stress induced JNK activation
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increased levels of Aβ production (90pg/ml) which is close to the situation in vivo
(Marques et al. 2003). After exposure to H2O2, APPsw PC12 cells displayed an
increase in 46 kDa JNK activation as compared to PC12cells transfected with a
control vector. H2O2 treatment of APPsw PC12 cells evoked phosphorylation of the
46 kDa JNK within two hours and the highest level of phosphorylated JNK was
detected after four hours (Marques et al. 2003). These data collectively indicated
that overexpression of APPsw rendered PC12 cells more sensitive to activation of
the 46 kDa isoform of JNK after exposure to an oxidative stress.
A SH-SY-5Y stable cell line overexpressing APP-Swedish mutation (APPsw
SH-SY-5Y) was a kind gift from Dr Richard Killick (Institute of Psychiatry, King’s
College London). Firstly, it was examined if, as with APPsw PC12 cells, that after
H2O2 treatment, APPsw SH-SY-5Y cells also display a higher expression level of
activated JNK as compared to SH-SY-5Y cells transfected with a control vector
(pEGFPN3).
Following this, the role of endophilin 1 in JNK activation induced by oxidative
stress in APPsw SH-SY-5Y cells was to be studied by transfecting dominant
negative forms of endophilin 1 (DN-endophilin1) including the SH3 domain deleted
form of endophilin 1 (delta SH3) and GFP-SH3 into APPsw SH-SY-5Y cells.
3.3.2.1 H2O2 treatment induces increased JNK activation in APPsw SH-SY-5Y cells
Initially, the effects of H2O2 on the JNK activation pathway in APPsw SH-SY-5Y
cells were studied. SH-SY-5Y cells were transfected with the pEGFPN3 empty
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vector. Transfected SH-SY-5Y cells and untransfected APPsw SH-SY-5Y cells
were seeded onto petri dishes at a density of 2x106 cells/culture dish (60 mm). 48
hours after transfection, cells were treated with H2O2 (freshly prepared solution;
250 µM). Marques et al. 2003 demonstrated that maximal JNK activation was
detected after 4 hours exposure to H2O2 in APPsw PC12 cells, so it was decided to
harvest cells after 4 hours treatment with H2O2. The cells were lysed in 2X SDS
sample buffer and loaded onto a 4-12% mini polyacrylamide gel for electrophoresis
followed by protein transfer to a nitrocellulose membrane. Proteins were visualized
with anti-phospho-JNK antibody as described in section 3.3.1. The membrane was
stripped and reprobed with an antibody to β-actin as an internal loading control.
Similar to the data shown previously, APPsw SH-SY-5Y cells, after 4 hours
exposure to H2O2, exhibited enhanced expression level of activated 46 kDa JNK as
compared to control vector transfected SH-SY-5Y cells (Figure 3.7).
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Figure 3.7 4 hours treatment of H2O2 led to an enhanced activation of 46 kDa JNK
in APPsw SH-SY-5Y cells. SH-SY-5Y cells were transfected with 2 μg pEGFPN3
empty vector (Lane 1 and Lane 3). 48 hours following transfections, SH-SY-5Y
cells (Lane 3) and APPsw SH-SH-5Y cells (Lane 4) were treated with 250 μM
H2O2 for 4 hours. Lane 2 denotes APPsw SH-SY-5Y cells without treatment. The
cells were then harvested in 2X SDS sample buffer and processed for Western blot.
The blot was probed with anti-phospho-JNK 1:2000 and secondary
anti-mouse-HRP 1:5000 (A) and stripped and reprobed for β-actin 1:5000 and
secondary anti-mouse-HRP 1:5000 (B) to control for equal protein loading.
Transfection efficiency is approximately 40–50% in this study. The experiments
were repeated twice.
3.3.2.2 Expression of DN-endophilin1 has no effects on JNK activation
Next, the role of endophilin 1 in oxidative stress induced JNK activation was
studied. If endophilin 1 contributes to the increased JNK activation in APPsw
SH-SY-5Y cells under oxidative stress condition, then expression of DN-endophilin
1 would attenuate JNK activation.
APPsw SH-SY-5Y cells were transfected either with the pEGFPN3 vector or with
GFP-SH3 using the Amaxa nucleofector system according to the protocol detailed
in section 2.2.5. Transfected APPsw SH-SY-5Y cells were cultured for 24 hours
and then subjected to treatment of 250 μM H2O2. 4 hours later, the cells were
Phospho-JNK46 kDa
1 2 3 4A
β-actin42 kDa
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harvested in 2X SDS buffer and loaded onto a 4-12% mini Bis-Tris gel for
electrophoresis and transfer. The blot was subjected to immunodetection of
phosphorylated JNK expression (section 3.3.1). The membrane was striped and
reprobed with β-actin antibody as a control for equal loading. To verify that
GFP-SH3 was transfected and expressed, the blot was stripped again and reprobed
with an anti-GFP antibody. As shown in Figure 3.8, equal amounts of protein were
loaded onto the protein gel. A protein band around 45 kDa corresponding to the
molecular weight of GFP-SH3 was observed in APPsw SH-SY-5Y cells transfected
with GFP-SH3. In two other lanes, as expected, no immunoblot bands around 45
kDa were detected. APPsw SH-SY-5Y showed an increased expression of activated
46 kDa JNK. However, the expression level of activated 46 kDa JNK in GFP-SH3
transfected APPsw SH-SY-5Y cells was comparable with that seen in APPsw
SH-SY-5Y cells transfected with a pEGFPN3 empty vector. Therefore, expression
of GFP-SH3 did not appear to affect the activation of the 46 kDa isoform of JNK in
response to H2O2 treatment (Figure 3.8).
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indicated that endophilin1 is not involved in the elevated JNK activation
SH-SY-5Y cells under oxidative stress condition. However, endophilin 1
had previously been linked to JNK activation via GLK mediated process
et al. 2001). Expression of GLK has been detected in a variety of tissues
rt, kidney and brain. Also, GLK expression has been observed in several
uch as HEK293 and HeLa cell lines (Diener et al. 1997). Expression of
-SY-5Y cells, however, has not been studied yet. Therefore, the reason
ssion of GFP-SH3 had no effects on H2O2 induced JNK activation could
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be because of low or no expression of GLK in SH-SY-5Y cells.
3.3.3 Endophilin 1 regulates Aβ induced JNK activation in cortical neurons
Extracellular Aβ has been reported to induce an enhanced activation of the 46kDa
isoform of JNK in primary cortical neurons. The highest level of JNK activity was
detected after exposure to Aβ for 8 hours (Morishima et al. 2001). Given these
findings, and that GLK is expressed in the brain (Diener et al. 1997), primary
cortical neuronal cultures were used to study if endophilin 1 contributes to
extracellular Aβ induced JNK activation.
3.3.3.1 Aβ peptides induces JNK activation in cortical neurons
Initially, the experiments which showed that treatment of cortical neurons with Aβ
induced an increased activation of 46 kDa JNK were repeated (Morishima et al.
2001). Primary neuronal cultures of embryonic age 14 days (E14) CD1 wild-type
mice were generated following the protocols described in section 2.2.3. E14 cortical
neurons were seeded onto 35 mm petri dishes pre-coated with poly D-lysine at a
density of 500,000 cells per well. 24 hours later, the culture medium was replaced
by serum free medium with B27 supplement. Following a further 72 hours, aged
Aβ25-35 peptides (50 μM), which were prepared according to the protocol
described in section 2.2.4, were added to experimental wells. Since Morishima et al.
2001 showed that maximum JNK activation was detected 8 hours after exposure to
Aβ peptides, neurons were harvested in kinase buffer at 8 hours time point
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following the protocol detailed in section 2.4.1. Protein extracts were quantified
using Bradford method as described in section 2.4.3. Equal amounts of proteins
were loaded onto a 4-12% SDS-PAGE mini gel for electrophoresis. The proteins
were subsequently transferred to a nitrocellulose membrane. The membrane was
then subjected to immunoblot detection of anti-phospho-JNK. To control for equal
loading, the blot was stripped and reprobed again with β-actin antibody. In the
control condition, a 46 kDa phospho-JNK immunoblot band was detected,
demonstrating a basal level of JNK activation. However, in cells treated with Aβ, a
higher expression level of 46 kDa phospho-JNK was observed. Consistent with the
published data, 50 μM of pre-aggregated Aβ resulted in an enhanced activation of
the 46 kDa isoform of JNK at 8 hours time point (Figure 3.9).
Figure 3.9 Aβ induced elevated JNK activation (46 kDa) in cortical neurons.
Untreated cortical neurons (Lane 1) and cortical neurons (Lane 2) which were
exposed to pre-aggregated Aβ25-35 (50 μM) for 8 hours, were harvested in kinase
buffer. The proteins were loaded onto a mini 4-12% Bis-Tris gel and transferred to
a nitrocellulose membrane. The membrane was probed with anti-phospho-JNK
1:2000 and secondary anti-mouse-HRP 1:5000 (A) and stripped and reprobed for
β-actin 1:5000 and secondary anti-mouse-HRP 1:5000 (B) to control for equal
protein loading. Transfection efficiency is approximately 30–40% in this study. The
experiments were repeated for five times.
46 kDa Phospho-JNK
1 2
A
B
42 kDa β-actin
1 2
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3.3.3.2 The role of endophilin 1 in Aβ induced JNK activation
Having successfully demonstrated that Aβ induced increased JNK activation in
primary cortical neurons, the next question was: is endophilin 1 involved in the
JNK activation pathway induced by Aβ? To answer this question, the effects of
overexpression of endophilin 1 and two forms of DN-endophilin 1 (the GFP-SH3
and delta SH3 constructs) on Aβ induced JNK activation were studied. If, as in
HEK293 cells, endophilin 1 plays a regulating role in JNK activation, then in
cortical neurons, overexpression of endophilin 1 will lead to an increase in the level
of activated JNK, whereas expression of DN-endophilin 1 will attenuate Aβ
induced JNK activation. In this study, using the immunoblotting method, the level
of activated JNK was monitored with anti-phospho-JNK antibody whilst the total
expression level of JNK was evaluated using an anti-JNK monoclonal antibody.
Since endophilin 1 and delta SH3 are expressed in pCDNA3 vector and GFPSH3 is
expressed in pEGFPN2 vector, cortical neurons were transfected with pCDNA3 and
pEGFPN3 empty vectors as controls. To investigate the function of endophilin 1 in
Aβ induced JNK activation, E14 neuronal cultures were transfected with endophilin
1 or the two forms of DN-endophilin 1, GFP-SH3 and delta SH3.
4X106 neurons were nucleofected with 2 μg DNA (pEGFPN3, pCDNA3,
endophilin 1 full length, delta SH3, GFP-SH3) using the Amaxa mouse neuron
nucleofector kit according to the protocol described in section 2.2.5. Transfected
neurons were then seeded onto 35 mm poly D-lysine coated petri dishes at a density
of 1X106 neurons per well. 24 hours later, culture medium was replaced by serum
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free medium with B27 supplement. Following a further 72 hours, aged Aβ peptides
were added to experimental wells at a concentration of 50 μM. 8 hours after Aβ
treatment, neurons were harvested in kinase buffer (section 2.4.1.), sonicated for
four times, five seconds each and then centrifuged for 15 minutes at 13,000 rpm,
4°С. The protein concentrations of the supernatants were determined using
Bradford assay (Section 2.4.3). Equal amounts of lysate proteins were run on a
4-12% precast Bis-Tris gel and transferred to a nitrocellulose membrane. The
nitrocellulose blot was blocked with 3% BSA in TBS/T for one hour and then
incubated with primary antibody anti-phospho-specific-JNK in TBS/T containing
3% BSA at 4°С overnight. After three five-minute washes in TBS/T, the blot was
incubated with secondary antibody anti-mouse HRP for one hour. The blot was then
washed in TBS/T for three times, five minutes of each, and subjected to ECL
reagents for immune-reactivity detection. The membrane was stripped and reprobed
with anti-JNK antibody following the same protocol for phospho-JNK antibody
apart from that secondary antibody anti-rabbit HRP was used instead of anti-mouse
HRP (Figure 3.10).
Each experiment was repeated three times using different animal tissues. The
intensities of the immunoblot bands for all three experiments were quantified using
ImageJ software. To control for internal variation, the levels of the phospho-JNK
bands were normalized to corresponding total 46 kDa JNK expression levels. The
results of the normalized expression of phospho-JNK under different conditions are
expressed as means ± S.E.M. from three independent experiments and summarized
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in Table 3.1. Statistical test was performed using student’s t test. A significance
level at p<0.05 was used. The P values for each comparison between different
conditions are displayed in Table 3.2.
In the absence of Aβ, cortical neurons overexpressing endophilin 1 exhibited a
significant increase in the activation of the 46 kDa JNK as assessed by normalized
expression of phospho-JNK compared to neurons transfected with a pEGFPN3
empty vector or a pCDNA3 empty vector. 8 hours of Aβ treatment caused an
elevated activation of the 46 kDa isoform of JNK in neurons transfected with
pEGFPN3 empty vector or pCDNA3 empty vector. After Aβ treatment, JNK
activation in cells transfected with endophilin 1 was also significantly increased
compared to neurons transfected with pEGFPN3 empty vector or pCDNA3 empty
vector without Aβ treatment. However, in the presence of Aβ, the level of activated
46 kDa JNK in neurons transfected with endophilin 1 was comparable with that in
cells transfected with pEGFPN3 or pCDNA3 vectors. In contrast, expression of
GFP-SH3 and delta SH3 markedly abolished JNK activation (46 kDa) in cortical
neurons (Figure 3.10).
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Figure 3.10 The role of endophilin 1 in Aβ induced JNK activation in cortical
neurons. Western blotting analysis was performed using anti-phospho-JNK and
anti-JNK antibodies for the analysis of activated JNK and total JNK expression.
Cortical neurons were transfected with pEGFPN3 (Lane 1 and Lane 4), pCDNA3
(Lane 2 and Lane 5), endophilin 1 (Lane 3 and Lane 6), GFP-SH3 (Lane 7), and
delta SH3 (Lane 8). 4 days after transfection, neurons were treated with 50 μM
pre-aggregated Aβ for 8 hours (Lane 4, 5, 6, 7, and 8). The cells were then
harvested in kinase buffer. Equal amounts of proteins for each sample were loaded
onto a 4-12% Bis-Tris mini gel for electrophoresis and immunoblotting. The blot
was subjected to immunodetecton with anti-phospho-JNK (A). The blot was
stripped and reprobed with anti-JNK to assess total JNK expression level (B).
Representative Western blotting images are shown from three independent
observations. (C) Immunoblott bands were quantified using ImageJ software.
Normalized expression of phosphor-JNK was compared between different
conditions. Results are expressed as means ± S.E.M. Without Aβ, neurons
transfected with endophilin 1 exhibited an enhanced expression level of
phospho-JNK compared to EGFPN3 and pCDNA3 transfected cells. Aβ evoked an
enhanced expression of activated JNK in neurons transfected with EGFPN3 or
pCDNA3. After Aβ treatment, overexpression of endophilin 1 also displayed a
B
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significant increase in JNK activation compared to cells transfected with EGFPN3
vector or pCDNA3 vector without Aβ treatment. However, after Aβ treatment, the
expression of activated JNK in neurons transfected with endophilin 1, neurons
transfected with EGFPN3 and neurons transfected with pCDNA3 was comparable.
In contrast, the expression of phospho-JNK was markedly reduced in neurons
transfected with GFP-SH3 or delta SH3. Transfection efficiency is approximately
30–40% in this study.
Table 3.1 Immunoblot bands were quantified using ImageJ software. Results are
expressed as normalized expression of phospho-JNK. Values displayed are means ±
S.E.M.
EGFPN3 0.16 ± 0.13
pCDNA3 0.56 ± 0.09
Endophilin 1 0.90 ± 0.08
EGFPN3+Aβ 1.46 ± 0.22
pCDNA3+Aβ 1.15 ± 0.08
Endophilin 1+Aβ 1.43 ± 0.08
GFP-SH3+Aβ 0.50 ± 0.08
Delta-SH3+ Aβ 0.16 ± 0.04
Relative expression of phospho-JNK
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Table 3.2 Student’s t test was used to analyze statistical significance between two
different conditions. The P values for all comparisons are summarized in Table 3.2.
3.3.3.3 The involvement of endophilin 1 in Aβ induced apoptosis
Increased JNK activation triggered by Aβ has been associated with cell death.
Overexpression of several dominant negative forms of JNK has been reported to
increase cell viability significantly (Marques et al. 2003; Morishima et al. 2001).
Data in section 3.3.3.2 showed that expression of endophilin 1 caused an increase in
JNK activation whereas overexpression of two dominant negative forms of
endophilin 1 significantly reduced Aβ induced JNK activation. Based on these data,
it was proposed that overexpression of endophilin 1 can cause JNK activation,
which in turn results in increased cell death. In contrast, expression of two forms of
DN-endophilin 1 can attenuate JNK activation and thus increase cell viability. To
test this hypothesis, in collaboration with Dr Fleur Davey from our group, cell
survival assays were performed to study if endophilin 1 is involved in Aβ induced
cell death.
Endophilin 1 EGFPN3+Aβ pCDNA3+Aβ Endophilin1+Aβ
EGFPN3 P=0.025 P=0.0031 P=0.00059
pCDNA3 P=0.04 P=0.0036 P=0.001
GFP-SH3+Aβ P=0.003 P=0.0002
Delta-SH3+Aβ P<0.0001 P<0.0001
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E14 cortical neurons were transfected with 2 μg each of pEGFPN3, pCDNA3,
endophilin 1, GFP-SH3 or delta SH3 constructs respectively. Transfected cells were
then seeded onto poly-D-lysine coated 96 well plates at a density of 200 cells per
well. After 24 hours, cell medium was replaced with serum free medium. The
neurons were serum starved for 72 hours, upon which time points, 50 μM of
pre-aggregated Aβ25-35 peptides were applied. 24 hours after Aβ treatment, cells
were fixed and DAPI stained. The total number of live cells (as assessed by DAPI
staining) per well at the completion of the trial, was counted. Each experiment was
performed three times. In each experiment, control and Aβ treated cultures were set
up in triplicate.
The numbers of viable cells under different conditions are summarized in Table 3.3.
Results are expressed as means ± S.E.M. from three independent experiments.
Statistical significance was analyzed using student’s t test. The P values for each
comparison made between different conditions are shown in Table 3.4.
Overexpression of endophilin 1 in cortical neurons significantly reduced cell
viability as compared with neurons transfected with control vectors (pEGFPN3 or
pCDNA3). After 24 hours treatment of Aβ, neurons transfected with endophilin 1,
pEGFPN3, or pCDNA3 all exhibited a marked decrease of cell viability compared
to cells transfected with pEGFPN3 or pCDNA3 without Aβ treatment. However,
after Aβ treatment, no significant difference in cell viability between neurons
transfected with endophilin 1, EGFPN3, or pCDNA3 was detected. In contrast,
after exposure to Aβ for 24 hours, neurons expressing GFP-SH3 or delta SH3
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displayed a significantly enhanced cell number as compared with cells transfected
with endophilin 1, pEGFPN3, or pCDNA3 (Figure 3.11).
Figure 3.11 The role of endophilin 1 in Aβ induced neuron death. Cortical neurons
were transfected with pEGFPN3, pCDNA3, endophilin 1, GFP-SH3 or delta SH3. 4
days after transfection, neurons were treated with 50 μM pre-aggregated Aβ for 24
hours. Total number of live neurons counted by DAPI-stained nuclei is expressed as
means ± S.E.M. and analyzed using student’s t test. Significance level was set at
p<0.05. Overexpression of endophilin 1 without Aβ induced decreased viable
neuron numbers. For neurons transfected with pEGFPN3, pCDNA3 and endophilin
1, 24 hours treatment of Aβ led to a significant decrease of neuron viability. In
contrast, expression of GFP-SH3 or delta SH3 protected neurons from Aβ induced
cell death. Transfection efficiency is approximately 30–40% in this study.
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Table 3.3 The numbers of viable neurons under different conditions. Values are
expressed as means ± S.E.M.
Table 3.4 The statistical difference between different conditions was analyzed
using student’s t test. The P values for each comparison are summarized in Table
3.4.
pEGFPN3 174 ± 22
pCDNA3 185 ± 24
Endophilin 1 127 ± 8
pEGFPN3+Aβ 103 ± 20
pCDNA3+Aβ 107 ± 18
Endophilin 1+Aβ 97 ± 17
GFP-SH3+Aβ 133 ± 14
Delta-SH3+Aβ 146 ± 19
Endophilin 1 EGFPN3+Aβ pCDNA3+Aβ Endophilin 1+Aβ
pEGFPN3 P=0.007 P=0.0004 P=0.0001
pCDNA3 P=0.003 P=0.0001 P<0.0001
GFP-SH3+Aβ P=0.024 P=0.006
Delta-SH3+Aβ P=0.009 P=0.002
Number of viable neurons per well
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3.4 Discussion
3.4.1 ABAD-Aβ interaction causes an increase in the expression of endophilin 1
Two dimensional electrophoresis analysis of cortex from different genotypes of
mice revealed that endophilin 1 was upregulated in Tg mAPP and Tg mAPP/ABAD
mice as compared to non-Tg littermates and Tg ABAD mice. Using Western
blotting, the proteomic results were confirmed. Furthermore, expression of
endophilin 1 was also found to be increased in the brains of AD patients as
compared to age matched non-demented control brain tissues.
3.4.2 Endophilin 1 is involved in Aβ induced JNK activation pathway
Endophilin 1 has been reported to regulate GLK mediated JNK activation (Ramjaun
et al. 2001). To examine if endophilin 1 induced JNK activation cascade is involved
in the pathogenesis of AD, two in vitro models of AD were used.
The first model was a stable SH-SY-5Y cell line overexpressing APP Swedish
mutation (APPsw SH-SY-5Y). Oxidative stress induced an increased expression of
activated 46 kDa JNK in APPsw SH-SY-5Y cells compared to SH-SY-5Y cells
transfected with a control vector (Figure 3.7). To examine if endophilin 1
contributes to the increased JNK activation in APPsw SH-SY-5Y cells under
oxidative stress condition, APPsw SH-SY-5Y cells were transfected with GFP-SH3,
a dominant negative form of endophilin 1. There were no differences in the
expression level of activated JNK between APPsw SH-SY-5Y cells transfected with
GFP-SH3 and APPsw SH-SY-5Y cells transfected with a pEGFPN3 control vector
112
after H2O2 treatment (Figure 3.8). Therefore, expression of GFP-SH3 did not affect
H2O2 induced JNK activation in APPsw SH-SY-5Y cells. It is possible that none or
very low level of GLK expression in SH-SY-5Y cells is responsible for this result.
GLK expression has been detected in brain tissue (Diener et al. 1997). Moreover,
extracellular Aβ has been shown to cause elevated JNK activation in primary
cortical neurons (Morishima et al. 2001). Therefore, E14 mice cortical neuronal
cultures were used as the second in vitro model. Application of aggregated Aβ
induced elevated 46kDa JNK activation and cell death in primary mouse cortical
neurons. In the absence of Aβ treatment, there was an increase in the expression
level of phospho-JNK in mouse cortical neurons transfected with endophilin 1
compared to cortical neurons transfected with control vectors. Expression of
DN-endophilin 1, including delta SH3 and GFP-SH3, however, led to a significant
reduction of Aβ induced JNK activation (Figure 3.10). Cortical neurons
overexpressing endophilin 1 showed exaggerated cell death as compared to cortical
neurons transfected with control vectors. In contrast, expression of GFP-SH3 and
delta SH3 in cortical neurons protected neurons from Aβ induced cell death (Figure
3.11).
These results suggested that endophilin 1 expression can regulate the JNK cascade
and thus contribute to the increased JNK activation and cell death in cortical
neurons after Aβ treatment. Thus, the increased expression of endophilin 1 may be
partially responsible for the increased JNK activation and neuron death in AD.
The exact isoform of JNK responsible for the increased activation after exposure to
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Aβ peptides remains to be established. Aβ induced increased activation of the 46
kDa isoform of JNK in cortical neuronal culture whereas in AD, both 46 kDa and
54 kDa isoforms of JNK were increased as compared to non-demented controls
(Zhu et al. 2001). One study showed that JNK3 null mice displayed a significant
reduction of Aβ induced apoptosis in cortical neurons. However, the Aβ induced
neurotoxicity was not completely abolished in cortical neurons indicating that JNK1
and JNK2 may also be involved (Morishima et al. 2001).
3.4.3 Multiple functions of Endophilin 1
This is the first report demonstrating that endophilin 1 is associated with
Alzheimer’s disease. Endophilin 1 is a multifunctional protein. It is involved in
synaptic vesicle formation by binding to other endocytic proteins such as
synaptojanin and dynamin through its SH3 domains (Reutens and Begley 2002).
Endophilin 1 can also affect intracellular biochemical events via complexing with
signaling molecules such as CIN85 and G-protein-coupled β1-adrenergic receptor
(section 1.4.1).
Endophilin 1 has been reported to regulate GLK-mediated JNK activation
(Ramjaun et al. 2001). In this study, endophilin 1 induced JNK activation signalling
cascade was shown to be involved in the pathogenesis of AD. Several of the other
functions of endophilin 1 may also be involved in the pathogenesis of AD. For
example, endophilin 1 can bind to SH3-domain GRB2-like (endophilin) interacting
protein 1, which has been identified as a neuronal protein that regulates energy
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balance (Trevaskis et al. 2005). A change in the overall energy balance is known to
be an important factor in the pathogenesis of Tg mAPP/ABAD animals and also in
patients with Alzheimer’s disease (Takuma et al. 2005). Furthermore, endophilin 1
has been reported to increase the production of Aβ (Schobel et al. 2006).
3.4.4 Blocking the interaction of Aβ with ABAD can reverse the expression
level of endophilin 1
Structural studies of ABAD indicated that residues 94-114 of ABAD interact with
Aβ (Powell et al. 2000). A peptide spanning this region of ABAD inhibited
ABAD-Aβ interaction in vitro and protected primary neuronal cultures from
Aβ-induced cytotoxicity. This peptide had been modified further by the addition of
the cell membrane transduction domain of the human immunodeficiency virus-type
1 Tat protein fused with a mitochondrial matrix protein targeting sequence to
produce Tat-mito-ABAD-DP (Lustbader et al. 2004). This chimeric peptide was
then used in living animals by intra-peritoneal injection which leads to a subsequent
improvement in the transgenic animals learning and memory (Yao et al. 2007).
Therefore, in a subsequent experiment to determine whether endophilin 1
expression is directly due to Aβ-ABAD interaction, Prof ShiDu Yan’s group
(College of Physicians and Surgeons, Columbia University) injected
intra-peritoneally either the forward (Tat-mito-ABAD-DP) or the reverse peptides
(Tat-mito-ABAD-RP) into Tg mAPP/ABAD animals. Western blot analysis of the
proteins from hippocampus of Tg mAPP/ABAD animals of 6 months of age,
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showed a significant increase in the expression level of endophilin 1 as compared to
non-Tg animals using β-actin as control. Tg mAPP/ABAD animals treated with the
reverse peptide (Tat-mito-ABAD-RP) also showed an elevated level of endophilin 1.
However, in those animals that were treated with Tat-mito-ABAD-DP, the
expression of endophilin 1 was significantly decreased (Figure 3.12). These data
indicated that the increased expression of endophilin 1 is a result of the interaction
of  Aβ and ABAD.
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Figure 3.12 (A) The increased expression of endophilin 1 can be reversed by the
intra-peritoneal injection in Tg mAPP/ABAD animals of a Tat-mito-ABAD peptide
(Tat-mito-ABAD-DP) but not a reverse peptide (Tat-mito-ABAD-RP). Tg mAPP
/ABAD mice and non-Tg at the age of 6 months daily received either
Tat-mito-ABAD-DP (80 µg) or Tat-mito-ABAD-RP (80 µg) via intra-peritoneal
injection for two weeks. The treated mice were then sacrificed and rapidly removed
the brains. The hippocampus was subjected to Western blot analysis. (B)
Quantification of the reversal of endophilin 1 of several experiments (n = 3-5)
showing that the administration of ABAD-DP reduces expression level of
endophilin 1 back to normal levels. The statistical test was analyzed by ANOVA
using STATVIEW program (Figure supplied by Prof Shi Du Yan, College of
Physicians and Surgeons, Columbia University).
A
B
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3.5 Conclusion
Elucidating the signaling pathways that underlie neuronal responses to Aβ can help
developing novel neuroprotective therapeutic strategies. The above study
demonstrated that ABAD-Aβ interaction can lead to an increase of the expression
of endophilin 1 in the CNS, which then stimulates GLK mediated JNK activation
(Figure 3.13). An increased activation of the JNK cascade has been observed in
brains of patients with AD. Enhanced JNK activation in AD has been proposed to
lead to neuron death and tau phosphorylation (section 1.4.4.2 and 1.4.4.3).
Therefore, pharmacological inhibitors of endophilin 1 may offer neuroprotection in
Alzheimer’s disease.
Figure 3.13 A hypothetical sequence of signaling events in AD. In an Aβ rich
environment, The ABAD-Aβ interaction causes an increased expression of
endophilin 1, which stimulates JNK activation. Increased JNK activation then leads
to neuron death and tau phosphorylation.
ABAD-Aβ
Endophilin 1
JNK
Neuron Tau phosphorylation
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Chapter 4: ABAD interacts with
Cyclophilin D in the mitochondria
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Chapter 4: ABAD interacts with Cyclophilin D in the
mitochondria
4.1 Introduction
4.1.1 Interaction of ABAD and Cyclophilin D
ABAD is a member of the short chain dehydrogenase/reductase family with broad
substrate specificity. Several lines of evidences suggested that ABAD contributes to
the maintenance of metabolic homeostasis and confers protection under metabolic
stress conditions (Yan et al. 2000). In contrast, in an Aβ-rich environment as occurs
in AD, ABAD was reported to potentiate cell stress and cytotoxicity (Takuma et al.
2005).
CypD is a mitochondrial isoform of cyclophilin which contains an N-terminal
targeting sequence that directs the translated proteins to the mitochondria (Connern
and Halestrap 1992). CypD is mainly found in the matrix and inner membrane of
mitochondria and has been proposed to be an essential component of MPTP.
Recruitment of CypD to the ANT on the inner mitochondrial membrane can elicit
MPT (Norenberg and Rao 2007).
It was previously demonstrated that CysA blocks MPTP formation by interacting
with CypD (Schinzel et al. 2005). Application of CysA significantly reduced
mitochondrial dysfunction and cell death in cortical neurons from Tg mAPP/ABAD
mice (Takuma et al. 2005). These data implicated the involvement of MPTP in
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neuron toxicity induced by ABAD-Aβ interaction. Indeed, Yan and Stern observed
that CypD binds ABAD (Yan and Stern, 2004, unpublished data). Therefore, they
proposed that ABAD binds to CypD and sequestrates it in the mitochondria matrix,
thus preventing the translocation of CypD to the inner mitochondria membrane and
bind to ANT. In contrast, in an Aβ rich environment, ABAD-Aβ interaction
displaces ABAD-CypD interaction and results in the translocation of CypD to the
inner mitochondrial membrane, which then leads to MPT and ultimately cell death
(Yan and Stern 2004).
4.1.2 FRET analysis method
Confocal light microscopy can reveal subcellular distribution and colocalization of
labeled or fluorophore tagged proteins. However, there is no indication if these two
proteins interact with one another because the order of the resolution of light
microscope is 100 nm.
In contrast, FRET is a phenomenon that occurs when two fluorophores are within a
distance of 1-10 nm and an appropriate relative orientation such that an excited
fluorophore (donor) can transfer its energy to a second, longer-wavelength
fluorophore (acceptor) in a nonradiative manner (Kenworthy 2001). Thus,
excitation of the donor can produce light emission from the acceptor, with
corresponding loss of emission from the donor. There are three requisites for FRET
to occur (Schaufele et al. 2005):
1) there needs to be sufficient separation in excitation spectra between the donor
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and acceptor fluorophore to allow the donor to be stimulated independently.
2) there needs to be an overlap between the emission spectrum of the donor and the
excitation spectrum of the acceptor to obtain efficient energy transfer (Figure 4.1).
3) there needs to be reasonable separation in emission spectra between donor and
acceptor fluorophore to allow the fluorescence of each fluorophore to be collected
separately.
Therefore, by attaching a pair of proteins to be investigated with donor and acceptor
fluorophores, FRET can be used as an ideal technique to determine protein-protein
interaction in cells. Two variants of green fluorescent protein (GFP) including
enhanced cyan fluorescent protein (ECFP) and enhanced yellow fluorescent protein
(EYFP) is a well characterized pair of fluoroproteins for FRET analysis (Figure 4.2).
ECFP has two excitation peaks: a major peak at 434 nm and a minor peak at 453
nm. EYFP exhibits single excitation maxima at 514 nm. The emission spectrum of
ECFP (460-520 nm) overlaps significantly with the excitation spectrum of EYFP
(450-565 nm). The emission spectrum of EYFP is from 495 nm to 615 nm. The
emission spectrum of ECFP exhibits two maxima (475 nm and 501 nm), whereas
EYFP shows only a single peak (527 nm) (Figure 4.1). A pair of proteins of interest
is fused with ECFP and EYFP respectively. If the two proteins interact with each
other, when ECFP fused protein is excited at 458 nm wavelength, a large proportion
of the energy from ECFP will be transferred to EYFP fused protein and result in an
EYFP emission peak (Figure 4.2).
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Figure 4.1 Illustration of the excitation and emission spectrum of EYFP and ECFP.
The overlapping region of the emission spectrum of the donor and the excitation
spectrum of the acceptor is shown as a gray region. Dotted lines indicate the
excitation spectrum of ECFP and EYFP. Plain lines indicate emission spectrum of
ECFP and EYFP.
From: Zaccolo et al. (2007) Circ. Res. 94, 866–873.
Figure 4.2 Illustration of the occurrence of FRET between ECFP attached protein
(A) and EYFP attached protein (B). Excitation of ECFP leads to an increase in
EYFP emission.
ECFP EYFP
BA
FRET
ECFP=Enhanced cyan
fluorescent protein (Donor)
EYFP=Enhanced yellow
fluorescent protein (Acceptor)
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Two different approaches are generally used to measure FRET (Schaufele et al.
2005):
1) Emission measurement. After excitation of the donor, both the donor and
acceptor emission in the presence of the other fluorophore were detected. When
FRET occurs, there is quenching of the donor fluorescence and an increase of
the acceptor fluorescence since energy is transferred from the excited donor to
the acceptor. As described previously, overlapping of the donor emission and
acceptor absorption spectra is required for the efficient transfer of energy. This
spectral overlap, however, causes a significant spectral bleed-through (SBT)
background to the FRET signal. Therefore, to characterize FRET efficiency,
image processing to remove the SBT background based on reference images
acquired from separate control cells is commonly used (Wallrabe and Periasamy
2005).
2) Acceptor photobleaching. Acceptor photobleaching method is based on the
principle that the acceptor is destroyed irreversibly by extensive illumination
from excitation light. After bleaching of the acceptor fluorophore, FRET is
stopped. Therefore, the donor shows an increase in fluorescence intensity after
the acceptor photobleaching. Compared to measurement of sensitized emission,
this method has the advantage that separate measurements from reference cells
are not required since each cell serves as its own control (Berney and Danuser.
2003). Therefore, in this study, I used acceptor photobleaching method to study
the interaction of ABAD and CypD in the mitochondria.
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4.2 Aims of chapter
MPTP has been associated with the pathogenesis of AD (Norenberg and Rao 2007).
Yan and Stern 2004 proposed that under physiological conditions, ABAD binds
CypD and sequestrate it in the matrix of the mitochondria, whereas, in an Aβ rich
environment, such as in AD, ABAD-Aβ interaction displaces CypD. CypD then
translocates to the inner membrane of mitochondria and binds ANT, which induces
MPTP and eventually neuron death (Yan and Stern 2004). To study if ABAD
interacts with CypD in the mitochondria, ABAD proteins were fused with the
EYFP acceptor fluorophore whereas CypD proteins were fused with the ECFP
donor fluorophore, and the acceptor photobleaching FRET method was used.
4.3 Results
4.3.1 Construction of the pMito-ABAD-EYFP plasmid
To study the interaction of ABAD and CypD in the mitochondria, I firstly
developed a YFP tagged, mitochondria targeted ABAD plasmid construct
(pMito-ABAD-EYFP). A schematic outline of the cloning procedure is illustrated
in Figure 4.3.
Previously, a mitochondrial targeted, and GFP tagged ABAD plasmid construct
(pMito-ABAD-GFP) has been produced in the laboratory by Margaret Taylor. The
mitochondria targeting sequence of pMito-ABAD-GFP was derived from the
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pDsRed2-Mito vector (Clonetech). The most convenient cloning sites in the
pMito-ABAD-GFP vector were Not 1 and BamH 1. However, there was a single
BamH I site between the mitochondria targeting sequence and ABAD sequence.
Therefore, a two-step cloning strategy was devised. First, pMito-ABAD-GFP was
digested with the restriction enzyme BamH 1, releasing a 786 bp fragment of
ABAD. Then, using pGT-EYFP as a template, EYFP was cloned by PCR using the
forward oligonucleotide, CGGGATCCATGGTGAGCAAGGGCGAGGAG, which
encodes a BamH1 site and the reverse oligonucleotide,
TTTTGCGGCCGCTTACTTGTACAGCTCGTCCATGCC, which encodes a Not 1
site. The PCR product containing the 720 bp of EYFP was subsequently digested
with the restriction enzymes Not 1and BamH 1. The pMito-ABAD-GFP vector was
also digested with Not 1 and BamH 1, and the digested PCR product containing
EYFP was ligated with it. The ligation mixture was transformed into E. coli (DH5α)
and prepared with Qiagen’s Miniprep Kit as described in section 2.1.8. Restriction
digest analysis showed that the ligated plasmid was present. This plasmid was then
digested with BamH 1, and the 786 bp of ABAD containing fragment was ligated
with it. As two orientations for this insert were possible, several digests were
performed to test both the presence and direction of the insert, and the complete
plasmid was further confirmed by sequencing.
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Figure 4.3 Two-step cloning strategy for pMito-ABAD-EYFP.
pMito-ABAD-EGFP plasmid was digested with BamH I and Not I. pGT-EYFP was
used as the template for PCR of EYFP. Both the PCR products containing EYFP
and the fragment digested from pMito-ABAD-EGFP which contains ABAD were
then sequentially ligated into the vector digested from pMito-ABAD-EGFP
plasmid.
PCR product
EYFP
BamHⅠ
NotⅠ
ABAD
BamHⅠ
BamHⅠ
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The plasmid pCypD-ECFP was a kind gift from Dr Anne Murphy (Department of
Pharmacology, University of California, San Diego). In this DNA construct, CypD
was cloned from human heart mRNA and ligated into the expression vector
pECFP-N1 resulting in a CypD-ECFP fusion protein.
4.3.2 Colocalization of pMito-ABAD-YFP, pCypD-ECFP, and pDsRed2-Mito
pDsRed2-Mito (clontech) is a mammalian expression vector that encodes a fusion
of Discosoma sp. red fluorescent protein (DsRed2) and the mitochondrial targeting
sequence from subunit VIII of human cytochrome c oxidase (Mito). The Mito
sequence targets the Mito-DsRed2 fusion protein to the cell mitochondria, and as
such, pDsRed2-Mito has been widely used as a marker of mitochondrial matrix
(Karbowski et al. 2002; Karbowski et al. 2004; Cordell et al. 2004).
To verify that Mito-ABAD-EYFP and CypD-ECFP are expressed in the
mitochondria, a colocalization study of DsRed2-Mito with Mito-ABAD-EYFP or
CypD-ECFP was performed. SK-N-SH cells were transfected with pDsRed2-Mito,
pCypD-ECFP, pMito-ABAD-EYFP alone or a combination of two of them using
Amaxa Cell line nucleofector Solution V according to the protocol described in
section 2.2.5. Transfected cells were seeded onto coverslips containing 35 mm petri
dishes at a density of 1X106 cells per dish. After 24 hours, cells were fixed in 4%
PFA and mounted with Moviol+Dapi solution. The fluorescent images were then
examined using a Leica TCS-SP confocal microscope equipped with 40X, and 63X
oil immersion objectives. Mito-ABAD-EYFP showed a mitochondrial distribution
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(4.4A, B and C) and the merged image clearly showed that it colocalized well with
DsRed2-Mito (Figure 4.5). CypD-ECFP also displayed a mitochondrial distribution
(4.4D, E and F). But, notably, the expression of CypD-ECFP was partially
colocalized with that of DsRed2-Mito (Figure 4.6).
Figure 4.4 Expression distributions of Mito-ABAD-EYFP and CypD-ECFP.
SK-N-SH cells were transfected with pMito-ABAD-EYFP and pCypD-ECFP.
Mito-ABAD-EYFP exhibited a mitochondrial distribution in the cells (A, B and C).
CypD-ECFP proteins were also localized to the mitochondria (D, E and F).
Transfection efficiency is approximately 40–50% in this study
A D
B C E F
34.32 μm 34.32 μm
8.20 μm 9.10 μm 8.20 μm 8.21 μm
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Figure 4.5 Colocalization of Mito-ABAD-EYFP and DsRed2-Mito in SK-N-SH
cells. SK-N-SH cells cotransfected with pMito-ABAD-EYFP and pDsREd2-Mito
were fixed and mounted for microscopic observation. Mito-ABAD-EYFP exhibited
mitochondrial distribution (A). pDsRed2-Mito has been widely used as a marker of
the mitochondrial matrix (B). Merged image demonstrated that Mito-ABAD-EYFP
colocalized well with DsREd2-Mito (C).
A
B
C
12.26 μm
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Figure 4.6 Colocalization of CypD-ECFP and DsRed2-Mito in SK-N-SH cells.
SK-N-SH cells cotransfected with pCypD-ECFP and pDsREd2-Mito were fixed
and mounted for microscopic observation. CypD-ECFP exhibited mitochondrial
distribution (A). pDsRed2-Mito has been widely used as a mitochondrial marker
(B). Merged image demonstrated that CypD-ECFP colocalized partially with
DsRed2-Mito (C).
A
B
C
15.46 μm
131
Furthermore, in accordance with the above results, a colocalization study of
Mito-ABAD-EYFP and CypD-ECFP revealed that the expression of
Mito-ABAD-EYFP only partially overlaps with the expression of CypD-ECFP in
the mitochondria of the cells (Figure 4.7).
Figure 4.7 Colocalization of CypD-ECFP and Mito-ABAD-EYFP in SK-N-SH
cells. SK-N-SH cells cotransfected with pCypD-ECFP and pMito-ABAD-EYFP
were fixed and mounted for microscopic observation. Both CypD-ECFP (A) and
Mito-ABAD-EYFP (B) exhibited mitochondrial distribution. Merged image
demonstrated that CypD-ECFP colocalized partially with Mito-ABAD-EYFP (C).
B
A
C
8.18 μm
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pMito-ABAD-EYFP and pDsRed2-Mito contain the same mitochondria targeting
sequence. This targeting sequence was reported to target proteins to the
mitochondrial matrix (Karbowski et al. 2002; Karbowski et al. 2004; Cordell et al.
2004). However, pCypD-ECFP has its own intrinsic N terminal mitochondria
targeting sequence of approximately 13 amino acids (Connern and Halestrap 1992).
CypD has been reported to be expressed in both the mitochondrial inner membrane
and mitochondrial matrix (Schinzel et al. 2005). These data might explain the
differential distribution in the mitochondria of the cells between
Mito-ABAD-EYFP proteins and CypD-ECFP proteins.
4.3.3 FRET analysis of ABAD-CypD interaction using acceptor photobleaching
method
Given that there are areas of colocalization between the tagged ABAD and CypD
proteins, acceptor photobleaching measurements were used to investigate if ABAD
interacts with CypD in mitochondria. In cells expressing EYFP tagged protein
acceptor fluorophore was photobleached. Interaction between two
fluorophore-tagged proteins permits energy transfer between the fluorophores,
which results in an unquenching of the fluorescence intensity of ECFP tagged
protein (donor fluorophore). FRET between the donor and the acceptor (D–A) can
be characterized by the efficiency of energy transfer (FRETEff), which is measured
as the relative variation of fluorescence intensity of ECFP pre and post bleaching
(FRETEff =Dpost-Dpre/Dpre).
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In this study, SK-N-SH cells were cotransfected with pMito-ABAD-EYFP and
pCypD-ECFP to study the FRET between Mito-ABAD-EYFP and CypD-ECFP.
The detection of FRET has been found to be sensitive to the ratio of the intensities
of donor and acceptor fluorophores (Zal et al. 2002). Therefore, 2 μg of
pMito-ABAD-EYFP plasmid DNA were cotransfected with 2 μg, 4 μg, or 6 μg of
pCypD-ECFP plasmid DNA respectively. Cells cotransfected with
pMito-ABAD-EYFP and pCypD-ECFP at a ratio of 1:3 showed similar fluorescent
intensities of ECFP and EYFP (unpublished observation). Therefore, in this study,
plasmid DNA encoding for EYFP fused to protein of interest was cotransfected
with plasmid DNA encoding for ECFP fused to protein of interest at a ratio of 1:3.
To confirm the occurrence of FRET, two negative controls were set up: 1)
SK-N-SH cells transfected with pCypD-ECFP alone and 2) SK-N-SH cells
cotransfected with pCypD-ECFP and pEYFP vector. SK-N-SH cells expressing a
fusion plasmid, pECFP-DEVD-EYFP (a kind gift from Prof Professor Tavaré,
Department of Biochemistry, University of Bristol) was also included to serve as a
positive control. ECFP-DEVD-EYFP is a hybrid protein consisting of ECFP and
EYFP linked by a spacer containing the amino acid sequence DEVD. It has been
demonstrated that in COS7 cells expressing pECFP-DEVD-EYFP, strong FRET
signals can be observed (Brophy et al. 2002)., Transfection of SK-N-SH cells was
performed using Amaxa’s nucleofactor system according to the protocol detailed in
section 2.2.5. Transfected cells were seeded onto 35 mm coverslips containing petri
dishes at a density of 1X106 cells per dish. 48 hours later, the cells were fixed and
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mounted in Moviol+Dapi solution. The slides were examined with Leica TCS-SP5
multiphoton confocal microscope equipped with 40X, and 63X oil immersion
objectives. The 458 nm and 514 nm argon laser lines were used for activation of
ECFP and EYFP respectively. Laser intensity was set at 20% of available power.
The emission window was set at 475–500 nm for visualization of ECFP and for
visualization of EYFP, the emission window was set at 520–600 nm. The 415 nm
laser was used to visualize Dapi stained nuclei to allow the focusing of cells. The
Leica FRET wizard in the application module was set up and the acceptor
photobleaching module was chosen. For photobleaching, 514 nm laser was set to
full power. 4-8 regions of interest (ROIs) within each cell were chosen and
photobleached by 514 nm laser until most of the fluorescence intensity was
bleached. Pre and post bleach images in both ECFP and EYFP channels were taken.
The FRET efficiency was calculated automatically by the Leica FRET wizard
software. For internal control of real FRET, 4-8 unbleached ROIs in cells
cotransfected with pMito-ABAD-EYFP and pCypD-ECFP were chosen, and the
corresponding FRET efficiency was calculated.
4.3.3.1 Characterization of FRET in SK-N-SH cells co-expressing
pMito-ABAD-EYFP and pCypD-ECFP
The data from a typical imaging FRET experiment are shown in Figure 4.8. The
initial acceptor (Mito-ABAD-EYFP) image represents acceptor fluorescence in the
presence of the donor CypD-ECFP (Figure 4.8A). After complete photobleaching
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of the acceptor, image of the acceptor was collected (Figure 4.8B). The images of
the donor pre and post photobleaching were also collected (Figure 4.8C and 4.8D).
As shown in Figure 4.8C and 4.8D, in the bleached regions, the fluorescence of the
donor was increased after acceptor photobleaching indicating the occurrence of
FRET. The fluorescence intensities of both donor and acceptor pre and post
bleaching and the values of FRET efficiency for different ROIs within one cell are
displayed in Table 4.1.
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Figure 4.8 Detection of FRET in SK-N-SH cells co-expressing
pMito-ABAD-EYFP and pCypD-ECFP by means of the increase in donor
fluorescence after acceptor photobleaching. Region of interests (ROIs) as indicated
were photobleached by 514 nm laser. (A) Acceptor (Mito-ABAD-EYFP) image
before photobleaching of the acceptor; (B) Acceptor (Mito-ABAD-EYFP) image
after photobleaching;(C) Donor (CypD-ECFP) image before acceptor
photobleaching; and (D) Donor (CypD-ECFP) image after photobleaching.
Figure 4.8B
Figure 4.8C Figure 4.8D
Figure 4.8A
7.98 μm
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ROI
D pre
D post
A pre
A post
FRETeff
(%)
(%)
ROI_1
73.78
69.57
104.67
28.88
0.00
ROI_2
40.14
49.51
73.10
16.20
18.92
ROI_3
193.98
204.47
132.05
45.18
5.13
ROI_4
126.82
148.06
111.00
33.82
14.34
ROI_5
173.80
190.21
100.81
29.36
8.63
ROI_6
105.07
107.52
105.67
24.15
2.27
ROI_7
140.58
155.50
84.97
25.06
9.59
Table 4.1 The fluorescence intensities and FRET efficiency calculated for different
ROIs within one cell as indicated. FRETeff = Dpost-Dpre∕ Dpost.
4.3.3.2 Characterization of FRET in unbleached ROIs in SK-N-SH cells
co-expressing pMito-ABAD-EYFP and pCypD-ECFP
As an internal control for real occurrence of FRET, within the same cell, 4-8 ROIs
in the unbleached regions were chosen as well. Pre and post bleaching images of
Mito-ABAD-EYFP and CypD-ECFP were captured. The fluorescence intensities of
Mito-ABAD-EYFP and CypD-ECFP in the unbleached ROIs were measured and
the corresponding FRET efficiency was calculated.
Representative FRET images of the unbleached regions in SK-N-SH cells
co-expressing pMito-ABAD-EYFP and pCypD-ECFP are shown in Figure 4.9.
Table 4.2 demonstrates the values of the FRET efficiency in the unbleached ROIs.
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Figure 4.9 Characterization of the FRET efficiency of in the unbleached ROIs of
SK-N-SH cells co-expressing pMito-ABAD-EYFP and pCypD-ECFP. (A)
Acceptor (Mito-ABAD-EYFP) image before photobleaching of the acceptor; (B)
Acceptor (Mito-ABAD-EYFP) image after photobleaching;(C) Donor
(CypD-ECFP) image before acceptor photobleaching; and (D) Donor (CypD-ECFP)
image after photobleaching.
Figure 4.9C Figure 4.9D
Figure 4.9A Figure 4.9B
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Table 4.2 Values of the fluorescence intensities and FRET efficiency for different
ROIs as indicated in unbleached regions within one cell. FRETeff = Dpost-Dpre∕ Dpost
4.3.3.3 Characterization of FRET in SK-N-SH cells expressing pCypD-ECFP
In this study, I also analyzed FRET of two negative controls including SK-N-SH
cells expressing pCypD-ECFP alone and SK-N-SH cells co-expressing pEYFP and
pCypD-ECFP. Representative FRET images of SK-N-SH cells transfected with
pCypD-ECFP alone are shown in Figure 4.10. Hardly any fluorescence was
detected in the EYFP channel. There was no increase in the fluorescence intensities
of the ROIs in the ECFP channel after photobleaching (Figure 4.10 C and D). Table
4.3 displays the values of the FRET efficiency in ROIs of cells expressing
pCypD-ECFP alone.
ROI
D pre
D post
A pre
A post
FRETeff
(%)
ROI_1
129.79
120.93
126.49
125.95
0.00
ROI_2
102.94
91.60
36.45
44.48
0.00
ROI_3
140.27
124.22
55.44
47.99
0.00
ROI_4
206.38
203.67
94.88
88.42
0.00
ROI_5
224.06
219.00
106.97
101.30
0.00
ROI_6
186.83
183.08
89.48
82.23
0.00
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Figure 4.10 Characterization of FRET in SK-N-SH cells expressing pCypD-ECFP
alone. (A) Image captured in the EYFP channel before photobleaching of the
acceptor; (B) Image captured in the EYFP channel after photobleaching; (C) Donor
(CypD-ECFP) image before acceptor photobleaching; and (D) Donor (CypD-ECFP)
image after photobleaching.
12.34 μm
Figure 4.10A Figure 4.10B
Figure 4.10DFigure 4.10C
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Table 4.3 Values of the fluorescence intensities and FRET efficiency for different
ROIs as indicated within one cell. FRETeff = Dpost-Dpre∕ Dpost
4.3.3.4 Characterization of FRET in unbleached ROIs of SK-N-SH cells
co-expressing pEYFP and pCypD-ECFP
SK-N-SH cells co-expressing pEYFP vector and pCypD-ECFP were also employed
as a negative control. In the EYFP channel, yellow fluorescence was distributed
diffusely in the cell. CypD-ECFP still showed a mitochondrial distribution.
Representative FRET images are shown in Figure 4.11. After photobleaching of the
acceptor (EYFP), there was no obvious increase in the fluorescence intensities of
CypD-ECFP. Table 4.4 demonstrates the values of the FRET efficiency in ROIs of
cells co-expressing pCypD-ECFP and pEYFP.
ROI
D pre
D post
A pre
A post
FRETeff
(%)
ROI_1
162.56
162.12
0.03
0.00
0.00
ROI_2
125.20
104.26
0.00
0.00
0.00
ROI_3
101.64
95.44
0.00
0.00
0.00
ROI_4
180.63
168.37
0.00
0.00
0.00
ROI_5
97.45
91.10
0.24
0.00
0.00
ROI_6
143.66
120.61
0.08
0.01
0.00
ROI_7
162.15
168.78
0.00
0.15
3.93
ROI_8
65.46
58.66
0.04
0.02
0.00
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Figure 4.11 Characterization of FRET in SK-N-SH cells co-expressing pEYFP and
pCypD-ECFP. (A) Acceptor (EYFP) image before photobleaching of the acceptor;
(B) Acceptor (EYFP) image after photobleaching;(C) Donor (CypD-ECFP) image
before acceptor photobleaching; and (D) Donor (CypD-ECFP) image after
photobleaching.
14.73 μm
Figure 4.11BFigure 4.11A
Figure 4.11DFigure 4.11C
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Table 4.4 Values of the fluorescence intensities and FRET efficiency in different
ROIs as indicated within one cell. FRETeff = Dpost-Dpre∕ Dpost
4.3.3.5 Characterization of FRET in ROIs of SK-N-SH cells expressing
pEYFP-DEVD-ECFP
To further verify that the FRET observed in bleached ROIs of SK-N-SH cells
cotransfected with pMito-ABAD-EYFP and pCypD-ECFP are true, a positive
control was used. SK-N-SH cells were transfected with a pEYFP-DEVD-ECFP
fusion plasmid. Both the yellow and blue fluorescence were distributed diffusely
throughout the cell. The 514 nm laser was used to bleach ROIs in the cells and a
significant increase of the fluorescence intensity of pCypD-ECFP was observed
after photobleaching. Representative FRET images are shown in Figure 4.12. Table
4.5 demonstrates the values of the FRET efficiency in ROIs of SK-N-SH cells
expressing an EYFP-DEVD-ECFP fusion protein.
ROI
D pre
D post
A pre
A post
FRETeff
(%)
ROI_1
102.51
96.41
23.10
1.04
0.00
ROI_2
74.42
47.12
20.01
2.88
0.00
ROI_3
83.37
60.42
21.11
4.06
0.00
ROI_4
86.06
57.98
24.76
1.24
0.00
ROI_5
59.63
36.17
22.98
0.43
0.00
ROI_6
63.29
48.29
30.33
1.03
0.00
ROI_7
15.98
11.94
26.45
1.47
0.00
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Figure 4.12 Detection of FRET signals in SK-N-SH cells expressing
pECFP-DEVD-EYFP by means of the increase in donor fluorescence after acceptor
photobleaching. Region of interests (ROIs) as indicated were photobleached by 514
nm laser. (A) Acceptor image before photobleaching of the acceptor; (B) Acceptor
image after photobleaching;(C) Donor image before acceptor photobleaching; and
(D) Donor image after photobleaching.
Figure 4.12A Figure 4.12B
Figure 4.12DFigure 4.12C
8.39 μm
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Table 4.5 Values of the fluorescence intensities and FRET efficiency for different
ROIs as indicated within one cell. FRETeff = Dpost-Dpre∕ Dpost
4.3.4 Quantitative analysis of FRET efficiency
14 cells co-expressing pMito-ABAD-EYFP and pCypD-ECFP, 11 cells expressing
pCypD-ECFP alone, 12 cells co-expressing pCypD-ECFP and pEYFP vector, and
12 cells expressing pECFP-DEVD-EYFP were quantitatively analyzed for detection
of FRET. For FRET analysis, 4-8 regions within each cell were chosen and the
corresponding FRET efficiency was calculated. Statistical significance was
performed using student’s t test. Significance level was expressed at 0.05% level.
The FRET efficiency data are expressed as means ± S.E.M. SK-N-SH cells
co-expressing pMito-ABAD-YFP and pCypD-ECFP displayed a FRET efficiency
of 11.46±1.17 (n=14cells). It is significantly higher than the FRET efficiency of the
SK-N-SH cells expressing pCypD-ECFP alone (3.70±1.15, n=11cells) or SK-N-SH
cells co-expressing pCypD-ECFP and pEYFP vector (2.53±0.5, n=12 cells). The
unbleached regions of SK-N-SH cells co-expressing both pMito-ABAD-EYFP and
ROI
D pre
D post
A pre
A post
FRETeff (%)
ROI_1
29.34
38.52
108.94
0.06
23.84
ROI_2
32.85
51.70
138.73
0.09
36.47
ROI_3
26.38
34.38
97.75
0.03
23.27
ROI_4
21.33
28.88
82.00
0.16
26.13
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pCypD-ECFP exhibited a FRET efficiency of 2.03±0.64 (n=14 cells). Serving as a
positive control, SK-N-SH cells expressing a pECFP-DEVED-EYFP fusion
plasmid showed a FRET efficiency of 16.12± 2.74 (n=12 cells) (Figure 4.13).
Figure 4.13 Quantitative analysis of FRET efficiency. The results are expressed as
means ± S.E.M. SK-N-SH cells co-expressing pMito-ABAD-EYFP and
pCypD-ECFP exhibited a FRET efficiency of 11.46±1.17 (n=14) in the
phototobleached ROIs. In contrast, the unbleached ROIs showed a markedly
reduced level of FRET efficiency (2.03±0.64, n=14). Two negative controls
including SK-N-SH cells expressing pCypD-ECFP alone and SK-N-SH cells
co-expressing pCypD-ECFP and pEYFP vector, however, displayed FRET
efficiency of 3.70±1.15 (n=11cells) and 2.53±0.5, (n=12 cells) respectively.
SK-N-SH cells expressing an ECFP-DEVD-EYFP fusion protein showed a FRET
efficiency of 16.12±2.74 (n=12 cells). * indicates a significance level of 0.05%.
*
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Quantitative analysis of the values of FRET efficiency indicated high FRET signals
between Mito-ABAD-EYFP and CypD-ECFP. Cells expressing an
ECFP-DEVD-EYFP fusion protein also exhibited high level of FRET efficiency. In
contrast, cells transfected with pCypD-ECFP alone or both pCypD-ECFP and
pEYFP displayed very low FRET signals. Taken together, these data demonstrated
that there is a tight intermolecular association between Mito-ABAD-EYFP and
CypD-ECFP in the mitochondria. In general, strong FRET signals imply that the
fluorophores are within 10 nm distance. Thus, these FRET results substantially
indicated a close association between Mito-ABAD-EYFP and CypD-ECFP in the
mitochondrial compartment of cells.
4.4 Discussion
Accumulating evidences suggested that high cytosolic levels of Ca2+ and oxidative
stress are two major factors for the induction of the MPTP (Hale strap et al. 1999);
Kwiatkowski et al. 2001). Opening of the MPTP led to dissipation of the
mitochondrial inner membrane potential, which then caused uncoupling of
oxidative phosphorylation and ATP synthesis deficiency. Also, such dysfunction of
the electron transport chain in the mitochondria resulted in ROS production
(Votyakova and Reynolds, 2005). Thus, while oxidative stress is a major cause of
the MPT, it can also be a consequence of the MPT. Moreover, MPT is involved in
the apoptotic cell death pathway by releasing of cytochrome c. Once released from
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the mitochondria, cytochrome c activated procaspase 9 to stimulate downstream
events related to apoptosis (Jemmerson et al. 2005).
It is well recognized that oxidative stress plays an important role in the
pathogenesis of AD (Butterfield et al. 2006). Furthermore, aggregated Aβ was
reported to lead to a dysregulation of Ca2+ homeostasis (Mattson et al. 1992).
Together, these results implicated the involvement of MPTP in the pathogenesis of
AD. However, the precise mechanisms by which high cytosolic levels of Ca2+ and
oxidative stress elicit the MPT remain to be established.
Yan and Stern 2004 proposed a novel signaling pathway which may contribute to
the MPTP formation in AD. Under physiological conditions, ABAD binds CypD,
whereas in AD, Aβ binds ABAD and disturbs the interaction of ABAD and CypD.
CypD is then recruited to ANT on the inner membrane of mitochondria and induce
MPT (Yan and Stern 2004).
In this study, using the acceptor photobleaching method, strong FRET signals were
detected in SK-N-SH cells co-expressing pMito-ABAD-EYFP and pCypD-ECFP.
In contrast, three negative controls including unbleached ROIs of SK-N-SH cells
co-expressing pMito-ABAD-EYFP and pCypD-ECFP, SK-N-SH cells expressing
pCypD-ECFP alone and SK-N-SH cells co-expressing pEYFP and pCypD-ECFP,
all exhibited low FRET signals. Moreover, as a positive control, SK-N-SH cells
expressing an ECFP-DEVD-EYFP fusion protein displayed strong FRET signals.
These data indicated that, ABAD may interact with CypD in the mitochondria of
SK-N-SH cells.
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Also of interest is that in SK-N-SH cells expressing an ECFP-DEVD-EYFP fusion
protein (positive control), strong FRET signals were detected in all bleached ROIs.
However, in SK-N-SH cells co-expressing pMito-ABAD-EYFP and pCypD-ECFP,
there were a small percentage of bleached ROIs which displayed very low FRET
signals. These data indicated that the interaction of ABAD and CypD may not be
global. It may only occur in some parts of the mitochondria of the cells. Apart from
the spatial context, ABAD-CypD interaction may also vary across different time
scales. Therefore, in future studies, FRET analysis of live cells should be performed
to study the dynamic relationship between ABAD and CypD in cell mitochondria.
Moreover, an Aβ rich environment can be set up by applying extracellular
aggregated Aβ to cells or transfecting mAPP into cells. Thus, the hypothesis that, in
an Aβ rich environment, ABAD-Aβ interaction displaces CypD which then results
in MPT and neuron death can be tested.
Despite the power of these FRET-based approaches, it is important to note that,
positive FRET results by themselves can not prove the direct interaction of the
labeled proteins. Other techniques, such as co-immunoprecipitation, epitope-tagged
protein pull-down, and two-hybrid assays are required to substantiate the direct
protein-protein interactions. However, it needs to be pointed out that the application
of these approaches is also limited due to the nonphysiological conditions of protein
extraction and analysis (Voss et al. 2005).
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Chapter 5: Two dimensional electrophoresis analysis of
RAGE knock out mice
5.1 Introduction
Receptor for advanced glycation end products (RAGE) is a cell surface receptor,
which binds to Aβ, AGEs, S100/Calgranulins and amphoterin (Lue et al. 2005). Tg
mice overexpressing neuron targeted RAGE in an Aβ rich environment (Tg
mAPP/RAGE) displayed accelerated/exaggerated spatial memory and learning
impairment and loss of density of cholinergic fibers and synapses at an early stage
compared to Tg mAPP, Tg RAGE and non-Tg littermates. In contrast, Tg
mAPP/DN-RAGE mice exhibited a preservation of cognitive function at an early
stage and the decrease in AChE-positive neurites in the subiculum, were virtually
completely prevented in Tg mAPP/DN-RAGE mice (Arancio et al. 2004). These
data collectively suggested that RAGE may accelerate Aβ induced cytotoxicity at
an early stage of AD and blocking of this interaction can rescue cognitive
dysfunction.
Prof ShiDu Yan (College of Physicians and Surgeons, Columbia University), our
collaborators in the United States, provided us with mice cortex of four different
genotypes including non-Tg littermates, Tg mAPP, Tg DN-RAGE and Tg
mAPP/DN-RAGE. A two dimensional electrophoresis method was employed to
study differential protein expression between different genotypes of mice brain. The
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results of the analysis could provide insights into the cognitive rescuing
mechanisms in Tg mAPP/DN-RAGE mice. Furthermore, the results could also be
important for finding potential therapeutic targets in the treatment of AD.
5.2 Two dimensional electrophoresis analysis using Hoefer-DALT
system
5.2.1 Identification of glyoxalase 1
Mice cortices (8-9 months old) from four different genotypes of animals including
non-Tg littermates, Tg mAPP, Tg DN-RAGE and Tg mAPP/DN-RAGE were sent
to us on dry ice by Prof ShiDu Yan (College of Physicians and Surgeons, Columbia
University). Sample preparation of mice cortex and the subsequent two dimensional
electrophoresis were performed as described in section 2.4.3. Mice cortices from
three different animals for each of the four genotypes were lysed in lysis buffer 1 [8
M Urea, 2 M Thio-Urea, 4% chaps, 1% IPG buffer (pH 3-10), 40 mM Tris base and
100 μl sigma protease inhibitor]. In the first dimension, mice cortex proteins were
separated by applying 1 mg of protein of each sample onto 18 cm IPG drystrips
with a pH interval of 3-10. After isoelectric focusing, the IPG drystrips were loaded
onto premade 10% SDS polyacrylamide gels for second dimensional separation.
Electrophoresis of 12 gels was carried out in Hoefer-Dalt system at 15°С for 16-20
hours. The SDS polyacrylamide gels were silver stained. Images of the gels were
captured using a Typhoon 9200 laser scanner and printed onto laser transparent
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papers after processing with Adobe Photoshop. Representative two dimensional gel
images are shown in Figure 5.1. Differential protein expression between different
genotypes of mice brain was analyzed by eye using these gel images. Only the
protein spots, which displayed a difference in the levels of expression in all three
gels of the same genotype as compared to that in all three gels of another genotype,
were selected. A protein was found consistently upregulated in Tg DN-RAGE and
Tg mAPP/DN-RAGE animals compared to Tg mAPP and non-Tg mice (Figure 5.2).
This protein spot was then excised from the gels and stored in 1 ml MQ at 4°С. 
Using MALDI-TOF mass spectrometry, this protein was identified as glyoxalase 1
(GLO1).
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Figure 5.1 Representative images of silver stained two dimensional gels. 1 mg of
protein sample from each genotype was loaded onto 18 cm IPG strips containing a
pH interval of 3-10. The focused IPG strips were loaded onto 10% SDS
polyacrylammide gels and the electrophoresis was carried out in Hoefer-Dalt
system. Two dimensional gels were then silver stained and images of the gels were
captured with an image scanner and processed with Adobe Photoshop. After
comparison studies by eye, one protein spot (indicated by red circles), latterly
identified as GLO1, was found to be increased in Tg DN-RAGE and Tg
mAPP/DN-RAGE mice brains compared to Tg mAPP and non-Tg mice brains.
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Figure 5.2 Partial images of two dimensional gels. The expression level of GLO1
(indicated by red circles) in Tg DN-RAGE and Tg mAPP/DN-RAGE mice was
significantly higher than in Tg mAPP and non-Tg animals.
5.2.2 mRNA expression of GLO1
The mRNA expression of GLO1 was studied by Prof ShiDu Yan’s group (College
of Physicians and Surgeons, Columbia University) using RT-PCR to confirm the
differential expression of GLO1 between different genotypes of mice brain. Tg
mAPP/DN-RAGE exhibited a 1.5 fold increase of the mRNA expression level of
GLO1 compared to non-Tg animals. However, unlike the results obtained by two
dimensional electrophoresis studies, the mRNA expression level of GLO1 in Tg
DN-RAGE mice was comparable with that in non-Tg and Tg mAPP animals
(Figure 5.3).
GLO1/ Non-TgGLO1/ Tg mAPP
GLO1/ Tg DN-RAGE GLO1/ Tg mAPP/DN-RAGE
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Figure 5.3 The mRNA expression level of GLO1 in non-Tg, Tg mAPP, Tg
DN-RAGE and Tg mAPP/DN-RAGE was assessed by real-time RT-PCR. Data are
presented as fold increase over non-Tg animals for each type of transgenic animals.
There was a significant increase of the expression level of GLO1 in Tg
mAPP/DN-RAGE animals as compared to non-Tg, Tg mAPP and Tg DN-RAGE
animals (Figure supplied by Prof Shi Du Yan, College of Physicians and Surgeons,
Columbia University).
5.2.3 Protein expression level of GLO1 in Tg mAPP and Tg mAPP/DN-RAGE
mice cortex
To confirm the RT-PCR results, protein expression level of GLO1 in Tg
mAPP/DN-RAGE and Tg mAPP animals was examined using immunoblotting
method. Mice cortices from three of each of Tg mAPP/DN-RAGE and Tg mAPP
animals were minced and lysed with RIPA buffer as described in section 2.4.1.
Protein concentrations were quantified using Bradford’s reagent. Equal amount of
proteins were loaded onto a 4-12% mini Bis-Tris gel for electrophoresis. Proteins
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were then transferred to a polyvinylidene fluoride (PVDF) transfer membrane. After
blocking overnight in 5% milk + TBS/T, the membrane was incubated with an
anti-GLO1 antibody (From Dr Carol Brown, Department of Pharmacology,
University of California, San Diego) at a dilution of 1:2000 overnight. After three
five minutes washes in TBS/T, the blot was incubated with HRP conjugated goat
anti-rabbit secondary antibody at a dilution of 1:5000 for one hour. The membrane
was washed in TBS/T for three times of ten minutes each and then subjected to ECL
detection. To control for equal loading of protein samples, after five ten minutes
washes, the blot was stripped and reprobed with β-actin antibody. Tg mAPP mice
displayed highly varied expression of GLO1 as shown in Figure 5.4A. The
immunoblot bands were quantified using ImageJ software. The intensities of the
GLO1 bands were normalized to β-actin signals. The relative expression of GLO1
is expressed as means ± S.E.M. Statistical analysis was performed using student’s t
test. No significant difference in the expression level of GLO1 between Tg mAPP
and Tg mAPP/DN-RAGE was observed (Figure 5.4B.).
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Figure 5.4 (A) Immunoblotting study of GLO1 expression in Tg mAPP and Tg
mAPP/DN-RAGE animals. The blot was reprobed with β-actin antibody as
indicated to control for equal loading. (B) The immunoblot bands were quantified
using ImageJ software. The GLO1 expression levels were normalized to actin levels.
Results of the relative expression of GLO1 are expressed as means ± S.E.M. There
was no significant difference in the expression level of GLO1 between Tg mAPP
and Tg mAPP/DN-RAGE animals.
GLO1
β-actin
Tg mAPP Tg mAPP/DN-RAGE
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5.3 Two dimensional electrophoresis using Ettan-Dalt system
With a new set of 8-9 months mice cortices from four different genotypes including
non-Tg, Tg mAPP, Tg DN-RAGE and Tg mAPP/DN-RAGE, which were kindly
provided by Prof ShiDu Yan (College of Physicians and Surgeons, Columbia
University) and our new Ettan-Dalt two dimensional electrophoresis system, a more
thorough screening analysis for differential protein expression between different
genotypes of mice brain was then able to be performed.
Longer IPG strips provide high resolution and protein loading capacity which
would allow the detection of more spots and facilitate the identification of proteins
in the spots. 18 cm IPG gels were used in the first dimension in the above
experiments. In the following two dimensional electrophoresis studies, 24 cm IPG
gels were used to achieve better resolution.
Beside the length of IPG gels, the pH intervals of IPG gels are also important.
Narrow pH range delivers high resolution and protein loading capacity. In the
following studies, IPG strips with a linear gradient pH 3–10 were used for an
overview of total protein distribution. IPG strips with pH 4–7 and pH 6–9 were
combined to obtain a more detailed study of protein distribution.
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5.3.1 Two dimensional electrophoresis studies using IPG strips containing a
linear gradient pH 3–10
5.3.1.1 Differential protein expression between wild type and Tg DN-RAGE mice
Sample preparation of mice cortex and the subsequent two dimensional
electrophoresis were performed following the protocol described in section 2.4.3.
Mice cortices from three different animals for each of the four genotypes including
non-Tg, Tg mAPP, Tg DN-RAGE and Tg mAPP/DN-RAGE were lysed in lysis
buffer 2 [8 M Urea, 4.5% chaps, 1% DTT, 2% IPG buffer (pH 3-10), 10 μl nucleic
acid inhibitor, 10 μl PMSF and 40 μl Roche protease inhibitor cocktail]. In the first
dimension, 1 mg of proteins of each sample was applied onto 24 cm IPG gels with a
pH interval of 3-10. After isoelectric focusing, the IPG gels were loaded onto
precast DALT Gel 12.5 gels for second dimensional separation. In total, six gels
were run in an Ettan-Dalt two dimensional electrophoresis system at 4°С for 16-20
hours. The proteins on the gels were visualized by silver staining. Gel images were
captured with a Typhoon 9,200 laser scanner and analyzed using ImageMaster
software as described in section 2.5.5. For each genotype of mice, three two
dimensional gels were used for analysis. Data of the relative spot volumes (volume
of a spot / total volume of all the spots in a gel) are expressed as means ± S.E.M.
Statistical significance was studied using student’s t test (p<0.05). Gap values for
each spot between two different genotypes were calculated automatically by
ImageMaster software. Only the spots that exhibited both positive gap values and a
statistical significance (p<0.05) were selected. Three proteins were found to be
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differentially expressed between Tg DN-RAGE mice and non-Tg littermates.
However, no protein spots were identified to be differentially expressed between Tg
mAPP mice and Tg mAPP/DN-RAGE mice. The three spots identified were then
excised from the gels and subjected to MALDI-TOF mass spectrometry analysis.
These proteins were identified as translation initiation factor eIF-5A (eIF-5A), glia
maturation factor beta (GMFB), and fatty acid-binding protein, epidermal
(E-FABP). The relative spot volume of E-FABP in Tg DN-RAGE mice (0.99±0.16)
was significantly higher than in non-Tg littermates (0.6±0.15). In contrast, the
relative spot volumes of eIF-5A and GMFB were decreased from 0.8±0.16 and
0.86±0.18 in non-Tg littermates to 0.52±0.05 and 0.47±0.01 in Tg DN-RAGE mice,
respectively.
Representative two dimensional gels of Tg DN-RAGE mice and non-Tg littermates
are shown in Figure 5.5. The spots indicated by red circles are proteins identified to
be differentially expressed between Tg DN-RAGE animals and non-Tg littermates.
The identified proteins including eIF-5A, GMFB, and E-FABP are also shown in
enlarged partial images of two dimensional gels (Figure 5.6).
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Figure 5.5 Representative two dimensional gel images of mice cortex from Tg
DN-RAGE mice and non-Tg littermates. 1 mg of proteins of each sample was
applied onto 24 cm IPG gels. After isoelectric focusing, the IPG strips were loaded
onto precast DALT gel 12.5 gels and run in an Ettan-Dalt system. After silver
staining, the gel images were captured with image scanner and analyzed with
ImageMaster software. Three proteins were found to be differentially expressed (as
indicated by red circles) between Tg DN-RAGE mice and non-Tg littermates.
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Figure 5.6 Partial images of two dimensional gels showing that three proteins
including translation initiation factor eIF-5A, glia maturation factor beta, and fatty
acid-binding protein, epidermal were differentially expressed between non-Tg
littermates and Tg DN-RAGE mice. Fatty acid-binding protein (epidermal)
(indicated by red circles) was found to be upregulated in Tg DN-RAGE animals
compared to non-Tg littermates, whereas eIF-5A and GMFB (indicated by red
circles) were downregulated.
5.3.1.2 Confirmation of differential protein expression between non-Tg and Tg
DN-RAGE using RT-PCR
The mRNA expression levels of eIF-5A, GMFB, and E-FABP were studied using
RT-PCR method by Prof ShiDu Yan’s group (College of Physicians and Surgeons,
Columbia University). On the contrary to the results obtained from the two
dimensional electrophoresis studies, Tg DN-RAGE exhibited a 0.8 fold decrease of
the mRNA expression level of E-FABP as compared to non-Tg animals. The mRNA
expression levels of eIF-5A, GMFB in Tg DN-RAGE mice were increased 1.3 and
Non-Tg Tg DN-RAGE
Fatty acid-binding protein,
epidermal
Translation initiation factor
eIF-5A
Glia maturation factor beta
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1.1 fold, respectively, compared to non-Tg animals (Figure 5.7).
Figure 5.7 The mRNA expression levels of eIF-5A, GMFB, and E-FABP in non-Tg
and Tg DN-RAGE animals were assessed by real-time RT-PCR. Data are presented
as fold increase over non-Tg mice for Tg DN-RAGE mice. There was a decrease of
the expression level of E-FABP in Tg DN-RAGE animals compared to non-Tg
animals (A). The mRNA levels of eIF-5A (B) and GMFB (C) were increased in Tg
DN-RAGE mice brains compared to non-Tg mice brains (Figure supplied by Prof
Shi Du Yan, College of Physicians and Surgeons, Columbia University).
B
A
C
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5.3.2 Two dimensional electrophoresis analysis using IPG strips containing a
linear gradient pH 4–7 or pH 6-9
Using IPG strips with pH 3-10, two dimensional electrophoresis studies had
successfully identified three proteins which were differentially expressed between
non-Tg littermates and Tg DN-RAGE mice. However, no protein spots were found
to be significantly differentially expressed between Tg mAPP and Tg
mAPP/DN-RAGE mice. In order to obtain a more detailed screening analysis of
differential protein expression between different genotypes of mice cortex, IPG
strips with pH 4-7 were combinely used with IPG strips with pH 6-9.
Mice cortex sample preparation and two dimensional electrophoresis were again
performed following the protocols described in section 2.5. Mice cortices from four
genotypes of mice including non-Tg littermates, Tg mAPP, Tg DN-RAGE and Tg
mAPP/DN-RAGE were lysed in lysis buffer 2. For each genotype of animals, mice
cortices from three different animals were used. 1 mg of proteins from each sample
was applied onto 24cm IPG gels with pH 4-7 and pH 6-9. Focused IPG strips were
then loaded onto precast DALT 12.5 gels. Electrophoresis of gels was carried out in
an Ettan-Dalt system. The proteins on the gels were visualized by silver staining.
Gel images were captured using a Typhoon 9200 scanner and analyzed with
ImageMaster software as described in 5.3.1.
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5.3.3 Differential protein expression between Tg mAPP and Tg
mAPP/DN-RAGE using IPG strips with pH 4-7
Three proteins were found to be differentially expressed between Tg mAPP mice
and Tg mAPP/DN-RAGE mice. The identified protein spots were excised from two
dimensional gels and sent for mass spectrometry analysis. These three proteins were
identified as NDUFV2 (NADH ubiquinone oxidoreductase flavoprotein 2), PSMB4
(Proteasome subunit beta type 4), and Nit protein 2 (Nitrilase family, member 2). In
comparison with Tg mAPP mice, NDUFV2 and PSMB4 were upregulated in Tg
mAPP/DN-RAGE mice whereas Nit protein 2 was down regulated. The relative
volumes of identified protein spots are expressed as means ± SD. The relative spot
volumes of NDUFV2 and PSMB4 were significantly increased from 0.09±0.06 and
0.18±0.02 in Tg mAPP mice to 0.3±0.08 and 0.26±0.01 in Tg mAPP/DN-RAGE
mice, respectively. In contrast, the relative spot volume of Nit protein 2 was
decreased from 0.08±0.01 in Tg mAPP mice to 0.054±0.005 in Tg
mAPP/DN-RAGE mice. Representative two dimensional gel images of Tg
mAPP/DN-RAGE and Tg mAPP using IPG strips with pH 4-7 are shown in Figure
5.8. The proteins which were identified to be differentially expressed between Tg
mAPP/DN-RAGE and Tg mAPP are indicated by red circles. The identified
proteins including NDUFV2, PSMB4 and Nit protein 2 are also shown in enlarged
partial images of two dimensional gels (Figure 5.9).
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Figure 5.8 Representative two dimensional gel images of Tg mAPP/DN-RAGE
and Tg mAPP mice cortex using IPG strips (pH 4-7). 1 mg of proteins of Tg mAPP
or Tg mAPP/DN-RAGE mice cortex was separated in the first dimension using IPG
strip (pH 4-7). In the second dimension, the proteins were separated on precast
DALT 12.5 gels. After silver staining, gels images were captured with an image
scanner and analyzed using ImageMaster software. Three proteins (indicated by red
circles) were identified to be differentially expressed between Tg mAPP and Tg
mAPP/DN-RAGE mice cortex.
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Figure 5.9 Partial images of two dimensional gels indicating the differential
expression of three proteins between Tg mAPP and Tg mAPP/DN-RAGE mice
cortex. The expression levels of NDUFV2 and PSMB4 were increased in Tg
mAPP/DN-RAGE mice compared to Tg mAPP mice. In contrast, the expression
level of Nit protein 2 was decreased in Tg mAPP/DN-RAGE mice compared to Tg
mAPP animals.
5.3.3.1 Study of protein expression levels of PSMB4 and NDUFV2 in Tg mAPP and
Tg mAPP/DN-RAGE mice cortex using immunoblotting method
Two dimensional electrophoresis studies had found that three proteins including
PSMB4, NDUFV2 and Nit protein 2 were differentially expressed between Tg
mAPP and Tg mAPP/DN-RAGE mice cortex. To confirm the results of the two
NDUFV2
PSMB4
Nit2
Tg mAPP Tg mAPP/DN-RAGE
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dimensional electrophoresis, immunoblotting method was used. A monoclonal
antibody for PSMB4 was obtained from Biomol international and monoclonal
anti-NDUFV2 was a kind gift from Dr Ian M. Fearnley (MRC Dunn Human
Nutrition Unit, Wellcome Trust / MRC Building, Cambridge). However, no
commercial or home made antibodies for Nit protein 2 were available.
Tg mAPP and Tg mAPP/DN-RAGE mice cortices were lysed in RIPA buffer as
described in section 2.4.1. Cortices from three different animals of each genotype
were used. The protein lysates were quantified using Bradford’s reagent. Equal
amounts of proteins were loaded onto 4-12% Bis-Tris mini gels. After
electrophoresis, the proteins were transferred to nitrocellulose membranes. The
membranes were blocked in TBS/T + 5% milk overnight at 4°С. Monoclonal 
anti-PSMB4 (1:2000) or monoclonal anti-NDUFV2 (1:5000) was incubated with
membranes for one hour. After three five minutes washes in TBS/T, the membranes
were incubated with HRP conjugated goat-anti-rabbit (1:5000) or goat-anti-mice
(1:5000) for an hour. The membranes were washed again in TBS/T for three times,
five minutes of each and then subjected to ECL detection. To control for equal
protein loading, the membranes were stripped and reprobed with β-actin antibody.
The immunoblot bands were quantified using ImageJ software. The intensities of
the protein bands of PSMB4 and NDUFV2 were normalized to those of β-actin
bands. The relative expression levels of PSMB4 and NDUFV2 are expressed as
means ± S.E.M. Statistical difference was analyzed by student’s t test (p<0.05).
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5.3.3.2 Protein expression level of NDUFV2 in Tg mAPP and Tg mAPP/DN-RAGE
mice cortex
A western blot image of detection of NDUFV2 in Tg mAPP and Tg
mAPP/DN-RAGE mice cortex is shown in Figure 5.10. The blot was stripped and
reprobed with β-actin as indicated. Both Tg mAPP and Tg mAPP/DN-RAGE mice
cortex exhibited varied expression level of NDUFV2. Quantitative analysis found
that there is no significant difference in the relative expression level of NDUFV2
between Tg mAPP and Tg mAPP/DN-RAGE mice cortex (Figure 5.11).
Figure 5.10 A western blot image of protein extracts of Tg mAPP and Tg
mAPP/DN-RAGE mice cortex probed with monoclonal anti-NDUFV2. The blot
was stripped and reprobed with β-actin antibody. Varied expression level of
NDUFV2 was observed in both Tg mAPP and Tg mAPP/DN-RAGE mice cortex.
Tg mAPP Tg mAPP/DN-RAGE
NDUFV2
β-actin
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Figure 5.11 Quantitative analysis of the relative expression of NDUFV2 in Tg
mAPP and Tg mAPP/DN-RAGE mice cortex. The immunoblot bands were
quantified using ImageJ software. The expression level of NDUFV2 was
normalized to that of actin. Data of the relative expression of NDUFV2 are
expressed as means ± S.E.M. There was no significant difference in the relative
expression level of NDUFV2 between Tg mAPP and Tg mAPP/DN-RAGE mice.
5.3.3.3 Protein expression level of PSMB4 in Tg mAPP and Tg mAPP/DN-RAGE
mice cortex
A western blot image of Tg mAPP and Tg mAPP/DN-RAGE probed with
monoclonal anti-PSMB4 is displayed in Figure 5.12. To control for equal loading,
the membrane was stripped and reprobed again with β-actin antibody. Quantitative
analysis revealed that the relative expression level of PSMB4 was significantly
increased from 0.068±0.04 in Tg mAPP mice cortex to 0.36±0.11 in Tg
mAPP/DN-RAGE cortex (Figure 5.13.).
N=3
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Figure 5.12 A western blot image of Tg mAPP and Tg mAPP/DN-RAGE mice
cortex probed with monoclonal anti-PSMB4. The blot was stripped and reprobed
with β-actin antibody. The expression level of PSMB4 was significantly increased
in Tg mAPP/DN-RAGE mice cortex compared to Tg mAPP mice cortex.
Figure 5.13 Quantitative analysis of the relative expression level of PSMB4 in Tg
mAPP and Tg mAPP/DN-RAGE mice cortex. The immunoblot bands were
quantified using ImageJ software. The expression level of PSMB4 was normalized
to that of actin. The results of the relative expression of PSMB4 are expressed as
means ± S.E.M. Tg mAPP/DN-RAGE mice cortex displayed a significantly
enhanced level of PSMB4 expression compared to Tg mAPP mice cortex. *
indicates a significance level of 0.05.
Tg mAPP Tg mAPP/DN-RAGE
PSMB4
β-actin
*
N=3
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5.3.4 Differential protein expression between Non-Tg and Tg DN-RAGE mice
cortex using IPG strips with pH 4-7
Three proteins were identified to be differentially expressed between non-Tg and
Tg DN-RAGE mice cortex. These protein spots were then excised from the gels and
sent for mass spectrometry analysis. The selected proteins were identified as alpha
enolase, sepiapterin reductase and triose-phosphate isomerase. All three proteins
were found to be upregulated in Tg DN-RAGE mice compared to non-Tg
littermates. The relative volumes of identified protein spots are expressed as means
± SD. The relative spot volumes of alpha enolase, sepiapterin reductase and
triose-phosphate isomerase were significantly increased from 0.09±0.03, 0.11±0.01,
0.13±0.04 in non-Tg mice to 0.18±0.02, 0.19±0.01, 0.24±0.03 in Tg DN-RAGE
mice, respectively. Representative images of two dimensional gels of Tg
mAPP/DN-RAGE and Tg mAPP mice cortex using IPG strips (pH 4-7) are shown
in Figure 5.14. The proteins that were identified to be differentially expressed
between Tg DN-RAGE mice and non-Tg littermates are indicated by red circles.
The identified proteins including alpha enolase, sepiapterin reductase and
triose-phosphate isomerase are also displayed in enlarged partial images of two
dimensional gels (Figure 5.15).
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Figure 5.14 Representative two dimensional gel images of mice cortex from Tg
DN-RAGE and non-Tg. 1 mg of proteins of each sample was applied onto 24 cm
IPG gels (pH 4-7). After isoelectric focusing, the IPG strips were loaded onto
precast DALT gel 12.5 gels and run in an Ettan-Dalt system. After silver staining,
the gel images were captured with image scanner and analyzed using ImageMaster
software. Three proteins were found to be upregulated (as indicated by red circles)
in Tg DN-RAGE mice cortex compared to non-Tg mice cortex.
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Figure 5.15 Partial images of two dimensional gels showing that three proteins
(indicated by red circles) were differentially expressed between non-Tg littermates
and Tg DN-RAGE animals. Alpha enolase, sepiapterin reductase and
triose-phosphate isomerase were all upregulated in Tg DN-RAGE mice cortex
compared to non-Tg mice cortex.
5.3.5 Two dimensional electrophoresis analysis using IPG strips containing a
6-9 pH gradient
With IPG strips (pH 6-9), a more detailed protein distribution in the alkaline pI
range was obtained. There were three two dimensional gels for each of the four
genotypes including non-Tg, Tg mAPP, Tg DN-RAGE and Tg mAPP/DN-RAGE.
The 12 gels were analyzed using ImageMaster software. No protein spots were
found to be differentially expressed between non-Tg mice cortex and Tg DN-RAGE
mice cortex. Quantitative comparisons of the protein spots between Tg mAPP and
Tg mAPP/DN-RAGE mice cortex revealed no significant differences as well. A
representative image of a two dimensional gel using IPG strip (pH 6-9) is shown in
Figure 5.16.
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Figure 5.16 A representative image of two dimensional gel using IPG strip (pH
6-9). 1 mg protein of mice cortex was applied onto IPG strip (pH 6-9). The focused
strip was then loaded onto a precast DALT 12.5 gel. After completion of
electrophoresis, the gel was silver stained.
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All the proteins that had been identified with altered expression levels between
different genotypes of mice are summarized in Table 5.1. The molecular weight and
pI of theses proteins are displayed. Also, the number of matched peptides and
sequences coverage for the mass spectrometry analysis are shown.
Table 5.1 List of characteristics of all identified proteins that were differentially
expressed between Tg mAPP and Tg mAPP/DN-RAGE mice, or non-Tg and Tg
DN-RAGE animals.
Protein name Accession
Number
Swiss-Prot
Molecular
mass (kDa)
pI Number of
matched
peptides
Sequence
coverage
(%)
GLO 1 Q09751 20.774 5.08 16 30
NDUFV2 Q8K2L0 27.61 7 6 33
PSB4 Q5IST4 24.83 5.5 3 14
Nit 2 Q9JHW2 30.825 6.44 22 40
eIF-5A Q5NCX0 17.049 5.08 16 51
GMFB Q9CQI3 16.752 5.07 6 16
EFABP Q05816 15.338 6.18 9 25
Alpha enolase Q5FW97 47.322 6.36 14 21
Triosephosphate
isomerase
AAH46761 26.907 7.08 12 41
Sepiapterin
reductase
Q91XH5 27.947 5.97 8 25
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5.4 Discussion
5.4.1 Altered expression of GLO1, PSMB4, NDUFV2 and Nit 2 between Tg
mAPP/DN-RAGE mice brain and Tg mAPP mice brain
Transgenic mice overexpressing neuronal targeted RAGE in an Aβ rich
environment displayed accelerated cognitive impairment whereas Tg mAPP/
DN-RAGE exhibited preserved cognitive function as compared to Tg mAPP
(Arancio et al. 2004). These data indicated a role of RAGE in the early stages of
Alzheimer’s disease. To elucidate the signaling mechanisms underlying the
involvement of RAGE in AD, a two dimensional electrophoresis method was used
to identify differential protein expression between Tg mAPP and Tg
mAPP/DN-RAGE mice cortex. This involved separating proteins with respect to
their pI by isoelectric focusing in the first dimension and according to size by
SDS-PAGE in the second dimension.
Four proteins, GLO1, PSMB4, NDUFV2 and Nit protein 2 were identified by two
dimensional electrophoresis to be differentially expressed between Tg mAPP and
Tg mAPP/DN-RAGE mice brains. These results were further tested using western
blotting and RT-PCR. Due to limited resources, we were not able to perform
RT-PCR analysis in our laboratory. All RT-PCR results were obtained from Prof
ShiDu Yan (College of Physicians and Surgeons, Columbia University). Therefore,
the mRNA expression levels of identified proteins were not all analyzed with
RT-PCR In the following sections, their known function and their possible
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involvement in the early stages of AD will be discussed.
5.4.1.1 AGEs, GLO1 and AD
AGEs are predominantly formed by the non-enzymatic and irreversible reaction of
the amino groups of proteins with reactive dicarbonyl compounds, such as
3-deoxyglycosone, glyoxal or MG. This process involves a complex sequence of
reactions, including intramolecular rearrangements, dehydration and
oxididation/reduction reactions. AGE modified proteins are less soluble and more
resistant to enzymatic hydrolysis (Kalousova et al. 2005).
It was previously demonstrated that intracellular AGE deposits increase in brains of
Alzheimer’s patients compared to age-matched, non-demented controls.
Histochemical analysis revealed the localization of AGEs in neuritic plaques and
neurofibrillary tangles in AD. Moreover, during the advancement of the disease,
there was a continuous increase in the immunoreactivity of AGEs (Staniszewska et
al. 2005; Takeuchi et al. 2004; Sasaki et al. 1998). These data suggested that
increased AGEs may contribute to the pathogenesis of AD. Further support of this
hypothesis came from an in vitro study which showed that AGEs can induce cell
toxicity in cortical neuronal cultures (Kikuchi et al. 1999).
Several AGEs related signaling mechanisms were proposed to be involved in AD.
Firstly, the polymerization of Aβ peptide was found to be accelerated by
crosslinking through AGEs in vitro studies (Smith et al. 1994; Sasaki et al. 1998).
This indicated that AGEs may be the driving force in the accelerated formation of
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insoluble Aβ plaques. Also, the main constituent of neurofibrillary tangles, tau
protein is enriched in lysine which is prone to AGE formation (Kuhla et al. 2007b).
Furthermore, protein AGEs can bind several receptors and lead to intracellular
responses (Schmidt et al. 1996; Bierhaus et al. 1998). In addition, compared to
normal proteins, AGE modified proteins were reported to increase the rate of free
radical production. This oxidative stress may contribute to DNA damage, lipid
peroxidation, protein oxidation in AD (Kikuchi et al. 1999).
The glyoxalase system is an efficient enzymatic detoxification system suppressing
the formation of methylglyoxal and glyoxal-derived AGEs. It consists of GLO1 and
glyoxalase 2 (GLO2), together with the cofactor glutathione. The glyoxalase system
detoxifies glyoxal and methylglyoxal, thereby preventing the formation of AGEs
(Kuhla et al. 2006). In situ hybridization analysis showed that GLO1 is expressed in
neurons and glial cells throughout the brain (Chen et al. 2004).
In healthy human brains, GLO1 RNA, protein and activities were diminished in old
age. However, in brains of AD sufferers, GLO1 was found to be generally
up-regulated at the beginning of the disease, and continuously decreased with
advancing stage of AD (Kuhla et al. 2007a).
In early and middle stages of AD, co-localization of AGEs and GLO1 was observed,
whereas in late stages of AD, immunoreactivity for GLO1 was diminished and
AGE deposits clearly dominated (Kuhla et al. 2007a). These immunohistochemical
results suggested that reduced GLO1 protein amounts may be the cause for
accumulating AGE deposits.
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In accordance with these data, several lines of evidence demonstrated a possible
causal relationship between low GLO1 levels and increased formation of AGEs.
Firstly, overexpression of GLO1 in endothelial cells was shown to prevent
hyperglycemia-induced AGE formation (Shinohara et al. 1998). Moreover, a
hemodialysis patient exhibited unusual high levels of AGEs and a very low activity
of GLO1 (Miyata et al. 2001).
However, the exact mechanisms regulating synthesis and enzymatic activation of
GLO1 are not understood yet. It was proposed that, in AD, GLO1 may be
upregulated to reduce levels of MG and to decrease AGE formation. Alternatively,
it may be up-regulated as a general stress response, independent of the levels of MG
(Chen et al. 2004). The decrease of GLO1 protein with advancing stage of AD may
be caused by post-translational downregulating influences.
In this study, by using two dimensional electrophoresis method, GLO1 was found
to be increased in Tg DN-RAGE and Tg mAPP/DN-RAGE mice brain as compared
to non-Tg and Tg mAPP animals. Using RT-PCR method, Prof ShiDu Yan’s group
(College of Physicians and Surgeons, Columbia University) found that the mRNA
expression of GLO1 was increased in Tg mAPP/DN-RAGE mice as compared to
Tg mAPP mice. However, further studies with western blot found no significant
difference of the protein expression level of GLO1 between Tg mAPP/DN-RAGE
and Tg mAPP mice cortex. This could be due to the small sample size for western
blotting and the high variation of the protein expression level of GLO1 within the
same genotype (Figure 5.4A). These data indicated that RAGE signaling may
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contribute to GLO1 expression reduction in AD. Both Aβ and AGEs bind RAGE
and trigger intracellular signaling events (Schmidt et al. 1996; Yan et al. 1998).
With the advancement of AD, both Aβ and AGEs were found to be continuously
increased in the brain (Staniszewska et al. 2005; Takeuchi et al. 2004). RAGE
ligands accumulation leads to an ascending spiral of the receptor-induced
intracellular responses which may account for the continuous decrease of GLO1
expression during the advancement of AD. The signaling events linking RAGE
activation to GLO1 expression remain to be established.
5.4.1.2 PSMB4 and AD
The pathogenesis of Alzheimer’s disease is characterized by protein misfolding and
aggregate formation. In the human body, these misfolded proteins are generally
degraded by the ubiquitin proteasome system in two successive steps: (i) covalent
attachment of multiple ubiquitin molecules to the protein substrate, and (ii)
degradation of the targeted protein by the 26S proteasome (Ciechanover and
Schwatz 1998). The 26S proteasome complex is a symmetric structure composed of
a core catalytic unit, a barrel-shaped catalytic 20S proteasome complex, which is
capped at both poles by a 19S regulatory ATPase complex (19S-20S-19S). The
proteasome complex is arranged as a stack of four rings, each containing seven
distinct subunits, α1–7, β1–7, β1–7, α1–7. The active sites reside in three β subunits,
β1, β2, and β5 (Wojcik and Di Napol 2004).
Accumulating evidences indicated that functional impairment of the proteasome is
183
associated with Alzheimer’s disease (Keller et al. 2000). It was shown that
overexpression of mutant amyloid precursor protein significantly inhibits
proteasome chymotryptic activity in transgenic mice brains and in cultured cortical
neurons and blocking of Aβ production by a γ-secretase inhibitor restores
proteasome activity to levels of wild-type neurons (Fretta et al. 2005; Almeida et al.
2006). Furthermore, recombinant Aβ peptides or paired helical filament tau led to a
significant reduction of the chymotryptic activity of the isolated human 20S
proteasome (Keck et al. 2003; Oh et al. 2005). In addition, the expression levels of
several isoforms of proteasome subunits including α4, α7, β2 and β7 were found to
differ between AD and non-demented controls (Gillardon et al. 2007). These
findings collectively suggested that in AD, misfolded proteins, including
aggregated Aβ and tau, directly affects function and expression of proteasome
which again favors protein misfolding and aggregation.
Several lines of evidence indicated that β7 subunit of proteasome (PSMB4) serves
as an interaction partner for several proteins, such as SNEV (senescence evasion
factor), a multifaceted protein that is involved in DNA doublestrand break repair
and splicing. Signaling of the transforming growth factor β superfamily was also
influenced by binding of Smad1 to PSMB4 (Loscher et al. 2005). Given these data,
it was suggested that PSMB4 might be a major site for proteasome regulation,
where signals from the outside might be transduced to the protease activities inside.
In the study here, by using two dimensional electrophoresis, the protein expression
level of PSMB4 was found to be significantly increased in Tg mAPP/DN-RAGE
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mice brain as compared to Tg mAPP mice brain. Further studies using
immunoblotting method confirmed this finding (Figure 5.12). This result indicated
that RAGE signaling may be involved in the regulation of PSMB4 expression. The
signaling pathways between RAGE activation and PSMB4 expression remain to be
elucidated. However, it was found that, in muscle cells, NF-κB functions as a
negative regulator of the transcription of proteasome subunit, α type 2 (PSMA2)
(Du et al. 2000). Since PSMB4 gene also contains potential NF-κB binding sites in
its promoter regions, NF-κB may regulate the transcription of PSMB4 in the same
way. Both in vivo and in vitro studies showed that, in an Aβ rich environment,
overexpression of RAGE leads to an increased NF-κB activation (Yan et al. 1996;
Arancio et al. 2004). Therefore, it is possible to speculate that, after binding to
ligands such as Aβ or AGEs, activated RAGE triggers activation of NF-κB, which
then suppresses transcription of PSMB4.
5.4.1.3 NDUFV2 and AD
NADH: ubiquinone oxidoreductase (complex I) is one of the energy metabolism
enzymes catalyzing the transport of electrons from NADH to ubiquinone for ATP
synthesis. Complex I comprise 41 subunits of which 7 are encoded in the
mitochondrial DNA (mtDNA) and 34 are encoded in nuclear DNA (nDNA)
(Smeitink and van den Heuvel 1999). By using chaotropic agents, complex I can be
separated into 3 different fractions, flavoprotein (FP) fraction including 24-kDa
subunit, iron-sulfur protein (IP) fraction including 75-kDa subunit and hydrophobic
protein (HP) fraction (Smeitink et al. 1998; Smeitink et al. 2004).
185
Complex I deficiency was associated with the pathogenesis of Alzheimer’s disease.
Biochemical findings demonstrated that in Alzheimer’s disease (AD) brain
mitochondria, there is a generalized depression of activity of all electron transport
chain complexes (complex I, II, III and IV) (Parker et al. 1994; Zhu et al. 2004).
Moreover, it was observed that the protein levels of NDUFV2 and 75-kDa subunit
of complex I were significantly decreased in Down’s syndrome and AD as
compared to controls (Kim et al. 2001).
Here two dimensional electrophoresis analysis revealed that NDUFV2 was
significantly increased in Tg mAPP/DN-RAGE mice brain as compared to Tg
mAPP mice brain indicating that ligand activated RAGE signaling events may be
involved in the regulation of NDUFV2 expression. However, when using western
blot with a monoclonal anti-NDUFV2 antibody, no significant difference of the
protein expression level of NDUFV2 between Tg mAPP/DN-RAGE and Tg mAPP
mice cortex was observed. This could be due to the small sample size for western
blotting and the high variation of the protein expression level of NDUFV2 within
the same genotype (Figure 5.10A). The biochemical events linking RAGE
activation and altered expression of NDUFV2 are still unknown. One possibility is
that after ligand binding, activated RAGE induces oxidative stress which would
then affect NFDUFV2 expression.
5.4.1.4 Nit2 and AD
In this study, Nit2 was found to be significantly decreased in Tg mAPP/DN-RAGE
animals compared to Tg mAPP animals. As no commercial or home made
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antibodies were available for this protein, immunoblotting confirmation of the
altered expression of Nit2 was not able to be performed. Nit2, a member of the
nitrilase superfamily, is ubiquitously expressed in multiple tissues. It was
demonstrated that Nit2 plays an important role in cell growth inhibition. Nit2 was
also linked to malignancies, indicating a potential as tumor suppressor (Lin et al.
2007). Although Nit2 has not been associated with AD, it was found to be
significantly reduced in fetal Down’s syndrome brain (Myung et al. 2003).
5.4.2 Differentially expressed proteins between non-Tg mice brain and Tg
DN-RAGE mice brain
Using two dimensional electrophoresis, I also analyzed differential protein
expression between non-Tg mice and Tg DN-RAGE mice cortex. These data would
provide further insights into the functions of RAGE.
Two dimensional electrophoresis studies had revealed that four proteins, including
E-FABP, sepiapterin reductase, alpha enolase and triose-phosphate isomerase, were
upregulated in Tg DN-RAGE mice brain as compared to non-Tg mice brain. Two
proteins, including eIF-5A and GMFB were downregulated in Tg DN-RAGE mice
brain as compared to non-Tg mice brain.
Using RT-PCR, Prof ShiDu Yan’s group (College of Physicians and Surgeons,
Columbia University) found that, contradictory to the results from my two
dimensional electrophoresis analysis, mRNA expression level of EFABP was
decreased in Tg DN-RAGE mice brain whereas mRNA expression levels of eIF-5A
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and GMFB were increased in Tg DN-RAGE mice brain as compared to non-Tg
mice brain. The reason why the two dimensional electrophoresis results were
opposite to the RT-PCR results could be because of the small sample size used for
analysis and high variation of mRNA expression among different animals with the
same genotype. Due to limited resources, we were not able to perform RT-PCR
analysis in our laboratory. All RT-PCR results were obtained from Prof ShiDu Yan.
Therefore, the mRNA expression levels of identified proteins were not all analyzed
using RT-PCR method. However for reasons explained below these proteins require
further analysis.
5.4.2.1 RAGE and E-FABP, eIF-5A and GMFB
Intracellular lipid binding proteins called fatty acid binding proteins (FABPs)
proteins are small, abundantly expressed cytoplasmic proteins that are involved in
fatty acid (FA) uptake, transport, storage, and metabolism. They may modulate FA
concentration and in this way influence function of enzymes, membranes, ion
channels and receptors, and gene expression and cellular growth and differentiation
(Makowski and Hotamisligil 2004). Nine different types of cytoplasmic FABP have
been identified up to now. Among which, four types are expressed in the nervous
system with a distinct spatial-temporal distribution. Myelin (M)-FABP is only
present in the peripheral nerves, brain (B)-FABP and epidermal (E)-FABP mainly
localized in glial cells and neurons of pre- and perinatal brain, respectively, and
heart (H)-FABP in adult brain (Liu et al. 2000; Veerkamp and Zimmerman 2001)
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The functional significance of the spatial-temporal pattern of the four FABP types
in nervous tissue is still unclear. In PC12 cells, it was demonstrated that E-FABP
expression is required for normal neurite outgrowth after nerve growth factor
treatment (Allen et al. 2000). Furthermore, one study showed that E-FABP is
involved in retinal ganglion cell differentiation and axon growth (Allen et al. 2001).
These results suggested a role of E-FABP in central nervous system during neuronal
migration and development. E-FABP is also expressed in adult brain although the
level is dramatically lower as compared to perinatal brain (Veerkamp and
Zimmerman 2001). The function of E-FABP in adult brain remains to be elucidated.
In all eukaryotic organisms, protein translation is regulated by a variety of
translation initiation factors. One of these is Eif-5A. eIF-5A was shown to promote
the formation of the first peptide bond between methionine (amino acid of the start
codon) and the first amino acid of the coding sequence thereby playing an essential
role in initiating translation (Langer et al. 2006). It was reported that loss of eIF-5A
activity leads to a reversible arrest of the cells in the G1- phase of the cell cycle and
inhibits the growth of mammalian cells. Also, eIF-5A was demonstrated to be
involved in cell proliferation (Huang et al. 2007).
GMFB is expressed predominantly in the brain, especially astrocytes and some
neuronal cells (Wang et al.1992). It is a protein of 141 amino acids and functions as
a growth and differentiation regulator for neurons as well as glia (Lim et al. 1989;
Hotta et al. 2005).
Two dimensional studies suggested a possible linkage between RAGE and E-FABP,
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eIF-5A and GMFB. As described above, E-FABP, eIF-5A and GMFB all seem to be
involved in growth and differentiation of neurons. RAGE was known to interact
with amphoterin and this interaction was proposed to play a prominent role in
neurite outgrowth (Sajithlal et al. 2002). Therefore, during development, it is
possible that E-FABP, eIF-5A and GMFB are subsequent signaling events of RAGE
activation. In the adult brain, however, the functions of these proteins are not clear.
They were proposed to be involved in neural survival after injury (Allen et al. 2001;
Hotta et al. 2005). In the adult brain, many ligands can bind and activate RAGE,
thus inducing multiple intracellular signaling events. Altered expression of E-FABP,
eIF-5A and GMFB may be part of these events.
5.4.2.2 RAGE and sepiapterin reductase, alpha enolase and triose-phosphate
isomerase
Glycolysis is the pathway which oxidizes glucose and converts it into pyruvate or
lactate, resulting in the production of energy. Glycolytic pathway is the main route
that provides energy to brain functioning (Magistretti et al. 2000). Alpha-enolase
and triose-phosphate isomerase are enzymes involved in the glycolytic pathway of
metabolism. Alpha-enolase is a metalloenzyme that catalyses the reaction of
2-phopho-D-glycerate to phophoenolpyruvate. Triosephosphate isomerase catalyzes
the interconversion of glyceraldehyde phosphate and dihydroxyacetone phosphate
in the glycolytic pathway.
Sepiapterin reductase catalyzes the final step of the biosynthetic pathway of
tetrahydrobiopterin (BH4). BH4 is an essential cofactor for multiple enzymes such
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as all three isoforms of nitric oxide synthase, tyrosine hydroxylase and
tryptophan-5-hydroxylase. NO is synthesized by the three forms of nitric oxide
synthase and has a variety of physiological roles. Tyrosine hydroxylase and
tryptophan-5-hydroxylase are rate-limiting enzymes for the production of the
biogenic amine neurotransmitters dopamine, norepinephrine, and serotonin
(Friedman et al. 2006; Yang et al. 2006; Tobina et al. 2007).
The results obtained by two dimensional electrophoresis analysis of Tg DN-RAGE
and non-Tg mice cortices suggested a potential relationship between RAGE and
sepiapterin reductase, alpha enolase and triose-phosphate isomerase. These data
indicated that activated RAGE signaling may be involved in the regulation of the
glycolytic pathway and BH4 synthesis. However, the underlying mechanisms
linking RAGE and altered expression of sepiapterin reductase, alpha enolase and
triose-phosphate isomerase remain to be elucidated.
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In the late stages of Alzheimer’s disease, multiple signaling pathways are impaired
and extensive neurodegeneration and neuron loss occur. Therefore, it is of essential
importance to identify the initiating events in the pathogenesis of Alzheimer’s
disease and find potential therapeutic strategy to prevent the disease at an early
stage. Our collaborator, Prof ShiDu Yan’s group (Department of Surgery, Columbia
University) have identified two receptors, ABAD and RAGE, which have been
proposed to bind Aβ and mediate Aβ induced neurotoxicity in the early stages of
AD (Yan et al. 2000).
6.1 The endophilin 1-GLK-JNK pathway in AD
To study the involvement of ABAD in AD, Prof ShiDu Yan’s group developed
transgenic mice overexpressing neuron targeted ABAD and double transgenic mice
overexpressing both ABAD and mAPP (Takuma et al. 2005). Using proteomic
analysis, previous work by Dr Jim Aiton and Margaret Taylor had found that
endophilin 1 is consistently upregulated in Tg mAPP and Tg ABAD/mAPP mice
brains as compared to non-Tg and Tg ABAD mice brains. Studies using
immunoblotting further confirmed that endophilin 1 expression is increased in brain
tissues of Alzheimer’s patients as well (section 3.1). Given the finding that injection
of a peptide which can disrupt the interaction between Aβ and ABAD in Tg
mAPP/ABAD animals resulted in a reversal of endophilin 1 expression (section
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3.4.4), these results collectively suggested that endophilin 1 expression is increased
in brains of AD patients and this increased expression is a direct consequence of the
Aβ-ABAD interaction.
How Aβ-ABAD interaction can lead to increased expression of endophilin 1 is still
unknown. The human endophilin 1 gene promoter is TATA-less, with multiple
potential transcription factor binding sites (e.g. Sp1, NF-KB, ATF, c-Jun) (Reutens
and Begley 2002). So, it seems possible to speculate that the signaling events after
Aβ-ABAD interaction lead to activation of several gene transcription factors for
endophilin 1 such as NF-KB, ATF or c-Jun, which then causes increased expression
of endophilin 1. In the future, using gel mobility-shift assays, experiments will be
performed in our laboratory to study if the Aβ-ABAD interaction can cause an
increase of the activity of transcription factors such as NF-KB, ATF or c-Jun in
cortical neurons. Moreover, experiments will also be performed to examine the
effects of these transcription factors on endophilin 1 expression.
Endophilin 1 is a SH3 domain containing protein which is expressed predominantly
in the presynaptic terminals of the brain (Ringstad et al. 2001; Micheva et al. 1997).
Endophilin 1 is a multifunctional protein (Reutens and Begley 2002). It was proposed
to participate in synaptic vesicle endocytosis through SH3 domain mediated
interactions with synaptojanin and dynamin (Gat et al. 2000). Endophilin 1 was also
identified to bind a number of diverse cellular proteins (Reutens and Begley 2002).
Ramjaun et al. 2001 reported that through its SH3 domain, endophilin 1 binds GLK
and regulates GLK mediated JNK activation in HEK293 cells. In vitro studies found
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that GLK can directly phosphorylate MEKK1 (Diener et al. 1997). Previous
findings indicated that MEKK1 interacts with inactive MKK4 to form a
MEKK1MKK4 complex. Active MEKK1 can phosphorylate and activate MKK4,
resulting in its dissociation from the complex. The free and active MKK4 then
specifically interacts with JNK. Once activated, JNK is now freed from the
MKK4JNK complex and translocated to the cytoplasm or the nucleus to
phosphorylate downstream effectors (Chang and Karin 2001).
Since increased JNK activation has long been associated with Alzheimer’s disease, I
studied the involvement of the endophilin 1-GLK-JNK pathway in AD (Zhu et al.
2001). Similar to the previously published observations (Morishima et al. 2001), it had
been found that JNK activation is increased in cortical neurons after Aβ treatment
(section 3.3.3.1). Overexpression of endophilin 1 in mice cortical neurons caused an
increase of JNK activation in the absence of Aβ. In contrast, expression of two
dominant negative forms of endophilin 1 significantly reduced JNK activation in
cortical neurons after treatment of Aβ (section 3.3.3.2).
There are at least three possibilities that increased activation of JNK may be involved
in the pathogenesis of AD. Firstly and most notably is that increased JNK activation
can lead to neuron death. It was found that extracellular Aβ induces an enhanced JNK
activation which then phosphorylates and activates c-Jun. Activated c-Jun led to neuron
death via Fas signaling pathway (Morishima et al. 2001). Indeed, in this study here,
expression of two forms of dominant negative endophilin 1 in cortical neurons
protected against Aβ induced neuron death (section 3.3.3.3). Given the finding that
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c-Jun activation is increased in brains of AD patients as compared to age-matched
controls, these data indicated that endophilin 1 regulated JNK activation may lead to
c-Jun activation, thus contributing to neuron loss in AD (Marcus et al. 1998).
Another possibility is that activated JNK may be involved in tau hyperphosphorylation.
In vitro studies showed that JNK can phosphorylate tau (Sato et al. 2002; Okazawa
and Estus 2002). By immunocytochemistry, activated JNK was colocalized with tau in
brains of AD sufferers (Zhu et al. 2001). These observations indicated that increased
JNK activation may result in tau hyperphosphorylation and NFT formation, thereby
leading to neurodegeneration.
In addition, Aβ was shown to inhibit long-term potentiation (LTP) in the
hippocampus. However, pretreatment of the hippocampal slices with JNK inhibitors
prevented the Aβ induced LTP inhibition (Wang et al. 2004). Synaptic plasticity,
especially LTP, is involved in learning and memory mechanisms (Morris et al.
2003). Therefore, the increased JNK activation may contribute to the cognitive
deficits in AD.
Given the findings from this study and the above evidences, a hypothetical
sequence of events that may occur during the pathogenesis of AD was proposed
(Figure 6.1). In an Aβ rich environment, as present in AD, Aβ-ABAD interaction
leads to increased expression of endophilin 1 which binds and activates GLK.
Active GLK phosphorylates and activates MEKK1, which then triggers activation
of MKK4. Phosphorylated MKK4 induces JNK activation, thereby leading to the
activation of c-Jun, which stimulates Fas signaling, and eventually neuron death.
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Increased JNK activation may also lead to abnormal phosphorylation of tau protein,
thus participating in NFT formation. In addition, activated JNK may contribute to
cognitive impairment in AD patients by inhibition of LTP.
Figure 6.1 A hypothetical sequence of events in AD. Endophilin 1 induces JNK
activation through a series of kinases including GLK, MEKK1 and MKK4.
Increased JNK activation leads to neurodegeneration, neuron loss and cognitive
deficits.
Aβ-ABAD interaction
Endophilin 1
GLK
JNK
MEKK1
MKK4
c-Jun
Fas signaling pathway
Neuron loss
Tau hyperphosphorylation
NFTs and neurodegeneration
LTP inhibition
Cognitive deficits
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In light of the above mentioned data implicating a role of JNK signaling in AD,
inhibition of JNK seems to be a promising therapeutic strategy for AD. Our study
indicated that endophilin 1 may act as a regulator of JNK activity in AD. Therefore,
inhibition of endophilin 1 may offer neuroprotection to patients with AD. In order
to examine if endophilin 1 is indeed a good therapeutic target, more studies need to
be done in the future. Firstly, a transgenic animal model overexpressing endophilin
1 in an Aβ rich environment should be developed to study if increased expression of
endophilin 1 can cause accelerated/enhanced cognitive deficits and neuron loss.
Followed by this study, transgenic mice expressing dominant negative endophilin 1
in an Aβ rich environment should be developed. Characterization of this transgenic
animal model will be able to allow us to investigate if inhibition of endophilin 1 can
rescue Aβ induced cognitive impairment and neuron death.
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6.2 The relationship between activation of RAGE and expression of GLO1 or
PSMB4
To study the role of RAGE in AD, Prof ShiDu Yan’s group have developed
transgenic mice overexpressing RAGE or dominant negative form of RAGE
(DN-RAGE) in an Aβ rich environment. They found that Tg mAPP/RAGE mice
displayed accelerated/enhanced cognitive impairment whereas Tg
mAPP/DN-RAGE showed preserved cognitive function as compared to Tg mAPP
mice (Arancio et al. 2004). In this study, in order to understand the molecular
mechanisms that protect cognitive function in Tg mAPP/DN-RAGE mice brains,
two dimensional electrophoresis method was used. Among the four proteins
identified to be differentially expressed between Tg mAPP and Tg
mAPP/DN-RAGE mice brains, GLO1 and PSMB4 are of particular interest. These
two proteins were found to be upregulated in Tg mAPP/DN-RAGE mice brains as
compared to Tg mAPP mice brains (section 5.2.1 and 5.3.3).
GLO1 is part of the glyoxalase system which detoxifies dicarbonyl metabolites,
such as MG. MG participates in the glycation of proteins and nucleotides, resulting
in the formation of advanced glycation end products (AGEs) (Kuhla et al. 2007a).
The levels of AGEs were increased in the brains of AD patients as compared to
non-demented controls (Staniszewska et al. 2005; Takeuchi et al. 2004; Sasaki et al.
1998). In vitro studies showed that AGEs cause neuron toxicity possibly via
oxidative stress-related pathways (Kikuchi et al. 1999). These results indicated that
interference with the AGEs production process may reduce the neuropathologic
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changes in AD. Therefore, GLO1 might be a useful therapeutic target for AD. By
increasing the expression or activity of GLO1, AGEs levels can be reduced.
However, the factors regulating GLO1 expression are still unclear. Several
transcription factors including activating protein-1 (AP-1) and NF-κB were
proposed to regulate GLO1 gene expression under oxidative stress conditions
(Ranganathan et al. 1999). Furthermore, IRE (insulin response element) was
identified in the promoter region of GLO1gene (Ranganathan et al. 1999).
In this study, GLO1 expression was identified to be upregulated in Tg
mAPP/DN-RAGE mice brains as compared to Tg mAPP mice brains indicating the
effects of RAGE signaling on GLO1 expression (section 5.2.1). The signaling
events between RAGE activation and GLO1 expression remain unknown. It is
rational to speculate that RAGE ligands bind RAGE and triggers intracellular
signaling events which then activate transcription factors such as AP-1, IRE or
NF-κB, thereby regulating the expression of GLO1. In the future, experiments will
be performed to test this hypothesis. Elucidation of the molecular mechanisms
linking RAGE activation and GLO1 expression will not only provide insights into
the involvement of RAGE and GLO1 in AD but also help developing novel
therapeutic methods for the treatment of AD.
The ubiquitin/proteasome protein degradation pathway is a major cellular
proteolytic system. In this pathway, damaged and abnormal proteins are targeted for
degradation by the covalent attachment of several ubiquitin moieties to form
ubiquitin conjugates. Ubiquitinated proteins are then rapidly degraded by the 26 S
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proteasome (Ciechanover and Schwatz 1998). Alzheimer’s disease is characterized
by abnormal protein aggregation such as amyloid plaques or NFTs (Mott and
Hulette 2005). Several studies showed that different forms of tau, including
phosphorylated tau (PHF-1) and non-phosphorylated tau (Tau-1) in rat brain cortex
extract are degraded by 26S proteasome in an ubiquitin- and ATP-dependent
manner (Zhang et al. 2004). Furthermore, when using lactacystin, an inhibitor of
the 26S proteasome, a marked decrease in Aβ degradation was detected in both
astrocytes and neurons (Lopez et al. 2003). In addition, in HEK293 cells transfected
with FAD-linked PS1, the proteasome was shown to participate in the degradation
of FAD-linked PS1, thereby directly influencing the production of Aβ (Marambaud
et al. 1998).
Given that impairment of proteasome function has been associated with AD, the
above findings together suggested that alterations in the Ub–proteasome pathway in
AD could affect the normal protealytic removal of Aβ and tau, resulting in an
abnormal accumulation of Aβ and tau (Keller et al. 2000).
In this study, PSMB4 was found to be significantly increased in Tg
mAPP/DN-RAGE mice brains as compared to Tg mAPP mice brains indicating the
involvement of RAGE signaling in PSMB4 expression (5.3.3). The factors
regulating PSMB4 expression are still unknown. However, NF-κB was identified to
be an important negative regulator of the transcription of one component of
proteasome, PSMA2 (Du et al. 2000). Since PSMB4 contains potential NF-κB -like
binding sites in its promoter regions as well, it is possible that RAGE ligands bind
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RAGE and induce activation of NF-κB, which then leads to decreased expression of
PSMB4 whilst expression of DN-RAGE blocks this pathway.
Therefore, given the above evidences, there are at least two reasons that prove that
RAGE is a good therapeutic target. First, blocking of RAGE leads to an increase of
GLO1 expression. Increased GLO1 expression may reduce AGEs formation,
thereby ameliorating AGEs induced neurotoxicity in AD (Figure 6.2).
Secondly, blocking of RAGE causes an increased expression of PSMB4. Increased
PSMB4 may lead to increased proteasome activity which will then result in
increased degradation of Aβ and tau. Therefore, by blocking of RAGE, abnormal
accumulation of Aβ and tau can be reduced (Figure 6.2).
More studies need to be done to investigate the signaling events between RAGE
activation and expression of GLO1 or PSMB4. This may provide help for
developing RAGE-targeted therapeutic strategy for the treatment of AD. Also, by
elucidating these mechanisms, novel therapeutic targets for treatment of AD may be
identified.
Figure 6.2 A schematic illustration of the possible neuroprotective mechanisms by
blocking of RAGE.
Blocking of RAGE
GLO1
AGEs
Neurotoxicity
PSMB4
Aβ and tau
Neurodegeneration
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Appendix 1: List of Suppliers
Supplier Address
Abcam Cambridge, UK
Amaxa Cologne, Germany
American Tissue Culture Collection (ATCC) Rockville, USA
Amersham- Pharmacia-Biotech Buckinghamshire, UK
Bachem Bubendorf, Switzerland
BD Biosciences/Clontech Oxford, UK
Biomol Interantional Exeter, UK
Fisher Scientific Loughborough, UK
Invitrogen/Gibco Paisley, UK
Millipore Watford, UK
New England Biolabs/Cell signaling Hertfordshire, UK
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Appendix 2: Antibody specific protocols
Primary antibody: anti-β-actin (Sigma) 1:5000
Secondary antibody: Santa Cruz anti-mouse-HRP 1:5000
Protocol: As described in section 2.4.6
Primary antibody: anti-PSMB4 (Biomol International) 1:2000
Secondary antibody: Santa Cruz anti-mouse-HRP 1:5000
Protocol: As described in section 2.4.6
Primary antibody: anti-NDUFV2 1:5000
Secondary antibody: Santa Cruz anti-rabbit-HRP 1:5000
Protocol: As described in section 2.4.6
Anti-NDUFV2 is a kind gift from Dr Ian Fearnley,
MRC Dunn Human Nutrition Unit, Cambridge.
Primary antibody: anti-Glyoxylase 1 1:2000
Secondary antibody: Santa Cruz anti-rabbit-HRP 1:5000
Protocol: As described in section 2.4.6
Anti-Glyoxylase 1 is a kind gift from Dr Carol Brown,
Department of Cell and Molecular Pharmacology, Hollings Cancer Center.
Primary antibody: anti-GFP (Sigma) 1:1000
Secondary antibody: Santa Cruz anti-mouse-HRP 1:10,000
Protocol: As described in section 2.4.6
Primary antibody: anti-FLAG M2 (Sigma) 1:500
Secondary antibody: Santa Cruz anti-mouse-HRP 1:10,000
Protocol: Block at room temperature 30 minutes 3% milk TBS
Wash 1x TBS
Primary antibody 1:500 3% milk-TBS 30 minutes
Wash 1x TBS 10 minutes
Secondary antibody 1:10,000 3% milk-TBS 30 minutes
Wash 8x 3minutes TBS
Primary antibody: anti-phospho-JNK (Cell signaling) 1: 2000
Secondary antibody: Santa Cruz anti-mouse 1:5000
Protocol: Block overnight 4°С 3% Bovine serum albumin (BSA) TBS/T
Wash 1x TBS/T
Primary antibody 1:2000 3% BSA TBS/T overnight
Wash 3x TBS/T 5 minutes
Secondary antibody 1:5000 3% BSA TBS/T 1 hour
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Wash 3x TBS/T 5 minutes
Primary antibody: anti -JNK (Cell signaling) 1: 2000
Secondary antibody: Santa Cruz anti-mouse 1:5000
Protocol: Block overnight 4°С 3% BSA TBS/T
Wash 1x TBS/T
Primary antibody 1:2000 3% BSA TBS/T overnight
Wash 3x TBS/T 5 minutes
Secondary antibody 1:5000 3% BSA TBS/T 1 hour
Wash 3x TBS/T 5 minutes
